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ABSTRACT 
 
Oral administration is the most convenient and popular route for drug administration. Therefore, there is a 
considerable interest both in basic research and in predictive screening for models of intestinal absorption. This 
is further stressed by the fact that still a large fraction of new potential drugs fail because of problems in 
absorption, distribution, metabolism and excretion (ADME) properties. Because the development of a single 
drug is progressively getting more expensive, the ADME problems of otherwise promising candidates need to be 
tackled away as early as possible. 
Cell culture models are used to evaluate the suitability of new chemical entities for drug applications. It is 
possible to get estimates of for example pharmacological activity, absorption potential, metabolic stability and 
toxicity without the use of animal experiments. The usefulness of this data depends essentially on the properties 
of the cell model and the understanding that the researcher has on the phenomenon of interest. 
Caco-2 cell line is the most widely used model for intestinal absorption. It predicts very well the permeability 
of molecules in vivo with moderate to high lipophilicity. However, there are problems with hydrophilic 
compounds and compounds that are substrates of active transporters. The active cytochrome P450 (CYP) 
mediated metabolism that is present in intestinal epithelium in vivo is defective in Caco-2 cells. Moreover, 
hydrodynamic constraints in permeability apparatuses may reduce the predictive value of in vitro permeability 
experiments. 
In the present study, the Caco-2 cell line was improved with a novel genetic approach. The nuclear receptors 
pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are endogenously expressed only at 
trace levels in Caco-2 cells. However, introducing their cDNA stably into Caco-2 cells render some of their 
target genes regulatable by corresponding ligands of the nuclear receptor. It was shown that the expression of 
efflux pumps can be quite easily upregulated by chemical induction and by transfection of nuclear receptors but 
CYP enzymes remain inactive despite increased transcription. Some modifications showed also adverse effects, 
such as decrease in the expression of endogenous transporters and compromise in monolayer integrity.  
Cell lines with increased P-glycoprotein expression were used to study the apparent shift in kinetic parameters 
of its substrates. It was shown that this efflux pump can effectively lower the intracellular amount of its 
substrates which causes bias in the obtained kinetic parameters. This complicates the in vitro-in vivo 
extrapolation and stresses the need to thoroughly characterize the experimental models in order to obtain 
meaningful and predictive results. 
The constrained hydrodynamics in standard permeability apparatus was studied using a novel custom-made 
magnetic stirrer. It was observed that the distribution of unstirred water layer is asymmetric which complicates 
the interpretation of permeability results of especially transporter substrates. Similarly, building of differential 
equation based simulation models is difficult because of the potential formation of radial concentration gradients. 
It was shown that efficient stirring conditions that are observed in intact intestine in vivo are difficult but not 
impossible to reproduce in vitro. 
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1 INTRODUCTION 
The intestine is the most important site for drug absorption since peroral route is a 
convenient and safe way to administer drugs. Therefore, there is a considerable interest both 
in basic research and in predictive screening for models of intestinal absorption. This is 
further stressed by the fact that a large fraction of new potential drugs has failed because of 
problems in absorption, metabolism, distribution and excretion (ADME) properties (Kennedy 
1997). Because the development of a single drug is progressively getting more expensive, the 
ADME properties of otherwise promising candidates need to be tackled away as early as 
possible. 
In vitro experiments for permeability, metabolism and toxicity offer valuable tools for drug 
discovery since new chemical entities can be subjected to these tests at very early stage when 
little is known about the compound and only small quantities are available for experiments. 
Cell-based methods have proved to offer a good balance between predictability and 
throughput. However, there are also several problems with the models (Balimane and Chong 
2005) and, therefore, the models and experimental setups are constantly developed to improve 
predictions. The complexity of an intact organism cannot be fully simulated. 
The improvements in in vitro models have increased the understanding on some basic 
mechanisms of drug disposition. For example, the interplay between transporters and 
cytochrome P450 (CYP) enzymes in the intestine (Fisher et al. 1999) and in liver (Lau et al. 
2004b) are beginning to be understood. Similarly, novel multiply transfected cell lines are 
revealing the great impact of transport proteins in coordinate transport of drugs and 
endogenous molecules in human tissues (Mita et al. 2006a; Kopplow et al. 2005).  This 
mechanistic understanding can be used to improve pharmacokinetic models. 
Cell-based experiments work to help people designing new drug molecules. Nowadays 
compounds can be virtually screened for pharmacological activity or ADME properties even 
before they are synthesized (Ekins et al. 2007). The goodness of these models is completely 
dependent on the biological data that were used to create them, often derived from cell-based 
in vitro assays. 
New and increasingly more complicated dynamic simulation models are constructed to 
understand the observed phenomena in in vitro experiments (Tran et al. 2005; Bartholome et 
al. 2007). Clearly, there is still need for improving both the cell models and basic 
understanding of the drug behaviour in biological systems. 
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2 REVIEW OF THE LITERATURE 
 
2.1 Epithelial cell culture models 
Different cell lines have been used to study drug transport through epithelia (Braun et al. 
2000). These studies can be used either to evaluate the probable fraction absorbed in vivo or 
study different mechanisms of permeability (Hubatsch et al. 2007). Typically, cell lines 
originating from one tissue is used to model the permeability of the respective epithelium in 
vivo. However, sometimes cell lines from different tissues or species are used to study 
intestinal absorption. Table 2.1 summarizes the example cell lines that are discussed more 
thoroughly below. 
 
Table 2.1: Some cell lines that are used to study intestinal permeability 
Cell line Origin Features 
Caco-2 Human colon 
adenocarcinoma 
Typically spontaneous differentiation into enterocyte like cells, many transporters 
expressed, absence of CYP enzymes, small paracellular pores 
HT-29 Human colon 
adenocarcinoma 
Inducible mucus secretion, higher paracellular permeability than in Caco-2 cells 
2/4/A1 Rat foetal small 
intestine 
Mimics well intestinal paracellular permeability, low transporter expression 
MDCK Dog kidney Only low endogenous transporter levels, rapid growth, tight monolayer 
 
2.1.1 Caco-2 
Caco-2 ("Carcinoma Colon") cells originate from human colonic adenocarcinoma (Fogh et 
al. 1977). They can be maintained in an undifferentiated state if subcultured routinely. Yet, 
these cells differentiate into enterocyte-like cells if they are maintained in post-confluent 
cultures. Caco-2 cells develop typical morphology of an enterocyte with distinct apical and 
basolateral membrane domains, microvillus and tight junctions. In addition, several brush 
border enzymes are expressed (Pinto et al. 1983). The cells can be grown on uncoated 
polycarbonate filters to obtain well differentiated monolayers for permeability experiments 
(Artursson 1990). Despite the fact that Caco-2 cells show similarities to small intestinal 
enterocytes, there are differences because the cells originate from colon (Delie and Rubas 
1997).  
Caco-2 cell line is the most widely used cell line to model gastrointestinal drug absorption. 
It was first used to study the uptake and transport of vitamins (Vincent et al. 1985) and ions 
(Mohrmann et al. 1986). In the late 1980s and early 1990s the polarized model was adapted 
also to drug transport studies (Hidalgo et al. 1989; Artursson 1990; Hilgers et al. 1990). There 
is considerable variability in exact methodologies used in different laboratories (Sambuy et al. 
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2005) and, therefore, an attempt was made recently to create a standard protocol for Caco-2 
transport studies (Hubatsch et al. 2007). 
The major drawbacks of Caco-2 cells, when considering predicting intestinal permeability, 
are tight paracellular space (Adson et al. 1994; Tavelin et al. 2003b) and the extremely low 
activity of phase I oxidative metabolism (Prueksaritanont et al. 1996). Some reports suggest 
that, qualitatively, the transporter profile in Caco-2 cells is fairly similar to that in jejunum but 
the absolute expression levels often remain lower (Seithel et al. 2006; Taipalensuu et al. 
2001). Qualitative differences have also been reported (Englund et al. 2006; Hilgendorf et al. 
2007). Furthermore, several transporters show stable expression over culture time and passage 
number (Seithel et al. 2006; Englund et al. 2006) while others are either up- or down-
regulated (Seithel et al. 2006; Yu et al. 1997; Sun et al. 2002; Englund et al. 2006). 
 
2.1.2 HT-29 
HT-29 cell line was isolated from human colon carcinoma in the 1970's (Fogh et al. 1977).  
The parental cell line can undergo differentiation into enterocyte-like cell when glucose is 
replaced in the medium by galactose (Zweibaum et al. 1985). The hallmark property of this 
cell line is that some subpopulations (usually selected with methotrexate- or fluorouracil-
treatments) can differentiate in the presence of glucose and secrete mucus (Lesuffleur et al. 
1993). Indeed, the heterogeneous parental cell line was shown to consist of columnar 
epithelial cells and goblet cells by rigorous subcloning  (Huet et al. 1987). 
The differentiated monolayer takes at least three weeks to form and is somewhat leakier 
towards hydrophilic compounds than Caco-2 cells (Wikman et al. 1993). The mucus layer that 
forms on HT-29 cells is on average 50-150 µm thick but fairly non-uniform (Wikman et al. 
1993; Behrens et al. 2001). The mucus layer decreases the permeability of lipophilic 
compounds in some (Wikman et al. 1993; Karlsson et al. 1993; Behrens et al. 2001) but not 
all studies (Wils et al. 1994; Pontier et al. 2001) while hydrophilic molecules are generally 
less affected. The P-gp expression in this cell line is low (Guichard et al. 2005). 
 
2.1.3 2/4/A1 
Most intestinal cell lines are transformed since the life span of a primary enterocyte is only 
few days long (Madara and Trier 1987; Karam 1999). However, a primary fetal rat cell line 
(2/4/A1) has been conditionally immortalized with temperature-sensitive Simian virus 40 
(SV40) antigen (Paul et al. 1993). This allows the cells to proliferate undifferentiated at 
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+33°C and revert them to their original intestinal phenotype upon increase in the temperature 
up to +37°C - +39°C (Paul et al. 1993; Tavelin et al. 2003a). 
2/4/A1 cell line was brought to drug permeability studies by the Artursson's group in the 
late 1990's (Tavelin et al. 1999). This cell lines forms a monolayer faster than Caco-2 cell line 
(Tavelin et al. 1999) but is unfortunately fairly difficult to grow routinely (Per Artursson, 
personal communication). Its primary advantage over Caco-2 cells is the higher paracellular 
permeability which improves the apparent permeability (Papp) vs. fraction absorbed (FA) 
correlation at hydrophilic compounds (Tavelin et al. 1999; Tavelin et al. 2003b). In addition, 
more complex pharmacokinetic models also benefit from 2/4/A1 data (Fliszar et al. 2007). 
However, this improvement of prediction appears to be confined to passively absorbed 
compounds since endogenous transporter activities are low in 2/4/A1 cells (Tavelin et al. 
2003a).  
 
2.1.4 MDCK 
MDCK (Madin Derby Canine Kidney) cells are epithelial cells from dog kidney (Gaush et 
al. 1966). There are two types of MDCK cell lines, namely MDCKI and MDCKII, which 
differ in morphology, ion pump activity and monolayer electrical resistance (Richardson et al. 
1981). It appears that the type I strain originates from collecting tubules and type II strain 
from more proximal areas of the tubules (Richardson et al. 1981). The MDCKII strain is the 
most widely used in transport studies (Irvine et al. 1999). Similar to Caco-2 cells, MDCK 
cells can be grown on uncoated filters on which tight monolayer and polarized morphology is 
formed (Misfeldt et al. 1976). The cells are generally grown on polycarbonate membranes for 
3-5 days to obtain suitable monolayers for permeability studies (Cho et al. 1989; Irvine et al. 
1999). 
Despite its different origin, similar permeability values are obtained for several compounds 
in MDCK and Caco-2 cell lines (Irvine et al. 1999). One of the advantages of MDCK is the 
absence of endogenous human transporters and low levels of many canine transporters (Goh 
et al. 2002). This means that, in principle, this cell line can be transfected and used to study 
single transport protein action free from significant background active transport. However, 
recent kinetic analysis show that endogenous canine transporters may complicate the analysis 
of active transporter kinetics (Acharya et al. 2007). 
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2.1.5 Variability between laboratories 
Different laboratories have their own protocols for cell culture and permeability 
experiments. Therefore, it is obvious that there are interlaboratory differences in the results of 
permeability experiments (Artursson et al. 2001). Sources of this variability has been 
extensively reviewed recently (Youdim et al. 2003; Sambuy et al. 2005; Volpe 2007) and 
some key points are summarised in Table 2.2. 
 
Table 2.2: Sources of interlaboratory differences in permeability experiments. Compiled from 
(Youdim et al. 2003; Sambuy et al. 2005; Volpe 2007) 
Parameter Effect 
Factor related to cell culture 
Source of cells Role of different subpopulations 
Serum batch Induction of cells by hormones and growth factors 
Seeding density Initial cell amount dictates time to reach confluence 
Growth medium Nutrient composition affects gene expression 
Growth time Altered expression of transporters and paracellular permeability 
Feeding regimen Cells at different nutritional status when used for experiments 
Passage number Expression of transporters and monolayer tightness,  
gradual dedifferentiation as passage number increases 
Subculturing Selection of laboratory-specific subpopulation 
Filter support & coating Cellular proliferation and differentiation, multilayer formation 
Factors related to experimental setup 
Solute concentration Saturation of possible transport proteins 
Apparatus material Adsorption of molecules to surfaces 
Buffer excipients Normally affect solubility, monolayer integrity and transporter function 
Stirring The unstirred water layer affects high permeability compounds 
pH  The ionization state of electrolytes, functionality of proton coupled 
transporters 
Apparatus dimensions Unstirred water layer effects 
Factors in data analysis 
Back flux Permeability coefficient underestimated 
Mass balance Initial donor concentration lower than applied 
Time interval of flux  Not steady state flux 
Lag time  J-shaped flux curve Æ permeability coefficient underestimated 
UWL  All modest and high permeability compounds reach the same plateau 
permeability coefficient 
 
The fact that such a plethora of factors can influence the outcome of a permeability 
experiment stresses the need for rigorous standardization and use of appropriate controls in 
order to minimize interlaboratory variability (Volpe 2007). Food and drug administration 
(FDA) has released guidelines on how the in vitro permeability model should be validated 
when biopharmaceutics classification system (BCS) class I (high solubility, high 
permeability) drug molecules are studied to obtain waivers of in vivo bioavailability studies 
(FDA 2003). Intestinal cell lines are accepted for surrogates of in vivo permeability studies for 
passively transported compounds. The guidance gives 20 compounds that should be used to 
determine and validate the limits for different permeability classes in a given in vitro model. 
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Later, draft guidance on the use of in vitro permeability experiments to detect possible 
transporter interactions has been released for public commenting (FDA 2006). 
 
2.2 Modification of cell lines 
As discussed above, every cell culture model has its shortcomings. Therefore, there have 
been many attempts to develop new models and improve old ones during the past couple of 
decades. From industrial perspective, the improvement of Papp vs. FA correlation has been the 
primary interest. This goal could be achieved if paracellular space and transporter profile of 
the cell line would be similar to the in vivo epithelium. The more basic research has yearned 
for models that would express higher or lower amounts of key transporters and enzymes 
which would allow detailed mechanistic understanding epithelial permeability. All 
researchers in the field would like to reduce the required culture time and uncontrolled factors 
(e.g. changing serum batches) from culture medium.  
 
2.2.1 Establishing new cell lines 
Organotypic primary cell lines can be derived directly from the corresponding tissue 
(Freshney 2005). However, many cell types, including mature intestinal epithelial cells, are 
very short-lived (Madara and Trier 1987; Karam 1999) and, therefore, their routine culture is 
very difficult. Some primary cell lines can, spontaneously or after induction by radiation or 
carcinogenic chemicals, form continuous cell lines (Freshney 2005). Transfection of viral 
proteins, such as SV40 large T antigen, to cells is another popular method to create 
continuous cell lines (Quaroni and Hochman, 1996; Freshney 2005). This has been elegantly 
applied to create conditionally immortalized epithelial cell line by putting the SV40 antigen 
under regulatable promoter (Paul et al. 1993) which allows reversal of the immortalized cells 
to their original phenotype. However, the properties of these continuous cell lines, starting 
from chromosomal composition, tend to drift away from the properties of the original tissue. 
The downside of transforming epithelial cells is that releasing them from growth control often 
removes contact inhibition which results in multilayer formation (Freshney 2005). The mature 
enterocytes are derived from epithelial stem cells that are located in vivo in the intestinal 
crypts (Madara and Trier 1987). Rat intestinal stem cells have been shown to survive for 
several months in vitro but the proliferation rate can be slow and they often fail to 
differentiate into mature enterocytes (Quaroni et al. 1979). However, one such cell line, IEC-
18, has been successfully applied to permeability experiments (Duizer et al. 1997). Because of 
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the problems with culturing the primary cells, majority of the epithelial cell lines are derived 
from tumors (Fogh et al. 1977). 
The basic research on cell cycle has revealed mechanisms that restrict the life span of non-
transformed cells. It appears that, despite many genes take part in regulating cell life cycle, 
the shortening the tips of chromosomes (so-called telomeres) is the primary reason for 
eventual cell death (Campisi and d'Adda di Fagagna 2007). This knowledge has enabled 
rational approaches to immortalize primary cells. It has been shown that transfecting human 
telomerase into fibroblasts or retinal pigment epithelial cells delays normal senescence and 
turns these cells into continuous cell lines while retaining normal karyotype (Bodnar et al. 
1998). Epithelial cells require also the inactivation of Rb/p16INKa4 gene for immortalisation 
(Kiyono 1998). Later, telomerase transfected mammary epithelial cells that had spontaneously 
lost Rb/p16INKa4 gene could efficiently postpone their senescence (Kim et al. 2002).  Thus far, 
no attempts to immortalize intestinal cell lines with telomerase have been published. 
 
2.2.2 Subcloning  
Tumour derived cell lines are usually polyclonal and they can yield unequal subpopulations 
when cultured under different conditions (Sambuy et al. 2005). Therefore, several attempts 
have been made to derive more homogeneous cell lines from the polyclonal starting material. 
The most widely used protocol is dilution cloning in which cell suspension is heavily diluted 
and subsequently growing colonies are assumed to originate from a single cell (Freshney 
2005).  
Caco-2 subclones have been isolated in several laboratories. Altogether forty subclones 
were isolated in an early attempt to study taurocholate transport (Woodcook et al. 1991). The 
growth curves were nearly identical to parent population and differences in transepithelial 
electrical resistance (TEER) values were generally only modest. Most importantly, however, a 
clone 40 was isolated that displayed higher taurocholic acid transport than the parental cell 
line and the activity was stable at least across 20 passages. It was also pointed out that 
obtaining uniform cell lines by subcloning is not trivial since recloning the clone 40 produced 
subclones some of which lost the high transporter activity. Probably most widely studied 
Caco-2 subclone, namely TC7, was isolated based on energy metabolism (Chantret et al. 
1994). It is a high passage (P198) clone that consumes little glucose and has high sucrase 
isomaltase activity. Later, it was noted that this clone expresses high level of CYP3A mRNA 
(Carriere et al. 1994) and that the enzyme activity comes mainly from CYP3A5 protein 
(Raeissi et al. 1997). Thus, TC7 has been suggested to be a suitable model to study CYP-P-gp 
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interplay during absorption (Raeissi et al. 1999) but it does not seem to possess real advantage 
over parental Caco-2 or HT-29-MTX cells with respect to Papp vs. FA correlation (Gres et al. 
1998; Pontier et al. 2001). It has been shown that despite dramatic differences in TEER values 
between parental Caco-2 cell lines and different clones the paracellular permeability of 
mannitol is largely unaffected (Ranaldi et al. 2003) which suggests that TEER measurements 
should not be used as sole indicators of paracellular permeability. Finally, subclones of Caco-
2 cells expressing high levels of P-gp were isolated and used in kinetic studies (Horie et al. 
2003). The P-gp activity in these clones was very stable and of similar magnitude than in high 
P-gp expressing MDCK-MDR1 cell line. 
HT-29 cell line is also frequently subcloned cell line since the parental population has been 
shown to consist of both columnar and goblet cells (Huet et al. 1987). Actually, usually only 
subclones have been used for permeability studies (Wikman et al. 1993; Collett et al. 1996; 
Behrens et al. 2001). Growth speed, paracellular permeability, mucin expression and mucus 
thickness have all been shown to vary between different subclones (Huet et al. 1987; Behrens 
et al. 2001). 
As described in section 2.2.1.4, the original MDCK cell line consists of at least two major 
subpopulations with distinct properties (Richardson et al. 1981). Nakazato et al. (1989) 
obtained motile and non-motile clones that morphologically corresponded to type I and type II 
strains, respectively. Later, Gekle et al. (1994) isolated two different clones of MDCK cells 
with either high or low TEER and distinct morphologies. The subclones differed also with 
respect to ion transport and intracellular pH.  
 
2.2.3 Chemical modifications 
The final phenotype of epithelial cells in vitro depends not only on the genotype of the cells 
but also on environmental conditions. As reviewed by Sambuy et al. (2005), practically every 
change in culture conditions leads to changes in cell properties. Some of these changes can be 
understood physiologically. For example, drastic decrease in medium glucose level increases 
the need for energy and biosynthetic precursors which results in increase of sucrase 
isomaltase (Chantret et al. 1994) and peptide transporter (D'Souza et al. 2003) activities in 
Caco-2 cells. This chapter will focus on few rational modifications of culture medium that 
have a goal of improving the cell lines for drug permeability studies. 
Cytotoxic agents 
Many tumor cell lines over-express efflux pumps which renders them resistant towards 
cytotoxic agents (Borst and Elferink 2002). Therefore, chronic and increasing exposure to 
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cytotoxic agents, such as vinblastine (Hoskins et al. 1993), vincristine (Eneroth et al. 2001) or 
doxorubicin (Tran et al. 2002), has been used to create cell lines that express increased 
amounts of these efflux pumps. For instance, vinblastine selection rendered the cells very 
resistant to some (vinblastine, colchicine) but not all (methotrexate, scirpenol, 
podophyllotoxin) cytotoxic compounds (Hoskins et al. 1993) and vincristine treatment of 
Caco-2 cells increased the sensitivity of Calcein-AM uptake test which indicates induction of 
P-gp (Eneroth et al. 2001). More recent work has characterized vinblastine treated Caco-2 
cells (Siissalo et al. 2007). P-gp was shown to be the only efflux pump that is strongly 
induced in response to treatment. Resistance pattern and induction of only P-gp agree since 
vinca alkaloids and colchicines are P-gp substrates but methotrexate is not (TP-search 2004). 
Adjusting vinblastine concentrations in culture medium has been shown to produce a 
selection of Caco-2 cell populations with different levels of P-gp that are useful in 
mechanistic permeability studies (Shirasaka et al. 2006). Anderle et al. (1998) studied the 
effect of exposure of Caco-2 to various P-gp substrates on the P-gp expression and showed 
that the most toxic compounds caused the highest induction of P-gp while some substrates 
elicited no effect. The mechanism of increase in efflux pump expression in response to 
vinblastine is probably a mixture of clonal selection, gene up-regulation and chromosomal 
duplication events. Some strains lost rapidly the drug resistant phenotype when exposure was 
ceased while others remained highly resistant for a long period of time in the absence of 
vinblastine (Hoskins et al. 1993).  
HT-29 cells have also been modified by cytostatic agents. Methotrexate and fluorouracil 
treatments select subpopulations that produce more mucus than the parental cell line 
(Lesuffleur et al. 1993) which can be an advantage in permeability studies. Colchicine 
treatment has been shown to increase P-gp and decrease cystic fibrosis transmembrane 
conductance regulator expression in HT-29 cells (Breuer et al. 1993). In contrast, a more 
recent study reported strong induction in MRP1 but not in P-gp expression in response to 
colchicine which renders the cells cross-resistant to doxorubicin, vincristine and taxol (Kok et 
al. 2000). Moreover, cell membranes were enriched in glucosyl and galactosylceramides. 
Receptor activation 
Nuclear receptors, especially PXR and CAR, are key regulators of CYP enzymes and efflux 
pumps (Honkakoski 2003). Therefore, activation of nuclear receptors is a lucrative method to 
increase the expression of those genes. The Caco-2 line does not express PXR, and 
rifampicin, a strong PXR agonist, does not produce induction of endogenous genes (Pfrunder 
et al. 2003). However, the same study showed induction of MDR1 and CYP3A4 genes in 
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another colonic cell line that expresses PXR. Another study identified low amounts of a PXR 
splice variant in Caco-2 cells but this receptor variant is not capable of inducing metabolic 
genes (Gardner-Stephen et al. 2004). 
One of the most important findings in the Caco-2 research during last ten years is the 
discovery of CYP3A4 induction by 1α,25-dihydroxyvitamin D3 (Schmiedlin-Ren et al. 1997). 
Although the maximal expression of functional CYP3A4 requires several modifications of the 
culture medium, the essential component that initiates the induction is 1α,25-
dihydroxyvitamin D3. The MDR1 and CYP reductase genes were also modestly upregulated. 
Later, it was shown that this induction is caused by vitamin D receptor activation and works 
also in some other cell lines (Schmiedlin-Ren et al. 2001). However, the response to 1α,25-
dihydroxyvitamin D3 seems to be variable also in Caco-2 subpopulations since doxorubicin 
selected Caco-2 population did not respond to 1α,25-dihydroxyvitamin D3 treatments (Tran et 
al. 2002). The 1α,25-dihydroxyvitamin D3 induced Caco-2 cell lines have been successfully 
used to study first-pass metabolism of midazolam during transcellular flux (Fisher et al. 1999) 
and the CYP3A4-P-gp interplay with dual substrates indinavir (Hochman et al. 2000) and 
saquinavir (Mouly et al. 2004). 
Modified culture conditions for accelerated growth 
The time required for differentiation of Caco-2 cells (three to four weeks in the standard 
protocol for permeability experiments) has drawn attention. It is especially in the interest of 
high throughput screening laboratories to cut down the time and costs of cell cultures. At least 
two different approaches have been taken to reduce the time needed for differentiated Caco-2 
monolayers. First, there is commercially available a method based on extracellular matrix 
coated polyethyleneterephthalate filters and serum-free medium that is fortified with growth 
factors and nutrients (Chong et al. 1997). This three-day method performs similarly to 
conventional three-week method on lipophilic passively transported compounds while more 
hydrophilic drugs permeate much faster in the three day protocol (Chong et al. 1997). Another 
laboratory observed increased permeabilities also with rapidly permeating compounds (Liang 
et al. 2000). It has been shown that this model does not form multilayers despite high initial 
seeding density (Rothen-Rutishauser et al. 2000). Further modification of the procedure by 
including serum and/or sodium butyrate in the growth medium for different periods of time 
generated tighter monolayers. Prolongation of the growth time by two days considerably 
increased transporter activities (Yamashita et al. 2002). The second published protocol is 
based on uncoated polycarbonate filters and growth medium that includes a low level of 
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serum in addition to several hormones and growth factors (Lentz et al. 2000). The cells grown 
with this rapid method were clearly less differentiated than the cells grown with standard 
protocol. Passive transcellular permeability was similar, paracellular transport faster and 
active taurocholate transport slower than in the standard protocol. Comparison of the second 
rapid growth method to cell grown in standard culture medium for four days showed that 
peptide transporter (PEPT1) activity is actually higher in standard medium and that there is no 
significant difference in paracellular permeability (Bravo et al. 2004). 
 
2.2.4 Genetic modifications 
Modern molecular biology and increasing genetic information has made it possible to 
transfer genes into cells and larger organisms. This enables studying a protein function in a 
model with either increased or decreased expression level. Similarly, a single gene can be 
studied in a suitable cell line without the interference of other organotypic protein expression. 
Usually, a complementary DNA (cDNA) of the desired gene is isolated and cloned into a 
suitable expression vector. This vector is then introduced to the desired cells by chemical, 
viral or physical methods. The transgene expression can be either transient or stable 
depending on the methodology and construct used. Transient vectors do not integrate into 
genome and do not replicate with cells and, therefore, eventually dilute out. Stable vectors, in 
contrast, integrate into and replicate with chromosomes. Stable vectors usually harbor some 
drug-resistance gene which can be used to select properly transfected colonies. Therefore, 
stable transfectants are usually derived from single colonies and should display more uniform 
properties than the heterogeneous parent cell line (Colosimo et al. 2000; Recillas-Targa 
2004). However, the downside of stable transfection is that often some endogenous cellular 
processes are disturbed. This can lead to aberrant phenotype such as loss of contact inhibition 
and multilayer formation (Blum et al. 2000). In addition, time consuming selection process 
inevitably increases the passage number of the cell line. There may be a need for decreasing 
instead of increasing the expression of some genes. This can be achieved with traditional 
antisense cDNA method (Recillas-Targa 2004) or by selective down regulation by small 
interfering RNA (siRNA) technique (Morris et al. 2004). 
Transporters 
Transporters are typical proteins that have been studied in stably transfected cell lines. 
Transfection of MDR1 gene into Caco-2 cells considerably increased P-gp activity during 
permeability studies but the induction was inferior to vinblastine treatment (Döppenschmitt et 
al. 1999). Based on these results, Caco-2 cell line does not seem to be a particularly fruitful 
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model for single efflux pump gene transfections since endogenous transporter expression 
creates background active transport which can confuse mechanistic and kinetic studies. 
Moreover, induction of endogenous genes is often easier and more physiological method than 
genetic modifications. However, PEPT1 transfection to Caco-2 cells increased the transporter 
activity considerably more (Hsu et al. 1998) than upregulation by glucose deprivation 
(D'Souza et al. 2003). Therefore, transfection is a good method to increase the activity of 
those transporters that cannot be induced chemically. 
Cell lines that have low endogenous human transporter expression, such as MDCK and a 
porcine kidney cell line LLC-PK1, have drawn much attention in mechanistic transporter 
studies. They can be genetically modified to express human transporters. Initially, cell lines 
were transfected with a single transporter gene like MDR1 (Pastan et al. 1988), MRP2 (Evers 
et al. 1998), MRP1 (Evers et al. 1996), bile salt transporter ASBT (Balakrishnan et al. 2005) 
or PEPT1 (Herrera-Ruiz et al. 2004). Since any given transporter is generally expressed only 
on one side of the epithelial cells (Mizuno et al. 2003), the localization of transgene products 
is crucial for the usefulness of the model. At least the efflux pumps are generally routed to the 
correct side of the cells both in MDCK (Evers et al. 1998) and in LLC-PK1 (Evers et al. 
1996) cells. Common characteristic of all these cell lines is that the directional transport of 
transporter substrates is increased over parental cell line. Such cell lines have been utilized for 
example for elucidating that MDR1 and MRP2 but not MRP1 are important efflux pumps for 
etoposide (Guo et al. 2002). Tang et al. (2002) compared MDCK cells transfected with 
MDR1 gene to Caco-2 cells and concluded that the transfected cell line has very high 
expression. However, the actual protein in MDCK cells may differ from the intact human P-
gp which may falsify experimental kinetic parameters. A similar concern was raised on the 
possible differences in apical lipid composition between MDCK and human cells (Tang et al. 
2002). However, because high transporter expression makes the transfected cell lines very 
sensitive to substrates in permeability assays, their use for screening new chemical entities has 
been encouraged (Polli et al. 2001). 
The gradual realization that transporters are truly significant in drug absorption along with 
passive diffusion has evoked a need to study vectorial transport of compounds by multiple 
transporters (Ito et al. 2005). It is difficult to identify the transporters responsible for transport 
of compounds in Caco-2 model since many individual transporters are expressed and there is 
a lack of transporter-specific inhibitors. Therefore, models that have low basal transporter 
activity and high activity of desired transporters are clearly needed. A couple of research 
groups have created MDCK (Cui et al. 2001; Sasaki et al. 2002; Kopplow et al. 2005) and 
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LLC-PK1 (Mita et al. 2006a) cell lines that express different sets of transporters on the apical 
and basolateral membranes. It was shown that the glucuronide conjugate of an estradiol 
metabolite, taurolithocholate sulfate, pravastatin (Sasaki et al. 2002) and several 
unconjugated/conjugated bile salts (Mita et al. 2006a) require transporters on both apical and 
basolateral membrane for efficient transepithelial transport. One double-transfected MDCK 
cell line was used to study the hepatic disposition mechanisms of enalapril together with in 
vivo liver perfusions and single transfected cells (Liu et al. 2006). The primary efflux pump 
appeared to be MRP2 but more than one OATP isoform was associated with hepatic uptake of 
enalapril. Another study used a double-transfected LLC-PK1 cell line to elucidate the mode of 
action of several known cholestatic drugs (Mita et al. 2006b). Some of these drugs increased 
the intracellular concentration of taurocholate by inhibiting only the efflux pump but others 
even decreased the intracellular bile acid level. Finally, transport data from double-transfected 
MDCK cells has been utilized to create a simulation model of transcellular transport based on 
differential equations (Bartholome et al. 2007). The analysis showed numerically that the 
highly expressed apical and basolateral transporters were the predominant rate-determining 
proteins in the system. However, endogenous transporters played a minor but significant role 
despite these transporters are often ignored in interpretation of MDCK studies. 
Metabolic enzymes 
In addition to transporters, a lot of attention is paid to CYP enzymes in the intestinal 
epithelium. As discussed in section 2.1.1, these enzymes are poorly expressed in many 
epithelial cell lines. Caco-2 cells have been transfected with extra-chromosomal CYP3A4 or 
CYP2A6 vectors (Crespi et al. 1996). Both of the genes showed basal activity that could be 
increased with a phorbol ester. Sodium butyrate also increased CYP activity but it was 
detrimental to the monolayer properties. The major problem with this cell line harbouring the 
extrachromosomal vector is its long-term stability which was, according to the manufacturer, 
the reason for withdrawal of the Caco/CYP3A4 cell line from the market (Kaisa Niemi, BD 
Biosciences, personal communication). Later, the issue of declining enzyme expression was 
improved by DNA methylase inhibitors (Hu et al. 1999). The same study reported also that 
CYP3A4 activity in Caco-2 cells is not limited by endogenous CYP oxidoreductase since its 
co-transfection did not increase CYP3A4-mediated activity. Similar to 1α,25-
dihydroxyvitamin D3-treated Caco-2 cells (see section 2.2.3.2), Caco-2 cells transfected with 
CYP3A4 have been successfully used to study the interplay of CYP enzymes and efflux 
pumps at the intestinal epithelium (Cummins et al. 2002). Later, transient CYP3A4 
transfections were made also to MDCK and LLC-PK1 cells (Crespi et al. 2000) which proved 
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to be better platforms than Caco-2 cells for CYP3A4 with respect to expression level and 
stability. 
Regulatory genes 
The discovery of nuclear receptors as key regulators of gene expression has been used in 
chemical modifications as described in section 2.2.3.2. The low endogenous PXR level in 
Caco-2 cells (Pfrunder et al. 2003) has resulted in a novel strategy of cell modification. 
Transfection of human PXR and HNF4 genes transiently into Caco-2 cells increased modestly 
expression of a reporter gene construct under CYP3A4 promoter control (Tirona et al. 2003). 
However, addition of rifampicin, a strong PXR activator to growth medium elicited 20-fold 
induction of reporter gene expression while no change was observed in untransfected cells.  
Knockdown models 
Selectively knocking down endogenous genes is a potential alternative to produce cell lines 
with decreased transporter expression (Tian et al. 2005). MDR1 gene has drawn a lot of 
interest in drug research and, therefore, several attempts to make Caco-2 cell lines deficient in 
P-glycoprotein have been taken. The first attempt was made using traditional antisense 
technique (Hilgendorf et al. 2005). The decrease in P-gp transcription and activity was indeed 
reduced. However, there were big intercolony differences and P-gp could not be completely 
removed. Two different groups have used the more modern siRNA technology to reduce P-gp 
activity in Caco-2 cells. Celius et al. (2004) generated stable siRNA-producing colonies some 
of which showed up to 96 % decrease in MDR1 mRNA expression while some 
immunoreactive protein remained. There were significant changes in transport parameters for 
several P-gp substrates but complete abolishment of P-gp activity was not achieved. It was 
speculated that the remnant polarization may be due to residual P-gp or to other efflux 
proteins. The other siRNA study reported stable Caco-2 cell lines which had completely lost 
both MDR1 mRNA and the resulting P-gp expression (Watanabe et al. 2005). More 
importantly, the polarisation normally observed with digoxin, vincristine, rhodamine-123 and 
daunomycin transport was completely abolished. This cell line was later used in a study that 
correlated P-gp expression to kinetic transport parameters (Shirasaka et al. 2007). It was 
observed that there was still some residual P-gp activity at low substrate concentrations. 
Other transporter genes have been silenced as well. Vavricka et al. (2004) decreased the 
expression of PEPT1 in Caco-2 cells. This resulted in reduced uptake of muramyl peptide 
decreased its access to intracellular effector site and, thus, the pharmacological response. The 
expression of type 2 L-amino acid transporter could be specifically reduced in LLC-PK1 cells 
with siRNA technology (Soares-Da-Silva et al. 2004). The movement of L-dopa across cell 
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membrane was greatly reduced in knockout cells and the results helped to quantify the 
relative importance of type 2 L-amino acid transporter in L-dopa transport. 
 
2.2.5 Co-culture 
Since the intestinal epithelium consists of several cell types (Madara and Trier 1987), there 
have been some attempts to simulate this non-homogenous epithelium by co-culturing 
different types of intestinal cells. The most typical combination has been Caco-2 and HT-29. 
This is rational since Caco-2 resembles the absorptive enterocytes and HT-29 can be steered 
into mature goblet cells. Tight junctions do form between these two cell lines and no 
multilayer formation was observed in one of the earliest works (Wikman-Larhed and 
Artursson 1995). The paracellular permeability of the co-culture was an intermediate between 
the Caco-2 and HT-29 monocultures. The culture medium required for adequate growth of 
both cell lines did not support mucus production from HT-29 cells in co-culture. A more 
recent study using a different HT-29 strain reported that co-cultures have higher paracellular 
and lower active permeability properties than pure Caco-2 monolayers (Hilgendorf et al. 
2000). This study found culture conditions in which mucus was secreted and spread over 
whole monolayer albeit not at uniform thickness. This mucus layer, however, did not elicit 
significant changes in permeability of model compounds through co-cultured monolayers. A 
recent study pursued a more reproducible co-culture model by omitting serum from the 
growth medium (Nollevaux et al. 2006). The conclusions on paracellular permeability were 
essentially similar to those in previous works (Wikman-Larhed and Artursson 1995; 
Hilgendorf et al. 2000). 
Drug bioavailability after an oral dose is not solely dependent on permeability through the 
intestinal epithelium but also on the first-pass extraction in the liver. A perfusion apparatus 
has been constructed where drug molecules have to absorb through Caco-2 cells and are 
subsequently exposed to liver cell line HepG2 (Brand et al. 2000). Because the experimental 
setup was rather complex, an attempt was made simplify the experiment by co-culturing 
Caco-2 cells on filters and a liver cell line on the bottom of basolateral chamber of regular 
Transwell® apparatus (Choi et al. 2004). The model was initially applied to toxicity studies of 
benzo[a]pyrene and caffeine. It was observed that Caco-2 cells could metabolize 
benzo[a]pyrene and protect HepG2 cells but caffeine passed rapidly through the monolayer 
and caused toxicity. The in vivo area under the time vs. concentration curve (AUC) category 
of over twenty drug molecules was successfully predicted with Caco-2 and human hepatocyte 
co-culture system (Lau et al. 2004a). 
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2.3 Unstirred water layer 
Normally, the concentration of a solute is uniform in a stirred vessel if no net inward or 
outward movement of the solute is happening. However, if solute exits or enters through a 
wall, a concentration gradient can form in the very vicinity of the surface. This is caused by 
the fact that the solvent speed next to the surface is considerably less than in the bulk solution. 
Therefore, rapidly exiting molecule has to move the last hundreds of micrometers by diffusion 
rather than by convection. A concentration gradient is then formed in this so-called unstirred 
water layer (UWL) (Fig. 2.1) which effectively acts as a permeability barrier (Barry and 
Diamond 1984). UWL is not a sharp edged but rather a diffuse zone where the concentration 
gradually increases from the surface value to the bulk value. The apparent unstirred water 
layer thickness (h) is defined by Eq. 2.1 (Pedley 1983) 
 
h
CC
dx
dC sb −=                          (Equation 2.1) 
 
Where Cb and Cs are solute concentrations at homogenous bulk solution and next to the 
surface, respectively. This is depicted as the tangential line in Fig. 2.1. The apparent thickness 
of the UWL depends on viscosity of the solvent, size of the molecule (diffusion coefficient) 
and the permeability speed across the wall. The solutes having higher wall permeability 
should face thicker apparent UWL resistance since the concentration next to the surface is 
lower than with low permeability compounds (Pohl et al. 1998). The hallmark property of 
UWL is that its thickness can be lowered by increasing agitation but never completely 
abolished.  
Small intestine can be considered a vessel which has a certain UWL on its surfaces 
(Strocchi and Levitt 1991). Moreover, intestinal epithelium is covered with mucus (Neutra 
and Forstner 1987) which may form a permeability barrier since the diffusion of some 
molecules is slower in purified mucus than in water (Larhed et al. 1998). The apparent UWL 
thickness in the intestine was originally assumed to be as high as 600 µm (Read et al. 1977; 
Harris et al. 1986). However, studies that yielded such results were done under non-
physiological conditions. It has been later shown that the peristaltic movements of the 
intestine of awake animals (Anderson et al. 1988) and humans (Levitt et al. 1990) effectively 
reduce the apparent unstirred water layer to considerably less than 100 µm. This might 
actually represent the intestinal mucus layer since rat jejunum has been reported to have a 
mucus layer of about 100 µm of which 20 µm is  firmly attached and cannot be removed  
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physically (Atuma et al. 2001). Further evidence of negligible UWL resistance in vivo was 
seen in human perfusion studies where neither the perfusate flow rate nor aqueous diffusion 
coefficient influenced the absorption rate of rapidly absorbed compounds glucose and 
antipyrine (Fagerholm and Lennernäs 1995). Therefore, it has been concluded that the UWL 
does not play a clinically significant role in intestinal absorption of drugs (Lennernäs 1998). 
 
 
Figure 2.1: A schematic picture of the effect of unstirred water layer in membrane 
permeability experiments. Solid line depicts the solute concentration profile of a rapidly (a) 
and slowly (b) permeating compound during steady state membrane permeation. Dashed line 
shows the concept of apparent UWL thickness calculation. Cb is bulk concentration, Cs is 
surface concentration, h1/2 is apparent UWL thickness on different sides of the membrane. 
Compiled from (Pedley 1983; Barry and Diamond 1984; Pohl et al. 1998). 
 
 
2.3.1 The impact of UWL on results of permeability experiments 
Barriers to permeability have each a certain resistance (R) which is a reciprocal of 
permeability (P) (Eq. 2.2). If these barriers are in series, the resistances can be summed up to 
yield the total resistance (Eq. 2.3) which can be expressed also as permeabilities (Eq. 2.4) 
(Topp 1999). 
 
P
R 1=                          (Equation 2.2) 
321 RRRRtotal ++=                          (Equation 2.3) 
321
1111
PPPPtotal
++=                         (Equation 2.4) 
 
The unstirred water layer can be remarkably thick in in vitro permeability apparatuses 
(Karlsson and Artursson 1991). The primary observation is that the apparent permeability 
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coefficient of molecules that have rapid transcellular movement, e.g. testosterone (Karlsson 
and Artursson 1991), is highly dependent on the stirring rate in in vitro permeability assays. If 
the contribution of UWL is ignored, moderately and rapidly permeating compounds have 
similar apparent permeability values and the Papp vs. FA correlations become weaker (Youdim 
et al. 2003) 
Another consequence of the UWL is the apparent increase of Km values of transporter 
substrates while the ultimate achievable Vmax remains unaltered (Wilson and Dietschy 1974). 
The kinetic parameters are determined based on the bulk donor concentrations. However, the 
UWL causes the surface concentration to be lower than the bulk concentration. The 
concentration at the transporter interaction site is lower than expected and the apparent 
affinity is therefore lower than the true affinity. This has been observed in permeability 
studies with both intestinal segments (Wilson and Dietschy 1974) and cell lines (Balakrishnan 
et al. 2007). Winne (1977a) derived equations that can be used to calculate the true Km value 
provided that the dimensions of the UWL are known. 
The unstirred water layer causes a notable effect on also on the pH-dependent passive 
permeability of acids and bases (Winne 1977b). According to traditional pH partition theory, 
only unionised molecule can passively traverse the cell membranes. Therefore, a plot of pH 
vs. Papp should show the half maximal permeability at pKa value. The UWL, however, is 
equally permeable to ionized and unionized forms and has two effects on the curves (Fig 2.2). 
First, the maximal obtained permeability is reduced. Second, the pKa is shifted to values 
where the ionization degree is lower, sometimes denoted as pKa
flux (Avdeef 2003). 
 
 
Figure 2.2: The effect of unstirred water layer on the pH-dependent apparent permeability of 
acids (a) and bases (b) both having true pKa of 7. The membrane permeability was set 400 on 
arbitrary scale. PUWL was given an arbitrary value of 200 (dashed line), 400 (dotted line) or 
1000000 (solid line). UWL decreases the maximal obtainable permeability and shifts the pH 
at which half maximal Papp is reached. 
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2.3.2 Methods to determine UWL thickness  
Because the UWL is a considerable permeability barrier in vitro but not in vivo, its effect 
must be taken into account when in vitro-in vivo correlations are considered. For some ideal 
and symmetrical geometries it may be possible to derive an analytical solution to UWL 
(Pedley 1983). However, normal apparatuses and in vivo situations are far from ideal 
hydrodynamics and, therefore, several experimental methods have been described to estimate 
the thickness of the UWL. It is noteworthy that the following methods yield the total UWL 
thickness which contains both h1 and h2 of the Fig. 2.1. Therefore, possible asymmetries in 
hydrodynamics cannot be directly quantified. 
The earliest method was based on following the build-up or decay of concentration gradient 
in the UWL (Diamond 1966). The method is applicable mainly to small ions that cause 
changes in transmembrane potentials which can be measured rapidly and accurately. The time 
to reach the steady state is measured and the thickness of the UWL can then be calculated 
from half-life of potential change by Eq 2.5  
 
D
hat
2
2/1
×=                          (Equation 2.5) 
 
where a is a proportionality constant, h is the thickness of the UWL and D is the aqueous 
diffusion coefficient. 
The shift in apparent Km can be also utilized to determine the UWL thickness. Levitt et al. 
(1992) analyzed the data from publications describing the hydrolysis rate of disaccharides in 
human intestines. The key idea was that access of substrates to the brush border 
disaccharidases is rate limited by UWL. When the apparent and true kinetic parameters are 
known, Eq. 2.6 can be used to determine the UWL thickness. 
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where D is aqueous diffusion coefficient, Km,app/true is the apparent/true Km, Vmax/cm
2 is the 
maximal activity per square centimetre. The usefulness of this approach is limited by the fact 
that it requires the true Km of the transporter which is difficult to determine. 
The previous two methods are rarely if ever used in modern pharmaceutical in vitro 
permeability experiments. Instead, there are two basically very simple methods that have been 
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used in in vitro permeability assays. First, Yu and Sinko (1997) measured the permeability of 
compounds through a bare filter and calculated the apparent UWL permeability using Eq. 2.4 
by subtracting the filter resistance from the observed total resistance. This method suffers 
from the fact that the absolute filter permeability is not known but calculated theoretically. In 
addition, filter without a cell monolayer lets water through easily which may cause convective 
transport which is absent in filters with cells. Another way of estimating UWL thickness is to 
measure the permeability of a rapidly absorbed compound (e.g. testosterone) and assume that 
the passage through cell monolayer is so rapid that only UWL contributes to the observed 
permeability (Hilgers et al. 1990). This approach is also common in in vivo perfusion 
experiments to determine UWL thickness (Levitt et al. 1990). The problem is that if cells 
and/or filter cause some resistance to the total permeability the UWL permeability will be 
overestimated. 
UWL thickness can be analyzed by conducting the permeability experiments at various 
stirring rates (Karlsson and Artursson 1991; Adson et al. 1995). This is based on the idea that 
the UWL permeability can be related to the stirring rate by Eq. 2.7 
 
αvKPUWL ×=                         (Equation 2.7) 
 
where K is a constant incorporating diffusivity, viscosity and geometric factors, v is the 
stirring rate and α is a stirring exponent reflecting hydrodynamics. Permeability coefficients 
are determined at several stirring speeds (rpm in orbital shaking, ml/min in gas bubbling) and 
1/Papp is plotted against 1/v
α. Eq. 2.8 defines the straight  
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where Pc is the permeability of the cell monolayer and Pf is the permeability of the filter 
support. Now, 1/K can be read from the slope and the y-intercept contains both cellular and 
filter resistances. The PUWL can then be calculated at any given stirring rate with Eq. 2.7. 
Originally, α term was omitted (α=1) and the data could be fitted well when orbital shaking 
was used (Karlsson and Artursson 1991). Another study using slightly different experimental 
setup obtained best fittings with α value of 0.8 (Adson et al. 1995). The latter study suggested 
that α could be considered as an indicator of stirring efficiency in such a way that a smaller 
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value would indicate better stirring. The advantage of this method is that it can, in principle, 
be applied to various apparatuses and it yields an estimate for cellular permeability. However, 
it has been pointed out that, as the filter permeability is the highest possible apparent 
permeability value, this method cannot detect differences in Pc at high values (Avdeef et al. 
2005). In addition, it is possible that the UWL in all geometries does not fit into Eq. 2.7. 
Finally, a method that is based on the shift of the apparent pKa value of acids and bases can 
be utilized to determine the UWL permeability (Winne 1977b; Avdeef 2003). The 
permeability experiments are conducted at the same stirring rate at several pH values and the 
resulting Papp vs. pH data is treated with Eq. 2.9, 2.10 or 2.11 
 
 
uuUWLapp PfPP ×
+= 111                         (Equation 2.9) 
 
where fu the fraction unionized calculated by the Henderson-Hasselbach equation and Pu is the 
cell/membrane permeability of unionized form of a compound. This is applicable to 
membranes through which only unionized molecules can traverse (e.g. parallel artificial 
membrane permeability assay, PAMPA) and can be simplified to Eq. 2.10 (Avdeef 2003) 
 
( )fluxUWLu pKapKaPP −±=− loglog                      (Equation 2.10) 
 
where pKa
flux is the pH at half maximal permeability. PUWL is the maximal permeability 
extrapolated from graphical representation of the Papp vs. pH data (Fig. 2.3)   
This pKa shift methodology has been applied also to Caco-2 experiments (Avdeef et al. 
2005). Here, the terms to account for permeability of unionized form across the cell 
monolayer and the filter permeability were added to yield (Eq. 2.11) 
 
filteriiuuUWLapp PPfPfPP
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Figure 2.3: Application of pH shift methodology to permeability experiments. Circles are 
individual observations (simulated Pu=10000, PUWL=100 and pKa=7.0, <±15% random error 
added). The dashed heavy line is the graphical fitting to this data. pKa
flux can be determined at 
the intersection of dotted lines and PUWL at the maximal extrapolated value (region where the 
compound is completely unionized and UWL is the predominant permeability resistance). 
Hence, log Pu - log 100 = (7-5) Æ Pu = 10000. Solid curve represents the permeability profile 
in the absence of UWL. 
 
pH vs. Papp methodology is a very robust way of determining the UWL and cell monolayer 
permeabilities. Because it relies on change in ionization degree rather than stirring conditions, 
it can produce remarkably high intrinsic monolayer permeability values in cellular studies 
(Avdeef et al. 2005). 
 
2.3.3 Apparatuses to control UWL in permeability assays 
Efficient stirring remains an issue in both low and high throughput permeability 
experiments. Very good stirring, ease of sampling and liquid handling, suitability for cell 
cultures, costs and labour intensity cannot all be optimized. Therefore, several apparatuses are 
constructed for permeability experiments. 
The most common platform for cell based permeability assays is the Transwell® type of 
apparatus (Fig 2.4). There plates with 6-24 filters are seeded with cells and maintained until 
the monolayer is ready. The actual experiment is conducted usually on an orbital shaker. The 
advantage is that cell culture is relatively easy and filters can be easily transferred to clean 
receiver plates for experiments. Moreover, there is vast amount of literature data available. 
The problem is usually the small chamber size and inefficient stirring. In addition, not all 
orbital shakers have similar rotatory movement and investigators very often neglect reporting 
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the stirring rate used. Therefore, there is still clearly need for permeability apparatuses with 
better hydrodynamics.  
 
 
Figure 2.4: A typical Transwell® type of apparatus. Cell monolayer is grown on a filter that 
separates the apical and basolateral chambers. 
 
Permeability experiments can also be conducted in a side-by-side apparatus (Fig. 2.5). This 
has the advantage of higher chamber volumes and efficient stirring but the throughput is low. 
 
 
Figure 2.5: A schematic presentation of the side-by-side apparatus. 
 
A more sophisticated apparatus (Fig. 2.6) was constructed by Hidalgo et al. (1991). Cells 
can be grown in Transwell® type of filters and mounted on the apparatus for experiments. The 
actual stirring is obtained by adjusting O2/CO2 flow through the apparatus. This apparatus 
gives a thinner UWL than the orbitally shaked Transwell® plate (Karlsson and Artursson 
1992). However, the throughput is probably even lower than with side-by-side apparatus. 
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Figure 2.6: The permeability apparatus based on gas lift stirring. (Figure 1 from: Hidalgo IJ, 
Hillgren KM, Grass GM, Borchardt RT: Characterization of the unstirred water layer in Caco-
2 cell monolayers using a novel diffusion apparatus. Pharm Res 8: 222-7, 1991 with kind 
permission from Springer Science and Business Media). 
 
Recently, an efficient stirring apparatus based on rotating discs (Fig. 2.7.) was described 
(Avdeef et al. 2004). Often, a strong double sink with proper pH and detergents is applied into 
receiver compartment. This prevents the backflux and abolishes the effect of receiver 
compartment UWL. Experimental UWL thickness can be reduced down to about 10 µm using 
stirring rate of 622 rpm. The clear advantage of this apparatus is the controllable UWL 
thickness and, since it comes in 96-well format, also throughput is good. The downside is that 
it is patented and comes from one supplier so the costs are higher than in other apparatuses. 
Originally, it was developed for PAMPA experiments. Later, the apparatus has been modified 
by applying similar stirring to the upper compartment and constructing suitable filters for cell 
growth (Alex Avdeef, personal communication). 
 
Figure 2.7: A novel stirring apparatus based on rotating discs. (Figure 1 from: Avdeef A, 
Nielsen PE, Tsinman O: PAMPA-a drug absorption in vitro model; 11. Matching the in vivo 
unstirred water layer thickness by individual-well stirring in microtitre plates. Eur J Pharm Sci 
22: 365-74, 2004 with kind permission from Elsevier). 
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3 AIMS OF THE STUDY 
The general objective of this study was to improve the predictive value of in vitro 
permeability experiments by modifying the Caco-2 cell line and Transwell® hydrodynamics. 
The specific aims were: 
 
1. To develop genetically modified Caco-2 cells that stably express nuclear receptors 
hPXR and mCAR and to compare their properties to wild type cells and several 
previously described cell lines 
2. To study in detail the functionality of the transfected nuclear receptors in the Caco-2 
cell line. 
3. To use the modified cell lines to determine apparent kinetic transport parameters of P-
glycoprotein substrates 
4. To improve hydrodynamics in Transwell® apparatus by a novel magnetic stirrer and to 
use it to elucidate the asymmetry of Transwell® hydrodynamics. 
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4 ABSORPTION PROPERTIES AND P-GLYCOPROTEIN ACTIVITY 
OF MODIFIED CACO-2 CELL LINES* 
 
Abstract. Caco-2 cell line is extensively used as an in vitro model in studying small intestinal 
absorption but it lacks proper expression of efflux pumps and cytochrome P450 enzymes that 
are involved in absorption and first pass metabolism of drugs. We created two novel Caco-2 
cell lines expressing orphan nuclear receptors pregnane X receptor and constitutive 
androstane receptor that regulate many genes involved in xenobiotic metabolism. We 
conducted a systematic study on expression of some metabolic genes, P-glycoprotein activity 
and absorption properties of several drugs with these new cell lines and previously described 
modified Caco-2 cell lines (MDR1 transfection, vincristine treatment and 1α,25-
dihydroxyvitamin D3 treatment). A short culture time medium was also included in the study. 
Most modified cell lines formed tight differentiated monolayers. MDR1, CYP2C9 and 
CYP3A4 genes were upregulated in some cell lines. Elevated P-glycoprotein activities were 
observed by calcein-AM uptake experiments but this did not affect significantly the 
permeability of selected P-glycoprotein substrates. Some cell lines had similar passive and 
active permeability properties to Caco/WT cells while in few cell lines these were altered. 
Passive transcellular permeability was modestly elevated in all modified cell lines. In 
addition, several compounds showed pH-dependent permeability properties. 
 
 
 
 
 
 
 
 
 
 
 
* Adapted from: Korjamo T, Honkakoski P, Toppinen MR, Niva S, Reinisalo M, Palmgren 
JJ, Mönkkönen J: Absorption properties and P-glycoprotein activity of modified Caco-2 cell 
lines. Eur J Pharm Sci 26: 266-279, 2005 with kind permission from Elsevier. 
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4.1 Introduction 
The majority of orally administered drugs are absorbed in the small intestine. During 
absorption process the drug molecules interact with oxidizing cytochrome P450 (CYP) 
enzymes and ATP-driven efflux pumps of the ATP binding cassette transporter (ABC) family 
that are expressed in the small intestinal epithelium (Suzuki and Sugiyama 2000). These 
proteins may lead to reduced bioavailability of drugs by metabolising them and pumping 
them back to the intestinal lumen from the enterocytes. A cell line expressing both CYP 
enzymes and ABC transporters at high levels would be a valuable in vitro tool for studying 
drug absorption across the intestinal epithelium. 
Our aim in the present study was to increase the CYP and efflux pump activities by 
transfecting Caco-2 cells with pregnane X receptor (PXR; NR1I2) and constitutive androstane 
receptor (CAR; NR1I3) genes. These orphan nuclear receptors have been found to regulate 
co-ordinately the expression of many metabolic genes in response to several xenobiotic and 
endogenous compounds in mice (Maglich et al. 2002; Rosenfeld et al. 2003) and in man 
(Synold et al. 2001). Nuclear receptors bind to certain DNA elements in the promoter regions 
of their target genes in response to ligands. They recruit co-activators and enhance mRNA 
synthesis of the target genes but can also repress transcription by recruiting corepressors 
(Aranda and Pascual 2001). Known target genes for both PXR and CAR include MDR1, 
MRP2, CYP2B6, CYP2C9 and CYP3A4 (Honkakoski 2003). Thus, in principle, many efflux 
pump and CYP genes may be regulated by transfecting only one gene.  
Previous attempts in increasing drug metabolism and efflux in Caco-2 cells have been 
focusing on modifying the activity of only a single gene product. As a result, several modified 
Caco-2 cell lines have been introduced. Transfection of Caco-2 cells with MDR1 cDNA has 
been shown to increase verapamil binding and decrease the apical-to-basolateral transport of 
quinidine and talinol (Döppenschmitt et al. 1999a). 1α,25-dihydroxyvitamin D3 can induce 
functionally active CYP3A4 expression in Caco-2 cell lines (Schmiedlin-Ren et al. 1997) 
presumably via binding of vitamin D receptor to PXR responsive elements of CYP3A4 
promoter (Mäkinen et al. 2002; Drocourt et al. 2002). Culturing Caco-2 cells in the presence 
of vincristine increases P-glycoprotein activity which has been determined by calcein-AM 
extrusion assay (Eneroth et al. 2001). Cytotoxic vinca alkaloids are substrates of P-
glycoprotein and prolonged exposure to vincristine leads to proliferation of only resistant 
subpopulations that express P-glycoprotein well (Hoskins et al. 1993). Also a modified 
culture medium that accelerates the differentiation of Caco-2 cells has been developed (Lentz 
et al. 2000). Individual cell lines have been characterised to some degree but a systematic 
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comparison is still lacking. Therefore we studied the gene expression and transport properties 
of the modified Caco-2 cell lines (Table 4.1). 
 
4.2 Materials and methods 
 
4.2.1 Chemicals 
Unlabelled molecules were either from Sigma (St. Louis, MO), MP Biomedicals (Irvine 
CA), Calbiochem (La Jolla, CA) or BD Gentest (Franklin Lakes, NJ).. Tritium labeled 
compound were bought from Perkin-Elmer (Boston, MA) or American Radiolabelled 
Chemicals (St. Louis, MO). 1α,25-dihydroxyvitamin D3 was from Leo Pharma (Denmark). 
 
4.2.2 Cell lines and culture conditions 
Caco/WT.  Caco-2 cells (ATCC HTB-37) were obtained from American type culture 
collection (Manassas, VA). All cell culture reagents were from Bio-Whittaker (Belgium) 
except foetal bovine serum (HyClone, Belgium). Cells were grown in flasks (Nunc, Denmark) 
at +37°C in 93% air / 7 % CO2 atmosphere and subcultured twice a week. Standard growth 
medium was Dulbecco’s modified Eagle’s medium (BE12-604F) supplemented with 10 % 
heat inactivated foetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml 
streptomycin and 1 x non-essential amino acids (BE13-114E). Caco/WT cells were used 
between passages 39-52. All modified cell lines are presented in Table 4.1. 
 
Table 4.1: The cell lines used in this study. 
Cell line Modification Rationale 
Caco/WT Wild type cells Control cell line 
Caco/hPXR 
Transfection with human pregnane X 
receptor 
PXR regulates metabolic genes 
(Honkakoski, 2003) 
Caco/mCAR 
Transfection with murine constitutive 
androstane receptor 
CAR regulates metabolic genes 
(Honkakoski, 2003) 
Caco/MDR 
Transfection with human P-glycoprotein 
(Döppenschmitt et al. 1999a) 
Increased expression of P-
glycoprotein 
Caco/VD3 1α,25-dihyroxyvitamin D3 in growth 
medium (Schmiedlin-Ren et al. 1997) 
Increased expression of 
CYP3A4  
Caco/VCR 
Vincristine in growth medium (Eneroth et 
al. 2001) 
Increased expression of P-
glycoprotein 
Caco/4d 
Modified growth medium (Lentz et al. 
2000) 
More rapid differentiation 
 
Transfected cell lines. Genetically modified cell lines were produced by transfecting Caco-
2 wild type cells with appropriate cDNA ligated into pCI-neo-plasmid (Promega, Madison, 
WI). Full length cDNAs of human pregnane X receptor (hPXR (Lehmann et al. 1998)), 
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murine constitutive androstane receptor (mCAR (Honkakoski et al. 2001)) or P-glycoprotein 
(MDR1 (Schinkel et al. 1993)) were cloned under CMV promoter and the vector contained 
neo selection cassette. Polyethyleneimine 25 (Sigma, St. Louis, MO) was used as DNA 
carrier in transfections. For selection, growth medium that was supplemented with 2 mg/ml 
G418 (Calbiochem, La Jolla, CA) was used. Proliferating colonies were picked and grown 
further. The best colonies were selected first by RT-PCR of the transfected gene and 
subsequently with transient transfection of PXR or CAR responsive reporter plasmids 
(Mäkinen et al. 2002). The stability of transfections was ensured by culturing the cells in the 
presence of 0.6 mg/ml G418. Passages were counted from colony picking and were 15-21, 21-
36 and 11-23 for Caco/MDR, Caco/hPXR and Caco/mCAR, respectively. 
Chemical modifications. Vitamin D treated cells (Caco/VD3) were obtained from wild type 
cells by supplementing the standard growth medium with 250 nM 1α,25-dihydroxyvitamin D3 
at various time points (Schmiedlin-Ren et al. 1997). Vitamin D3 was added to the cells after 8 
days when grown on filters (permeability experiments) and after 2 days when grown on 96-
well plates (calcein-AM experiments). To obtain vincristine treated cells (Caco/VCR), wild 
type Caco-2 cells were grown in the standard growth medium supplemented with 10 nM 
vincristine sulfate for 8 passages. Thereafter, the concentration of vincristine was elevated to 
25 nM (Eneroth et al. 2001). Caco/VCR cells were used between passages 75-91. Wild type 
cells were also grown on filters with a special short culture time medium that allows rapid 
differentiation and monolayer formation (Caco/4d). The method was adapted with minor 
modifications form Lentz et al. (2000). Short culture time medium was DMEM/F12 (Gibco 
BRL, Gaithersburg, MD) containing 2 % iron supplemented calf serum, 10 µg/ml insulin, 10 
µg/ml transferrin, 10 nM dexamethasone, 50 ng/ml epidermal growth factor, 50 µg/ml 
ascorbic acid, 25 ng/ml cholera toxin, 50 µg/ml endothelial cell growth supplement (all from 
Sigma, St. Louis, MO) and 1 mM sodium butyrate (Calbiochem, La Jolla, CA) 
Filters. For permeability experiments, 82000 cells/cm2 were seeded onto uncoated 
polycarbonate filters (pore size 0.4 µm, area 1.1 cm2; Costar, Corning, NY) and grown for 21 
days. The volumes of apical and basolateral chambers were 0.5 and 1.5 ml, respectively. The 
medium was changed three times a week and always on the day before the experiment. 
Standard growth medium was used for Caco/WT, Caco/hPXR , Caco/mCAR, Caco/MDR and 
Caco/VCR cells. For Caco/VD3 cells the standard medium was supplemented with 250 nM 
1α,25-dihydroxyvitamin D3 on day 8 (Schmiedlin-Ren et al., 1997). Caco/4d were obtained 
by seeding wild type cells at density of 360000 cells/cm2 onto filters and using 0.2 ml of 
DMEM/F12 in the apical and 1.5 ml of short culture time medium in the basolateral chamber. 
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The medium was changed after 2 and 3 days and the monolayer was used for experiments 
after 4 days. 
 
4.2.3 Alkaline phosphatase activity 
Alkaline phosphatase (EC 3.1.3.1) is an enzyme that is present in the microvillus of 
enterocytes and commonly used as an indicator of enterocytic cell differentiation (Paul et al. 
1993). Cells grown in filters were washed with and scraped into cold PBS and lysed in 0.05 
M Tris-HCl pH 9.8  – 1 % Triton X-100 by repeating freeze/thaw cycle (liquid 
nitrogen/+37°C) five times. Total protein content of the supernatant was determined using 
Serva Blue G (Serva GmbH, Germany) dye and bovine serum albumin standards (Sigma, St. 
Louis, MO). The reaction mixture contained 0.05 M Tris – HCl pH 9.8, 2 mM MgCl2 and 1 
mM phosphatase substrate (Sigma, St. Louis, MO). Samples and standards (Sigma, St. Louis, 
MO) were incubated at +37°C for 15 minutes and the reaction was terminated with 0.1 M 
NaOH. Absorbance was measured at 405 nm with VICTOR2 (Wallac, Finland). The results 
are expressed as alkaline phosphatase activity per µg total protein. 
 
4.2.4 Quantitative RT-PCR 
The expression levels of MDR1 (multidrug resistance protein 1), MRP2 (multidrug 
resistance associated protein 2), BCRP (breast cancer resistance protein) and cytochrome 
P450 isoforms CYP2B6, CYP2C9 and CYP3A4 were measured by quantitative RT-PCR and 
normalized to β-actin. The primers and probes are presented in Table 4.2. Total RNA was 
isolated, treated with DNase, reverse transcribed and subjected to quantitative RT-PCR 
reaction (see Table 4.2 for details). The results were calculated according to comparative Ct-
method assuming equal amplification efficiencies of 2 and normalized to β-actin mRNA. 
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Table 4.2: Quantitative PCR primers and probes. 
Gene  Sequence Forward primer TaqMan probe Reverse primer 
MDR1 NM_000927 
gatcacaagcccaag
acaga 
ttagtaccaaagaggctct
ggatgaaagtatacc 
caacaaaataaggcc
attcagt 
MRP2 NM_000392 
acatctgccattcgaca
tga 
caattttgacaaagccatg
cagttttctga 
ccaggttcacatctcg
gact 
BCRP NM_004827 
caggactcaatgcaac
aggaaa 
ccttgtaactatgcaacat
gtactggcgaagaa 
agatcgatgccctgctt
tacc 
CYP2B6 NM_000767 
gacttcgggatgggaa
agc 
cttcggaaatccaagggg
gc 
tggcggtaatggactg
gaa 
CYP2C9 NM_000771 cagcctgccccatgca 
tcagaaactatctcattcc
caagggcac 
ctttgttgtcatgtagca
cagaagtca 
CYP3A4 NM_017460 
gcaggaggaaattgat
gcagtt 
tacccaataaggcaccac
ccacctatga 
gtcaagatactccatct
gtagcacagt 
β-actin NM_001101 cggcaccaccatgtaccc atcaagatcattgctcctc 
acacggagtacttgcg
ctca 
Sequences are in 5’-3’ direction. All other probes were regular oligonucleotides labeled with 
5’ 6-carboxyfluorescein / 3’ tetramethylrodamine (Sigma Genosys, UK) except the probe for 
β-actin which was labeled with 5’ VIC/ 3’ quencher/minor groove binding moiety (Applied 
Biosystems, UK). Total RNA was isolated with TRI-reagent (Sigma, St. Louis, MO) and 
treated with DNA-free kit (Ambion, Austin, TX). RNA concentration was determined with 
RiboGreen dye (Molecular Probes, Netherlands). 2 µg of RNA was reverse transcribed with 
M-MuLV reverse transcriptase (Fermentas, Hanover, MD) using random priming. 20 ng of 
cDNA was used for sample and the concentrations of primers and probes were optimized. 
Quantitative PCR reaction was carried out with ABI Prism 7500 (Applied Biosystems, UK) 
using TaqMan universal master mix (Applied Biosystems, UK). Standard thermal profile was 
used for CYP-genes and β-actin while an extra annealing step of 15 s at +55°C was used for 
MDR1, MRP2 and BCRP genes. Threshold cycle (Ct) was determined with Auto Ct-function 
of Sequence Detection System software (Applied Biosystems, UK). 
 
4.2.5 Calcein-AM uptake 
P-glycoprotein activity was assessed by incubating the cells with calcein acetoxymethyl 
ester (calcein-AM) and measuring cellular retention of fluorescent calcein according to 
Eneroth et al. (2001). Briefly, the cells were grown in 96-well plates (Nunc, Denmark) for 4 
days. Medium was aspirated and the cells were preincubated with either PBS alone or PBS 
supplemented with an inhibitor (cyclosporin A, progesterone or verapamil) for 15 min at 
+37°C. Calcein-AM (Calbiochem, La Jolla, CA) in PBS was added to the wells and the plates 
were incubated for 20 min at +37°C. Inhibitors and calcein-AM were dissolved in DMSO and 
all the solutions contained 1 % DMSO when incubated with the cells. Final concentrations 
were chosen according to data on Km from Eneroth et al. (2001) and were cyclosporin A 15 
µM, progesterone 170 µ M, verapamil 600 µM and calcein-AM 2 µM. The inhibitors were not 
toxic to the cells at these concentrations according to 60 min MTT-reduction and LDH-release 
tests (data not shown). Calcein-AM containing solutions were replaced with ice cold blank 
buffer and the fluorescence was measured with VICTOR2 using 480 nm for excitation and 
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535 nm for emission. Experiments were conducted in 6 parallel wells. Results are expressed 
as fluorescence in the presence of an inhibitor relative to fluorescence without an inhibitor. 
 
4.2.6 Permeability experiments 
The permeability experiments were conducted both in apical-to-basolateral and basolateral-
to-apical directions. Apical (pH 6.0) and basolateral (pH 7.4) transport buffers were Hanks’ 
Balanced Salt Solution (HBSS; Biowhittaker, Belgium) supplemented with 25 mM of 2-
morpholinoethanesulfonic acid (MES; Sigma, St. Louis, MO) or N-(hydroxyethyl)piperazine-
N’-ethanesulfonic acid (HEPES; Biowhittaker, Belgium), respectively. A pH gradient was 
used to enable certain active transporter functions (Tsuji et al. 1994; Hu et al. 1996). The 
correlation between fraction absorbed and apparent Caco-2 permeability (Yamashita et al. 
2000; Sun et al. 2002) and between in vivo jejunal permeability and apparent Caco-2 
permeability (Sun et al., 2002) has also been shown to improve in the presence of  a 
physiological pH gradient. However, as pH gradient has been shown to strongly affect the 
bidirectional permeability of  ionisable drugs (Neuhoff et al., 2003), we performed the 
permeability experiments also in iso-pH conditions (7.4/7.4) with the Caco/WT cells in order 
to be able to evaluate the relative importance of passive and active transport mechanisms.  
Filters were washed twice with transport buffer and equilibrated for about 20 min in 
temperature controlled (+37°C) orbital shaker (Titramax 1000, Heidolph, Germany) with 
constant stirring (135 rpm). The experiment was started by adding compounds dissolved in 
appropriate buffer to the donor chambers. Samples (100 µl) were withdrawn from receiver 
chamber at appropriate time points up to 3 hours and replaced with fresh buffer. Apparent 
permeability coefficients were calculated according to the equation Papp=J/AC0 (cm/s), where 
J=flux across cell monolayer (nmol/s), A=area of the filter (cm2) and C0-initial donor 
concentration (µM). The flux was determined from time frame in which it had reached a 
steady state and the concentration in the receiver chamber was less than 0.1 x C0. All transport 
experiments were conducted in triplicate. Mass balance was calculated as (amount in donor at 
last time point + amount in receiver at last time point) / amount initially added x 100 %. 
The permeability of tritium-labelled mannitol was used to check the monolayer integrity on 
day 20 or on day 4 (Caco/4d). The radioactivity was measured with MicroBeta liquid 
scintillation counter (Wallac, Finland) using OptiPhase HiSafe scintillation cocktail (Wallac, 
Finland). 
A cassette dosing approach was used to study different absorption mechanisms (Palmgrén 
et al., 2004). Seven drugs were administered simultaneously and analysed with HPLC - 
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UV/fluorescence. Compounds were atenolol (200 µM), antipyrine (20 µM), propranolol (50 
µM), baclofen (500 µM), cephalexin (300 µM),  ibuprofen (20 µM) and verapamil (20 µM). 
The samples were analysed by HPLC as previously described (Palmgrén et al., 2004). 
P-glycoprotein activity was also measured with permeability of fluorescent P-glycoprotein 
substrate rhodamine-123 (Wang et al., 2001). It was dissolved in DMSO and the final 
concentration in the donor compartment was 10 µM. The donor contained 2 % DMSO. The 
fluorescence was measured with VICTOR2 using 480 nm for excitation and 535 nm for 
emission. 
 
4.2.7 Statistical analysis 
Differences between multiple groups were compared with non-parametrical Kruskal-Wallis 
rank order test and differences were considered significant when P<0.05. Thereafter, pair wise 
comparisons between Caco/WT and other cell lines were done with Dunn’s rank order test 
(Neave and Worthington 1988). This multiple group non-parametrical testing was done 
manually. Permeability data between Caco/WT cells under different pH conditions were 
compared with non-parametrical Mann-Whitney U-test. Pearson correlations were calculated 
with SPSS software (SPSS inc, Chicago, IL). 
 
4.3 Results 
 
4.3.1 Monolayer integrity and cell differentiation 
The apparent permeability of mannitol across Caco/WT cells was 1.29x10-6 cm/s and it was 
independent of pH (Table 4.3). Caco/4d cells were more and Caco/VCR less permeable for 
mannitol than Caco/WT cells. Other cell lines were close to the Caco/WT cells. All modified 
cell lines had higher alkaline phosphatase activity than the Caco/WT cells indicating adequate 
cellular differentiation (Table 4.3). 
 
4.3.2 mRNA levels of metabolic genes 
The results of quantitative RT-PCR experiments are shown in Table 4.4. All modified cell 
lines, except in Caco/4d, had 2.4-6.7 times higher MDR1 mRNA levels than Caco/WT cells. 
MRP2 levels in modified cell lines, on the other hand, seemed to be very close to that in 
Caco/WT cells and BCRP levels were generally even lower. CYP2B6 was upregulated only 
in Caco/4d cells and CYP2C9 in Caco/mCAR cells. The CYP3A4 level in Caco/WT cells was 
very low. However, supplementing the growth medium with 250 nM 1α,25-dihydroxyvitamin 
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D3 increased the expression level 900 fold as previously reported (Schmiedlin-Ren et al. 
1997). Caco/hPXR cells had 11 times more CYP3A4 mRNA than Caco/WT but other 
modifications seemed ineffective 
. 
Table 4.3: Papp of mannitol and alkaline phosphatase activity of modified cell lines. 
 Mannitol a,c AP b,c 
Caco/WT 1.29 (±0.04) 240 (±30) 
Caco/hPXR 1.18 (±0.07) 670 (±120) 
Caco/mCAR 1.10 (±0.10) 760 (±50)d 
Caco/MDR 1.37 (±0.14) 740 (±100) 
Caco/VD3 1.29 (±0.06) 340 (±50) 
Caco/VCR 0.69 (±0.04) 620 (±40) 
Caco/4d 4.02 (±0.62) 550 (±100) 
Caco/WT (pH 7.4/7.4) 1.31(±0.02)  
Apparent permeability of mannitol was determined in the apical-to-basolateral direction 
according to the equation Papp=J/(A x C0). Apical pH was 6.0 and basolateral pH 7.4. Alkaline 
phosphatase activity was determined form cell lysate and the activity was related to the total 
protein content. Values represent mean (±S.E.M). n=4 (Mannitol) and n=3 (AP). 
a Apparent permeability of 60 nM mannitol (10-6 cm/s) in apical-to-basolateral direction 
b Alkaline phosphatase (AP) activity pmol/min/µg protein 
c Significant differences between groups according to Kruskal-Wallis test, P<0.05 
d Significantly different from Caco/WT, P<0.05 
 
Table 4.4: Quantitative RT-PCR results. Expression levels of efflux pump and CYP genes 
relative to wild type Caco-2 cells. 
Gene Ct
a Caco/
WT 
Caco/ 
hPXR 
Caco/ 
mCAR 
Caco/ 
MDR 
Caco/ 
VD3 
Caco/ 
VCR 
Caco/ 
4d 
MDR1b 30.3 1.0 
4.6 
(±1.0) 
6.7  
(±1.4) 
2.4 
(±1.0) 
3.3 
 (±1.2) 
5.5 
(±1.2) 
0.1 
(±0.0) 
MRP2 b 25.3 1.0 
0.9 
(±0.1) 
1.5  
(±0.1) 
0.8 
(±0.1) 
1.7  
(±0.3) 
1.2 
(±0.1) 
0.3 
(±0.0) 
BCRP b 27.3 1.0 
0.3 
(±0.0) c 
1.0  
(±0.1) 
0.5 
(±0.1) 
1.1  
(±0.2) 
0.5 
(±0.1) 
0.7 
(±0.7) 
CYP2B6 b 28.3 1.0 
1.3 
(±0.2) 
0.5  
(±0.1) 
0.2 
(±0.0) 
1.4  
(±0.1) 
0.3 
(±0.1) 
2.0 
(±0.4) 
CYP2C9 b 25.1 1.0 
1.3 
(±0.1) 
2.9  
(±0.4) 
0.9 
(±0.1) 
1.9 
 (±0.3) 
1.2 
(±0.1) 
0.0 
(±0.0) 
CYP3A4 b 34.1 1.0 
10.9 
(±1.5) 
0.9  
(±0.1) 
1.1 
(±0.1) 
900  
(±140) c 
1.5 
(±0.1) 
0.4 
(±0.1) 
Total RNA was isolated from filter grown cells, treated with DNase and reverse transcribed to 
cDNA. Amplification and detection was done with ABI Prism 7500 Sequence detection 
system using TaqMan chemistry. Data was normalized to β-actin and results are expression 
levels of each gene relative to Caco/WT. Values represent mean (±S.E.M.); n=4. 
a Mean threshold cycle for Caco/WT cell line 
b Significant differences between groups according to Kruskal-Wallis test, P<0.05 
c Significantly different from Caco/WT, P<0.05 
 
4.3.3 Calcein AM uptake 
All modified cell lines seemed to retain less calcein than the Caco/WT cells, but the 
difference reached statistical significance only in Caco/mCAR, Caco/MDR and Caco/VCR 
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cells (Fig. 4.1 A). Further, preincubation with P-glycoprotein inhibitors cyclosporin A (Fig. 
4.1 B), progesterone (Fig. 4.1 C) and verapamil (Fig. 4.1 D) increased the inhibitor/buffer 
fluorescence ratio relative to Caco/WT cells only in these cell lines. 
 
Figure 4.1: Calcein-AM retention experiments. Cells were preincubated with either an 
inhibitor or buffer before adding calcein-AM. Cellular calcein accumulation was measured 
with fluorometer. (A) Basal calcein retention in different cell lines without any inhibitors 
relative to Caco/WT. Calcein retention in different cell lines in the presence of P-gp inhibitors 
(B) cyclosporin A 15 µM, (C) progesterone 170 µM and (D) verapamil 600 µM relative to 
buffer control of each cell line. Bars represent mean (±S.E.M.); n=5-11. * significantly 
different from Caco/WT, P<0.05 
 
4.3.4 Permeability experiments 
Passively absorbed compounds. The apparent permeability coefficients of passively 
absorbed compounds are presented in Table 4.5. The apparent permeability of atenolol in the 
AB direction was very low (Papp=0.13 x 10
-6 cm/s) and it was pH dependent. The differences 
among 21 days old monolayers were small since only Caco/VCR was clearly less and 
Caco/MDR clearly more permeable than the Caco/WT cells. Caco/4d cells were an order of 
magnitude more permeable than the Caco/WT cells. The transport in the BA direction was 
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faster than in the AB direction but the relative rank order of the cell lines was quite similar in 
both directions. 
 
Table 4.5: Bidirectional apparent permeability coefficients (10-6 cm/s) across cell monolayers 
of passively transported compounds atenolol (200 µM, paracellular), antipyrine (20 µM, 
transcellular) and propranolol (50 µM, transcellular). 
  pH gradient 6.0/7.4   pH 7.4/7.4 
  
Caco/ 
WT 
Caco/ 
hPXR 
Caco/ 
mCAR 
Caco/ 
MDR 
Caco/ 
VD3 
Caco/ 
VCR 
Caco/ 
4d 
 
Caco/ 
WT 
Atenolol           
ABa 
0.13 
(±0.02) 
0.19 
(±0.01) 
0.10 
(±0.01) 
0.30 
(±0.07) 
0.17 
(±0.01) 
0.07 
(±0.01) 
1.91 
(±0.10) 
 
0.41 
(±0.06)c 
BAa 
0.44 
(±0.01) 
0.53 
(±0.02) 
0.45 
(±0.03) 
0.49 
(±0.07) 
0.57 
(±0.02) 
0.19 
(±0.05) 
2.25 
(±0.34) 
 
0.33 
(±0.05) c 
AB/BAa 0.30  0.35  0.23 0.62  0.29  0.36  0.85   1.25 c 
Antipyrine         
ABa 
52.5 
(±3.7) 
60.8 
 (±1.4) 
64.5 
 (±2.5) 
68.1 
(±2.1)b 
58.1 
(±1.6) 
60.1 
(±1.4) 
61.1 
(±4.0)  
44.4 
 (±3.8) 
BA 
52.6 
(±2.1) 
52.5  
(±2.5) 
59.2  
(±1.5) 
56.3 
 (±3.8) 
60.1 
(±3.7) 
49.8 
(±4.2) 
52.4 
(±3.2)  
45.8 
 (±1.7) 
AB/BA 1.00  1.16  1.09  1.21  0.97  1.21  1.17   0.97  
Propranolol         
AB 
5.8 
(±0.4) 
6.5  
±0.6) 
6.7 
 (±0.6) 
6.9  
(±0.2) 
5.8 
(±0.2) 
6.3 
(±0.6) 
7.0 
(±0.7)  
35.4 
(±5.9)c 
BA 
90.4 
(±2.9) 
98.7  
(±6.7) 
105.1 
(±2.7) 
101.4 
(±8.7) 
95.8 
(±1.6) 
85.1 
(±7.9) 
86.8 
(±5.3)  
37.3  
(±4.0) c 
AB/BA 0.06  0.07  0.06  0.07  0.06  0.07  0.08    0.95 c 
Apparent permeabilities were determined under sink conditions according to the equation 
Papp=J/(A x C0). Apical pH was either 6.0 (pH-gradient experiments) or 7.4 (iso-pH 
experiments) Basolateral pH was always 7.4. AB=apical-to-basolateral direction; 
BA=basolateral-to-apical direction; AB/BA=apical-to-basolateral / basolateral-to-apical ratio. 
Values represent mean (±S.E.M.); n=4 except Caco/VD3 n=3. 
a Significant differences between groups according to Kruskal-Wallis test, P<0.05 
b  Significantly different from Caco/WT 6.0/7.4, P<0.05 
c Significant differences between two pH-conditions according to Mann-Whitney U-test, 
P<0.05  
 
The apparent permeability coefficient of antipyrine in the AB direction was lowest in 
Caco/WT cells (Papp=52.5 x 10
-6 cm/s) and highest in Caco/MDR cells. The transport was 
equally unpolarised under both pH conditions. However, the absolute values of permeability 
coefficients were slightly but statistically insignificantly lower under iso-pH conditions. The 
transport of propranolol in Caco/WT cells was highly polarised as the apparent permeability 
was 5.8 x 10-6 cm/s in the AB direction and 90.4 x 10-6 cm/s in the BA direction. The 
transport was equally polarised in all cell lines and the apparent permeabilities did not differ 
significantly between cell lines, but removing the pH gradient abolished the polarisation of 
transport. 
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Actively absorbed compounds. The results of transport experiments with actively absorbed 
compounds are presented in Table 4.6. Baclofen is a substrate for the large neutral amino acid 
carrier which is not proton coupled (Cercos-Fortea et al., 1995). Its apparent permeability in 
Caco/WT cells was 0.53 x 10-6 cm/s in the AB direction and 0.22 x 10-6 cm/s in the BA 
direction. The transport in the AB direction is lowered when the pH gradient is removed but 
the transport still remains somewhat polarised. In addition to the Caco/WT cells, Caco/VD3, 
Caco/hPXR and Caco/mCAR were capable of polarised transport of baclofen (AB to BA 
ratio=2.06-2.71).  
Cephalexin is a substrate for peptide transporters PEPT1 (intestinal) and PEPT2 (renal) of 
which PEPT1 is expressed in Caco-2 cells (Ganapathy et al. 1995). The apparent permeability 
of cephalexin in the AB direction was 0.90 x 10-6 cm/s and the transport was polarised (AB to 
BA ratio=6.56) indicating functional active transport. The removal of the pH gradient 
essentially abolished this polarisation of transport. Caco/VD3, Caco/hPXR and Caco/mCAR 
are less permeable for cephalexin in the AB direction than Caco/WT but still the transport was 
polarised and the active transport functional. Caco/MDR and Caco/VCR were not capable of 
polarised transport of cephalexin.  
Ibuprofen is a substrate for the monocarboxylic acid transporter MCT1 (Tamai et al. 1995). 
The apparent permeability of ibuprofen across Caco/WT cell monolayer in the AB direction 
was rapid (Papp=104 x 10
-6 cm/s) and the transport was highly polarised (AB to BA 
ratio=15.1). This polarisation is strongly dependent on pH gradient since the AB to BA ratio 
was 0.82 under iso-pH conditions. Apparent permeability of ibuprofen was of similar 
magnitude in all cell lines. 
P-glycoprotein substrates. The apparent permeabilities of P-glycoprotein substrates 
verapamil (Polli et al. 2001) and rhodamine-123 (Wang et al. 2001) are shown in Table 4.7. 
The apparent permeability coefficients for verapamil across Caco/WT monolayers were 5.4 x 
10-6 cm/s in the AB direction and 100 x 10-6 cm/s in the BA direction. The transport was 
similar in all modified cell lines under pH gradient conditions but the BA to AB ratio 
decreased significantly when the pH gradient was removed.   
The apparent permeability for rhodamine-123 in the Caco/WT cells was 0.25 x 10-6 cm/s in 
the AB direction and 5.37 x 10-6 cm/s in the BA direction. Of cell lines with elevated MDR1 
expression, only Caco/mCAR cells had both lower AB and higher BA permeability than 
Caco/WT cells. Removing the pH gradient caused a modest but insignificant reduction of 
basolateral to apical permeability of rhodamine-123.   
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Table 4.6: Bidirectional apparent permeability coefficients (10-6 cm/s) across cell 
monolayers of actively transported compounds baclofen (500 µM, amino acid transporter), 
cephalexin (300 µM, peptide transporter PEPT1) and ibuprofen (20 µM, monocarboxylic acid 
transporter MCT1). 
  pH gradient 6.0/7.4   
pH 
7.4/7.4 
  
Caco/ 
WT 
Caco/ 
hPXR 
Caco/ 
mCAR 
Caco/ 
MDR 
Caco/ 
VD3 
Caco/ 
VCR 
Caco/ 
4d 
 
Caco/ 
WT 
Baclofen         
ABa 
0.53 
(±0.04) 
0.53 
(±0.04) 
0.50 
(±0.03) 
0.45 
(±0.03) 
0.63 
(±0.07) 
0.26 
(±0.03) 
2.05 
(±0.13)  
0.35 
(±0.06)b 
BAa 
0.22 
(±0.01) 
0.24 
(±0.03) 
0.19 
(±0.02) 
0.31 
(±0.06) 
0.30 
(±0.03) 
0.16 
(±0.04) 
2.21 
(±0.32)  
0.19 
(±0.03) 
AB/BAa 2.42  2.18  2.71  1.47  2.06  1.62) 0.93   1.79  
Cephalexin         
ABa 
0.90 
(±0.14) 
0.48 
(±0.05) 
0.42 
(±0.05) 
0.35 
(±0.02) 
0.73 
(±0.06) 
0.20 
(±0.04)b 
1.92 
(±0.12)  
0.31 
(±0.03)b 
BAa 
0.14 
(±0.01) 
0.15 
(±0.02) 
0.12 
(±0.02) 
0.31 
(±0.09) 
0.21 
(±0.01) 
0.13 
(±0.04) 
1.56 
(±0.23)  
0.23 
(±0.02)b 
AB/BAa 6.56 3.26  3.58  1.14 b 3.48) 1.51  1.23 b  1.35b 
Ibuprofen         
AB 
104  
(±9) 
121  
(±8) 
134  
(±7) 
117  
(±6) 
124  
(±7) 
107  
(±6) 
102 
 (±12)  
44.3 
(±6.7)b 
BA 
6.9  
(±1.2) 
4.8 
(±0.3) 
6.5 
(±0.1) 
6.5 
(±0.4) 
8.6 
(±1.7) 
5 7  
(±1.4) 
7.6 
 (±2.2)  
54.2 
(±1.7)b 
AB/BA 15.1  25.3  20.7  18.0  14.4  18.9 13.5   0.82 b 
Apparent permeabilities were determined under sink conditions according to the equation 
Papp=J/(A x C0). Apical pH was either 6.0 (pH-gradient experiments) or 7.4 (iso-pH 
experiments) Basolateral pH was always 7.4. AB=apical-to-basolateral direction; 
BA=basolateral-to-apical direction; AB/BA=apical-to-basolateral / basolateral-to-apical ratio. 
Values represent mean (±S.E.M.); n=4 except Caco/VD3 n=3. 
a Significant differences between groups according to Kruskal-Wallis test, P<0.05 
b Significant differences between two pH-conditions according to Mann-Whitney U-test, 
P<0.05  
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Table 4.7: Bidirectional apparent permeability coefficients (10-6 cm/s) across cell monolayers 
of P-glycoprotein substrates verapamil (20 µM) and rhodamine-123 (10 µM). 
  pH gradient 6.0/7.4   pH 7.4/7.4 
  
Caco/ 
WT 
Caco/ 
hPXR 
Caco/ 
mCAR 
Caco/ 
MDR 
Caco/ 
VD3 
Caco/ 
VCR 
Caco/ 
4d 
 
Caco/ 
WT 
Verapamil         
AB 
5.4  
(±0.5) 
5.5 
(±0.3) 
6.1 
(±0.9) 
6.3 
(±0.6) 
6.1 
(±1.1) 
4.5 
(±0.1) 
6.1 
(±1.0)  
33.8  
(±4.1)b 
BA 
100  
(±3) 
104  
(±5) 
110 
 (±2) 
107 
(±11) 
103  
(±3) 
90  
(±10) 
93  
(±6)  
36.8  
(±0.3)b 
BA/AB 18.5  18.9  18.3  16.9  16.9  20  15.2   1.09 b 
Rhodamine-123         
ABa 
0.25 
(±0.07) 
0.27 
(±0.03) 
0.16 
(±0.02) 
0.68 
(±0.04) 
0.27 
(±0.02) 
0.22 
(±0.02) 
1.79 
(±0.08)b  
0.30 
(±0.02) 
BAa 
5.37 
(±0.46) 
6.01 
(±0.24) 
7.52 
(±0.22) 
3.82 
(±0.14) 
4.80 
(±0.04) 
4.17 
(±0.32) 
2.62 
(±0.17)b  
3.93 
(±0.69) 
BA/AB a 21.5 22.2 47 5.6 17.8 18.9 1.46   13.1 
Apparent permeabilities were determined under sink conditions according to the equation 
Papp=J/(A x C0). Apical pH was either 6.0 (pH-gradient experiments) or 7.4 (iso-pH 
experiments) Basolateral pH was always 7.4. AB=apical-to-basolateral direction; 
BA=basolateral-to-apical direction; AB/BA=apical-to-basolateral / basolateral-to-apical ratio. 
Values represent mean (±S.E.M.); n=4 except Caco/VD3 n=3. 
a Significant differences between groups according to Kruskal-Wallis test, P<0.05 
b  Significantly different from Caco/WT 6.0/7.4, P<0.05 
c Significant differences between two pH-conditions according to Mann-Whitney U-test, 
P<0.05  
 
4.4 Discussion 
Our goal was to modify Caco-2 cells to better predict intestinal drug absorption. 
Specifically, we aimed at increasing cytochrome P450 and apically located efflux pump 
activities. This study introduces two novel Caco-2 cell lines (Caco/mCAR and Caco/hPXR) 
and compares their characteristics systematically with wild type cells and some previously 
described modified Caco-2 cells. 
 
4.4.1 Monolayer growth  
A fully differentiated and tight monolayer is required for permeability experiments. Sun et 
al. (2002) studied extensively gene expression in differentiated and undifferentiated Caco-2 
cells and found that several genes, including transporters and xenobiotic metabolising 
enzymes, become expressed in Caco-2 cells only when they differentiate. Differentiation also 
includes formation of tight junction between the cells. Many transporters are only weakly 
active in Caco-2 cells (Table 4.6) and excessive paracellular permeability may prevent 
detecting interactions with these proteins. On the other hand, too tight a monolayer may 
underestimate the absorption of hydrophilic compounds that are not substrates for any 
absorptive transporters.  
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Our Caco/WT cells were relatively permeable for the paracellular marker compound, 
mannitol (Table 4.3). Identical apparent permeabilities under both pH conditions studied 
confirms that lower apical pH does not have adverse effects on the monolayer integrity. 
Transfected cell lines formed moderately tighter monolayers than the Caco/WT cells with the 
exception of Caco/MDR. In a study by Crespi et al. (1996) Caco-2 cells transfected with 
cytochrome P450 containing vectors had either increased or decreased mannitol permeability. 
Thus, the transfection vector itself does not seem to have a predictable effect on phenotype 
but differences may arise from clonal selection and random integration of the vector. 
Caco/VCR cells formed considerably tighter monolayers than Caco/WT cells. One 
contributing factor may be the high passage number of the Caco/VCR cells since paracellular 
permeability has been reported to generally decrease at high passages (Yu et al. 1997). The 
apparent permeability for mannitol across Caco/4d cells was clearly higher than that in 
Caco/WT cells and also higher than previously reported (Lentz et al. 2000). 
Alkaline phosphatase is an enzyme that is mainly localised in the membrane fraction of 
differentiated Caco-2 cells (Matsumoto et al. 1990) and is considered as an indicator of 
cellular differentiation. The differentiation of the Caco-2 cells proceeds in a mosaic pattern, 
where several enzyme activities and microvillus appear in apparently uncoordinated fashion. 
Still, the terminally differentiated cells have practically all enzyme activities and good 
microvillus (Vachon et al. 1996). Although the alkaline phosphatase activity and microvillus 
formation are not directly coupled, some studies report parallel increase of these two (Pinto et 
al. 1983; Halline et al. 1994). Our Caco/WT cells had alkaline phosphatase activity of 240 
pmol/min/µg protein which is moderately higher than other published values (Yu et al. 1997; 
Lentz et al. 2000). All modified cell lines had elevated alkaline phosphatase levels (Table 4.3) 
and they thus seem to differentiate well. There can be several mechanisms resulting increased 
alkaline phosphatase levels and good differentiation, but elucidation of the actual mechanisms 
was not possible from our data.  
 
4.4.2 Gene expression 
As a cancer cell line from colon, Caco-2 expresses many efflux transporters of ATP binding 
cassette (ABC) family (Taipalensuu et al. 2001), but has low CYP levels (Prueksaritanont et 
al. 1996; Nakamura et al. 2002). We created two novel Caco-2 cell lines overexpressing 
nuclear receptors PXR and CAR that are normally weakly functional in Caco/WT cells. The 
mRNA levels of PXR in Caco/WT cells are very low (Pfrunder et al. 2003) and known PXR 
activators clotrimazole or rifampicin are unable to induce CYP3A4 (Engman et al. 2001; 
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Pfrunder et al. 2003; Schmiedlin-Ren et al. 2001). According to our semi-quantitative RT-
PCR experiments, CAR is expressed in low amounts in differentiated Caco/WT cells (data not 
shown). Human isoform of PXR and murine isoform of CAR were selected for use in the 
present study because they have well defined agonistic ligands (Moore et al. 2002). These two 
novel cell lines should allow the adjustment of the general level of metabolic gene expression 
with PXR/CAR activators and repressors. This would be an advantage in studying inter-
individual differences in drug metabolism and efflux in human small intestine. We also 
studied gene expression in Caco/VCR (Eneroth et al. 2001), Caco/VD3 (Schmiedlin-Ren et 
al. 1997) and Caco/MDR (Döppenschmitt et al. 1999a) cell lines that have been previously 
described but not thoroughly characterized. 
Our PCR results show altered patterns of gene expression in different cell lines (Table 4.4). 
Genes that were clearly upregulated in Caco/hPXR were MDR1 and CYP3A4, while BCRP 
was downregulated. This may reflect the coordinated regulation of efflux transporters where 
alterations in level of one transporter causes changes in intracellular concentrations of its 
substrates and, as the ligand specificity of several transporters overlap, expression of another 
transporter (compensatory up/downregulation) (Chan et al. 2004). On the other hand, 
Caco/mCAR had elevated levels of MDR1 and CYP2C9, but the expression of CYP2B6, a 
prototypic target gene for CAR (Sueyoshi et al. 1999), was downregulated. Thus, these 
receptors can alter gene expression in Caco-2 cells even without exogenous ligands. Of 
course, the cells themselves or more likely the cell culture medium supplemented with foetal 
bovine serum may contain some compounds that can activate the receptors. Especially PXR 
has many steroidal compounds as ligands (Honkakoski 2003). CAR has an interesting 
property that, normally when it is unliganded, it resides in the cytoplasm, but is translocated 
into the nucleus upon ligand binding (Kawamoto et al. 1999). When CAR is transfected to 
HepG2 cells, however, it localises in the nucleus and upregulates target genesin the absence 
of added ligands (Kawamoto et al. 1999). Therefore, it is surprising that CYP2B6 was not 
upregulated in the Caco/mCAR cell line. Perhaps another factor that is required for CYP2B6 
expression was missing in Caco/mCAR cells. Nuclear receptors cannot alter the gene 
expression alone but they require many cofactors that can be either coactivators or 
corepressors (Xu et al. 1999). Competition on these factors between different nuclear 
receptors may cause deviations from expected induction patterns. Our preliminary results 
show, that Caco/hPXR and Caco/mCAR also respond to their prototypic activators rifampicin 
and TCPOBOP, respectively. 
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Caco/MDR cells had modestly elevated MDR1 levels as expected but two genes, namely 
BCRP and CYP2B6, were downregulated. The reason for apparently low upregulation of 
MDR1 gene on mRNA level at 21 days (Table 4.4) compared to the high P-glycoprotein 
activity at calcein-AM experiments at 4 days (Fig. 1) may be the gene construct that was used. 
The cDNA of MDR1 gene was under CMV promoter and thus relatively independent of 
cellular events. Thus its expression is probably higher in the undifferentiated state than that of 
the other cell lines, which require also endogenous events in the upregulation process. At later 
stages of differentiation the endogenous MDR1 gene of Caco/MDR cells is not appreciably 
upregulated or may be even compensatorily downregulated due to “exogenous” P-
glycoprotein. CYP3A4 gene was strongly activated in Caco/VD3 cells as previously 
described (Schmiedlin-Ren et al. 1997) and these cells had also elevated mRNA levels of 
MDR1. Increases in other mRNA levels in Caco/VD3 cells were modest. In Caco/VCR cells, 
the level of MDR1 gene was elevated and the level of MRP2 gene was unchanged as was also 
reported in another study (Eneroth et al. 2001). The increased expression of P-glycoprotein 
involves probably both clonal selection and gene regulation (Hoskins et al. 1993). The mRNA 
levels of all genes except CYP2B6 were lower in Caco/4d than in Caco/WT cells, which 
probably reflects insufficient differentiation. Thus, several modifications could increase the 
MDR1 levels. BCRP, on the other hand, was unaffected or even downregulated and MRP2 
did not response to our modifications. Different CYP genes could be activated with nuclear 
receptor transfections and with 1α,25-dihydroxyvitamin D3. 
Rough estimates of relative expression levels between different genes can be made based 
on threshold cycle values which represent the PCR cycle in which the fluorescence from 
degraded TaqMan probes exceeds the base line fluorescence. Our results suggest that relative 
expression levels were MRP2 > BCRP > MDR1 (Table 4.4) while in another study an order 
of  MRP2 > MDR1 >> BCRP was found (Taipalensuu et al. 2001). Also studies by Nakamura 
et al. (2003) and Pfrunder et al. (2003) report that MRP2 and MDR1 levels in Caco-2 cells are 
of similar magnitude. Based on threshold considerations the relative expression levels of 
CYP-genes in Caco/WT cells were CYP2C9 > CYP2B6 > CYP3A4. 
 
4.4.3 Calcein-AM uptake 
The efflux pumps affect the cellular accumulation of calcein in two ways. Lipophilic non-
fluorescent calcein-AM is a substrate of two efflux pumps, P-glycoprotein and MRP1, which 
lower the intracellular calcein-AM levels and slow down its hydrolysis to fluorescent calcein 
by intracellular esterases (Essodaigui et al. 1998). Hydrophilic calcein, that causes the 
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measured fluorescence, diffuses across lipid bilayers only slowly and it exits the cell by the 
aid of MRP1 and MRP2 but not by P-glycoprotein (Essodaigui et al. 1998; Prime-Chapman et 
al. 2004). It has been shown recently that MRP2 is primarily responsive for calcein efflux in 
Caco-2 cells (Prime-Chapman et al. 2004). Cyclosporin A, progesterone and verapamil are all 
capable of inhibiting P-glycoprotein function (Döppenschmitt et al. 1999a; Ambudkar et al. 
1999; Garrigos et al. 1997). Cyclosporin A can also modulate efflux by MRP2 (Chen et al. 
1999) but verapamil lacks this property (Prime-Chapman et al. 2004). The increase of 
fluorescence in the presence of verapamil and progesterone was quite modest in Caco/WT 
cells (Fig 1 C and 1 D). Cyclosporin A could produce clearly higher inhibitor/buffer 
fluorescence ratio in Caco/WT, which is probably caused by MRP2 inhibition (Fig 1 B). 
These results together with quantitative RT-PCR results (Table 4.4) suggests that P-
glycoprotein activity in our wild type cells in quite low and that MRP2 is well expressed. 
Progesterone and verapamil caused higher increase in inhibitor/buffer ratio than cyclosporin 
A in Caco/mCAR, Caco/MDR and Caco/VCR cells relative to Caco/WT cells (Fig. 1 B, 1 C 
and 1 D). This suggests that P-glycoprotein activity in these cells is elevated but MRP2 
activity is not. These results agree with the RT-PCR data (Table 4.4). Similar results have 
been presented by Döppenshcmitt et al. (1999a) and Eneroth et al. (2001) who reported 
increased P-glycoprotein activities in Caco/MDR and Caco/VCR cells, respectively. 
Apparently the MDR1-levels in Caco/VD3 and Caco/hPXR cells after 4 days are not elevated 
to similar extent as after 21 days (Table 4.4) because calcein-AM results are not significantly 
different from Caco/WT cells (Fig. 1). 
 
4.4.4 Permeability experiments 
Passively transported compounds. As a hydrophilic compound atenolol permeates 
primarily through paracellular pores although a significant contribution of transcellular route 
at pH 7.4 has been suggested (Neuhoff et al. 2003). The paracellular transport route is 
supported by the correlation between the apparent permeability of atenolol and mannitol 
(Pearson correlation: mannitol vs. atenolol AB 0.874) but polarised transport across cell 
monolayer (AB to BA ratio < 1) with a pH gradient suggests that this weakly basic drug also 
traverses across the cell membranes and that the degree of ionisation affects the permeability. 
Abolished polarisation of transport under equal pH on both sides of the membrane further 
supports partial transcellular transport for atenolol. The relative contribution of transcellular 
route decreases as the paracellular permeability increases because the AB to BA ratio in 
Caco/4d cells approaches one. 
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Antipyrine and propranolol are passively transported by transcellular diffusion. Because 
they are highly permeable, their transport rate is influenced by the unstirred water layer 
(UWL) (Karlsson and Artursson 1991). It is therefore likely, that the possible differences in 
monolayer properties are masked in in vitro transport studies and that the UWL contributes to 
their permeability also in vivo. Antipyrine at the physiological pH range is an unionised 
relatively hydrophobic compound. Propranolol is a highly permeable compound and, as it is a 
weak base (calculated pKa=9.04 (Palmgrén et al. 2004)), its degree of ionisation and thus 
lipophilicity varies strongly in the physiological pH range. Although a study with rabbit 
corneal cells reports that P-glycoprotein affects propranolol transport at very low 
concentrations (Yang et al. 2000), another study did not support this result (Polli et al. 2001), 
and, thus, propranolol is apparently not a good substrate for P-glycoprotein. The paracellular 
route is of little significance for these drugs since their apparent permeabilities in Caco/4d 
cells were similar to those in the tighter cell monolayers (Table 4.5). The general trend with 
modified cell lines was slightly elevated permeability in the AB direction but the differences 
were small and they are unlikely to affect the absorption classification of compounds. The 
transport of antipyrine was unpolarised since the AB to BA ratio was close to one in all cell 
lines and its transport was independent of the pH conditions, as should be for passively 
transported neutral compound. However, propranolol displayed highly polarised transport, 
which is primarily caused by the pH gradient employed in the transport experiments, as can 
be seen from the permeability data under different pH. Similar findings with other bases were 
made by Neuhoff et al. (2003). BA permeabilities of propranolol are not identical under 
different pH conditions because the ionisation degree in the receiver (apical) compartment 
affects the maintenance of sink conditions and the extent of UWL effect on permeability.  
Actively transported compounds. Table 4.6 summarizes the results for the actively absorbed 
compounds. The active absorptive transporters studied here use inward directed ion gradients 
as their energy source. PEPT1 and MCT1 use proton gradient but neutral amino acid carrier is 
sodium coupled (Tsuji and Tamai 1996). 
Baclofen (an amino acid carrier substrate) and cephalexin (a PEPT1 substrate) are 
transported slowly across Caco-2 monolayer. As they are relatively hydrophilic (calculated 
LogD6.0 values –0.94 and –1.88 (Palmgrén et al., 2004)), their transcellular diffusion is small 
and the paracellular route is important for passive absorption. Slow transport rates suggest 
that these active transporters were expressed only in low amounts in Caco-2 cells which is in 
agreement with previous results (Putnam et al. 2002). Removing the pH gradient reduces the 
proton gradient over the cell membrane that is used as a driving force for PEPT1. This 
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strongly reduces the apical to basolateral transport of cephalexin. Baclofen is also affected but 
to a smaller extent. Caco/VD3, Caco/hPXR and Caco/mCAR apparently have retained most 
of the transporter activities but Caco/VCR and Caco/MDR have lower levels of this 
transporter since the apparent absorptive permeabilities were lower and the transport was not 
polarised. High passage number has been shown to reduce paracellular permeability and 
transporter activity (Yu et al. 1997) and this may be the reason for altered permeabilities in 
Caco/VCR cells. Caco/4d is a special case, since it is leakier than other cell lines and the 
possible active transport is effectively masked by high paracellular permeability and the lack 
of polarised transport is evident. Thus, only four of the studied cell lines (Caco/WT, 
Caco/mCAR, Caco/hPXR, Caco/VD3) are capable of detecting substrates of large neutral 
amino acid carrier and PEPT1. 
Ibuprofen, a substrate for MCT1, differs from baclofen and cephalexin because its apparent 
permeability is very high. The apparent permeabilities were of similar magnitude in all cell 
lines and the transport was clearly polarised. In this case, the sink conditions are lost at an 
early stage of the experiment, which may cause inaccuracy in the absolute values of the 
apparent permeability coefficient. Monocarboxylic acid transporter has been shown to 
function well in Caco-2 cells (Putnam et al. 2002) but as ibuprofen is lipophilic (calculated 
LogD6.0 value 2.12 (Palmgrén et al. 2004)) and its ionisation varies considerably at the 
physiological pH range, the passive transcellular route is considerably more important than 
for baclofen or cephalexin. In addition, the pH gradient causes polarisation of transport and 
unstirred water layer is probably a significant barrier at least in the AB-direction. Further 
elucidation of how important MCT1 activity is on ibuprofen permeability would require 
experiments with inhibitors and different concentrations. 
P-glycoprotein substrates. Table 4.7 shows the transport data of two P-glycoprotein 
substrates. Verapamil is a lipophilic (calculated LogD6.0 value 2.14 (Palmgrén et al. 2004)), 
weakly basic (calculated pKa value 9.04 (Palmgrén et al. 2004)) compound, which is a 
substrate for P-glycoprotein (Polli et al. 2001). The transport of verapamil in our experimental 
setting was rapid and highly polarised. The comparison between the two pH conditions with 
Caco/WT cells reveals that the polarised transport is mainly due to different degrees of 
ionisation and P-glycoprotein plays only a minor role with this highly permeable compound. 
Similar to other rapidly transported compounds, UWL probably contributes to the overall 
permeability of verapamil. Although the mRNA levels of MDR1 were elevated and calcein-
AM experiments showed increased P-glycoprotein activities in several cell lines, the apparent 
permeabilities of verapamil in different cell lines were essentially unchanged. The apparent 
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permeability coefficients of verapamil in the BA direction correlated strongly with antipyrine 
and propranolol (Pearson correlations 0.816 and 0.914, respectively). The correlation was 
much less evident in the AB direction. This suggests that the passive component in the 
transport of verapamil is relatively large and possible differences in P-glycoprotein activity do 
not contribute significantly to overall transport. This has been also suggested by 
Döppenschmitt et al. (1999b). 
Rhodamine-123 is a P-glycoprotein substrate (Wang et al. 2001) that is more hydrophilic 
than verapamil. It is also a basic compound (pKa 7,2 (Duvvuri et al. 2004)) so the pH gradient 
causes some polarisation of transport, as seen from Table 4.7. In addition to P-glycoprotein, 
organic cation transporter is involved in the transport of rhodamine-123 (van der Sandt et al. 
2000). It has been suggested that the transport of rhodamine-123 in the AB direction is 
primarily paracellular and in the BA direction active transport is involved both in the apical 
and basolateral membrane (Troutman and Thakker 2003). The elevated MDR1 expression 
was evident in rhodamine-123 transport only in Caco/mCAR cells. It is possible that 
Caco/MDR and Caco/VCR have defective basolateral transport of rhodamine-123 and, hence, 
the rate limiting step in transport is moved from apical to basolateral membrane. The high 
paracellular permeability of Caco/4d cells was evident as the transport of rhodamine-123 was 
only weakly polarised. It appears that the transport of verapamil and rhodamine-123 were not 
significantly altered under our experimental settings, despite some differences were observed 
in MDR1 mRNA-levels and P-glycoprotein activity in calcein-AM assay. 
 
4.5 Conclusions 
We have created two novel Caco-2 cell lines expressing nuclear receptors PXR and CAR. 
The expression of the metabolic genes is altered in these cell lines and P-glycoprotein is also 
activated at functional level in Caco/mCAR cells. The possibility of regulating metabolic 
genes with specific ligands and functionality of CYP enzymes is a subject for further studies. 
A systematic comparison of absorption properties of several modified cell lines shows that the 
permeabilities of our model compounds were essentially unaffected. Further studies are 
needed to clarify the role of efflux protein levels and properties of compounds in in vitro 
absorption models. For classical permeability screening, modified cell lines offer little 
advantage over Caco/WT cells, provided that metabolic properties and efflux pump 
interactions are screened with other high throughput methods. When efflux pump interactions 
are screened, high expression profile is obviously beneficial but passive transport should not 
be altered. Nuclear receptor transfected cell lines respond to their respective ligands and may 
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thus be utilised in induction studies. Finally, active oxidative metabolism is required for 
studying the interplay with efflux pumps and CYP enzymes. Caco/VD3 has been shown to be 
capable of first-pass metabolism (Fisher et al. 1999) and, according to our RT-PCR data, the 
nuclear transfected cell lines are potential in this regard. 
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5 METABOLIC AND EFFLUX PROPERTIES OF CACO-2 CELLS 
STABLY TRANSFECTED WITH NUCLEAR RECEPTORS* 
 
Abstract: Cell lines transfected with hPXR and mCAR were treated with established ligands, 
and gene expression of CYP and efflux pump genes were quantified by qRT-PCR and 
western blot. P-glycoprotein activity was assessed by measuring calcein-AM accumulation 
and bidirectional permeability coefficients of digoxin and quinidine. CYP activities were 
measured with both fluorescent and non-fluorescent substrates. hPXR and mCAR upregulated 
some CYP and efflux pump genes ligand dependently. P-glycoprotein level was increased, 
but CYP3A4 protein remained below the limit of detection. P-glycoprotein activity was 
markedly elevated in Caco/mCAR cells and more modestly in Caco/hPXR cells. CYP3A4 
activity remained lower than that in vitamin D-treated Caco-2 cells. Nuclear receptors can 
modulate the expression of metabolic genes in Caco-2 cells, but the overall level of 
metabolism could not be efficiently controlled. P-glycoprotein activity increased, but CYP 
activities remained very low. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Adapted from: Korjamo T, Mönkkönen J, Uusitalo J, Turpeinen M, Pelkonen O, 
Honkakoski P: Metabolic and efflux properties of caco-2 cells stably transfected with nuclear 
receptors. Pharm Res 23: 1991-2001, 2006 with kind permission from Springer Science and 
Business Media 
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5.1 Introduction 
We introduced two novel Caco-2 cell lines that are transfected with orphan nuclear 
receptors, namely the human pregnane X receptor (Caco/hPXR) and the murine constitutive 
androstane receptor (Caco/mCAR) (Chapter 4). Since these two orphan nuclear receptors 
regulate several genes involved in xenobiotic metabolism (Honkakoski 2003), our approach 
can, in principle, control the general level of xenobiotic metabolism. Such a model could be 
used both in mechanical studies on the role of active and passive processes at the intestinal 
level and for screening potential new molecules.  
The purpose of the present study was to characterise the inducibility of metabolic genes in 
Caco-2 cell lines stably transfected with nuclear receptors hPXR or mCAR and the resulting 
changes in efflux pump and CYP activities. The effect of established nuclear receptor ligands 
on the gene expression was studied on the mRNA and protein level, and the functional 
activity of P-glycoprotein and CYP3A4 was assessed. 
 
5.2 Materials and methods 
Section 4.2 describes the culture of Caco-2 cells (Caco/WT, Caco/hPXR and Caco/mCAR), 
calcein-AM and quantitative RT-PCR experiments. Permeability experiments were modified 
by using a stirring rate of 450 rpm. 
 
5.2.1 Chemicals 
Most of the chemicals were of commercial origin and described in section 4.2. 1,4-bis[2-
(3,5-dichloropyridyloxy)]benzene (TCPOBOP) was synthesized and purified according to 
Honkakoski et al. (1996). GF120918 was a gift from GlaxoSmithKline (Research Triangle 
Park, NC). 
 
5.2.2 Receptor activation 
Different activation schemes for nuclear receptors were used in this study. The applied 
concentrations were: rifampicin 10 µM (hPXR activator) (Bertilsson et al. 1998), TCPOBOP 
1 µM (mCAR activator) (Tzameli et al. 2000), androstenol 10 µM (mCAR inhibitor) (Forman 
et al. 1998) and vitamin D 250 nM (Schmiedlin-Ren et al. 1997). Cells grown on filters were 
induced with chemicals for 4, 7 or 14 days at the end of the 21-day growth period. The cells 
used for calcein-AM experiments were activated for the full 4-day growth period. 
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5.2.3 Western blotting 
CYP3A4 and MDR1 protein expression were quantified using antibodies. The cells were 
suspended into the lysis buffer (Hamilton et al. 2001) and allowed to stand on ice for 30 
minutes. The supernatant was collected, and the protein concentration was measured with 
Bradford reagent according to the manufacturer's instructions (Sigma, St. Louis. MO). 
Samples were mixed with sample buffer and boiled for 1 minute. Samples (50 µg for 
CYP3A4, 20 µg for MDR1) were electrophoresed into 12 % SDS-PAGE gel and blotted onto 
a nitrocellulose membrane (Biorad, Hercules, CA).  
For CYP3A4 immunoblot, the membrane was rinsed with Tris buffered saline (TBS) and 
blocked with 5 % fat-free milk powder for 1 hour at room temperature. The anti-CYP3A4 
antibody was provided by Dr. Robert J. Edwards (Imperial College School of Medicine, 
London, UK)(Edwards et al. 1998). Blocked membrane was incubated at RT for 1 hour in a 
1:5000 dilution of primary antibody in TBS containing 0.5 % fat-free milk powder. The 
membrane was washed 3 times for 5 minutes with TBS containing 0.1 % Tween20, incubated 
in a 1:12500 dilution of Goat anti-rabbit HRP conjugated secondary antibody (Promega, 
Madison, WI) for 1 hour and washed again 3 times for 5 minutes with TBS. Proteins were 
detected using SuperSignal west chemiluminescent substrate (Pierce, Rockford, IL). The 
exposure time was 30 seconds. Human CYP3A4 Supersomes (BD Gentest, Franklin Lakes, 
NJ) were used as standards.  
For MDR1 immunoblot, the membrane was blocked with 3 % fat-free milk powder in 
phosphate-buffered saline (PBS) containing 0.3 % Tween20 for 2 hours at room temperature. 
The primary antibody (P-glycoprotein antibody [C494], AbCam, UK) was diluted 1:500 in 
PBS containing 0.5 % BSA and 0.3 % Tween20 and incubated with the membrane overnight 
at +4°C. The membranes were washed three times for 10 minutes with PBS-0.3% Tween 20. 
The anti-mouse secondary antibody (Promega, Madison, WI) was diluted 1:2000 in PBS 
containing 3 % fat-free milk powder and 0.3 % Tween20 and incubated with the membrane 
overnight at +4°C. The membranes were washed 3 times for 10 minutes and the proteins were 
detected by chemiluminescence. The total cellular protein of MDCK-MDR1 cells that were 
grown on filters for 4 days was used as a positive control.  
 
5.2.4 Assessing P-glycoprotein activity 
P-glycoprotein substrates digoxin and quinidine were used as model compounds in 
permeability studies. Their bi-directional apparent permeability coefficients were determined 
in the presence and absence of strong P-glycoprotein inhibitor GF120918. 
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Both passive and active transport contribute to the apparent permeability. It has been 
pointed out, e.g. by Troutman and Thakker (2003b) and Collet et al. (2004), that P-
glycoprotein activity should be evaluated by comparing the total apparent permeability (Papp) 
to the passive permeability (Ppass) determined in the presence of an inhibitor. Therefore, we 
also present absorptive (AQ) and secretory (SQ) quotients described by Troutman and 
Thakker (2003b). The absorptive quotient describes the percentage by which P-glycoprotein 
is able to reduce absorptive transport. Similarly, the secretory quotient reflects the relative 
increase in secretory transport. The formulas are AQ=(Ppass-Papp)/Ppass and SQ=(Papp-
Ppass)/Ppass. 
 
5.2.5 CYP metabolic experiments 
Initially, we measured the activity of 9 different CYP isoforms in modified cell lines using 
the LC/MS cocktail approach described by Turpeinen et al. (2005) with minor modifications. 
Substrates were administered in HBSS-Hepes at 2-60 µM concentrations, and the incubation 
time was up to 24 hours. Only Caco/VD3 cells produced detectable amounts of metabolites of 
midazolam and omeprazole indicating CYP3A4 activity. Therefore, we switched to a more 
sensitive fluorescent probe. 
CYP3A4 activity was measured with a coumarin derivative (7-benzyloxy-4-
(trifluoromethyl)-coumarin) that is dealkylated into fluorescent 4-(trifluoromethyl)-coumarin 
(HFC) by CYP3A4, CYP1A2 and to a lesser extent by CYP2B6 (Donato et al. 2004). Cells 
were grown and activated as in the permeability experiments. Filters were washed with 
HBSS-Hepes that contained 1 % DMSO. BFC (50 µM) was added in both apical and 
basolateral compartments with or without a potent CYP3A4 inhibitor ketoconazole (5 µM). 
Cells were incubated at +37°C for 6 hours, and 80 µl samples were collected from both 
chambers into B&W Isoplates (Wallac, Finland). A standard curve (5-500 nM) was 
constructed from HFC (Sigma, St. Louis, MO). Fluorescence was recorded with VICTOR2 
(Wallac, Finland). In initial experiments the cells were also lysed and the cellular fluorescence 
measured, but accumulation of HFC was low (<40 % of the amount in the apical chamber) 
and correlated well with the extracellular HFC. Therefore samples were later taken only from 
the buffer. To hydrolyse possible conjugates the samples were also initially treated with 5 
units of glucuronidase/sulfatase enzymes (Sigma, St. Louis, MO) at +37°C for 1 hour; but the 
amounts of HFC were not elevated. As Matrigel coating has previously been shown to 
increase CYP3A4 activity (Schmiedlin-Ren et al. 1997), we also tested its effect on metabolic 
activity in our cell lines. Filters were coated with 30 µg of Matrigel (BD Gentest, Franklin 
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Lakes, NJ) according to the manufacturer's instructions. Metabolic activities were, however, 
not markedly elevated. 
 
5.2.6 Statistical analysis 
All cell lines and treatments were compared to the Caco/WT cells with the programs in the 
SPSS package (SPSS inc. Chicago, IL) using one-way ANOVA and Dunnett's pair-wise test. 
The effects of CAR and PXR ligands on the Caco/mCAR and Caco/hPXR cells were tested 
with ANOVA or t-test depending on the number of groups. 
 
5.3 Results 
 
5.3.1 Quantitative RT-PCR 
The mRNA expression of several metabolic genes was changed in fully differentiated cells 
(Table 5.1). Caco/hPXR cells showed elevated levels of CYP3A4, MDR1 and CYP2C9 
mRNA. In the uninduced Caco/mCAR cells, the expression of CYP2B6, CYP2C9 and MDR1 
was slightly altered. BCRP did not respond to any modifications or treatments (0.7 to 1.1 
times Caco/WT), and these data were omitted from Table 5.1. For comparison, data from 
Caco/VD3 cells were taken from chapter 4. 
Nuclear receptor ligands were able to modulate gene expression in Caco/hPXR and 
Caco/mCAR cells, but these ligands had no effect on the gene expression of Caco/WT cells. 
CYP3A4, MDR1 and MRP2 genes showed the best and time-dependent responses to 
rifampicin treatment in Caco/hPXR cells (Table 5.1), but the changes did not reach statistical 
significance. A prototypical mCAR activator, TCPOBOP, induced the most pronounced 
activation on the CYP2B6 gene. In addition, the CYP2C9 gene was significantly activated by 
TCPOBOP, but the other genes responded to a lesser extent. The mCAR inhibitor androstenol 
was able to decrease only CYP2B6 transcription. 
The influence of nuclear receptors on the gene expression of relatively undifferentiated 
Caco-2 cells was also measured (Table 5.2). The mRNA levels of all genes were higher in 
Caco/hPXR than in Caco/WT cells, but rifampicin treatment did not increase the expression 
any further. mCAR transfection was most effective on CYP2B6, CYP2C9 and MDR1, which 
also responded to TCPOBOP. The inhibitory action of androstenol is clear only with the 
CYP2B6 gene, as was also the case with filter grown cells. Furthermore, Table 5.2 shows that 
the expression of all the studied genes is increased during the differentiation of Caco-2 cells. 
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Table 5.1: Quantitative PCR results of filter-grown (21 days) Caco-2 cell lines 
Cell line Treatment Days CYP3A4 CYP2B6 CYP2C9 MDR1 MRP2 
Caco/WT DMSO 14 1.0 ± 0.3 1.0 ± 0.3 1.0 ± 0.2 1.0 ± 0.5 1.0 ± 0.3 
 Rifampicin 14 1.3 ± 0.4 0.8 ± 0.3 0.9 ± 0.2 1.3 ± 0.4 0.9 ± 0.2 
 TCPOBOP 14 1.0 ± 0.5 0.9 ± 0.3 0.8 ± 0.2 1.0 ± 0.3 1.2 ± 0.4 
 Androstenol 14 1.2 ± 0.5 0.9 ± 0.3 1.0 ± 0.2 1.0 ± 0.4 1.2 ± 0.4 
Caco/hPXR DMSO 14 21.2 ± 4.7b 1.4 ± 0.5 2.4 ± 0.6 6.5 ± 1.5 1.4 ± 0.3 
 Rifampicin 14 39.7 ± 11.2b 1.5 ± 0.4 2.9 ± 0.7b 11.7 ± 1.3b 2.3 ± 0.5b 
 Rifampicin 7 42.0 ± 12.5b 1.4 ± 0.3 2.5 ± 0.5 9.8 ± 1.3b 2.1 ± 0.5b 
 Rifampicin 3 29.5 ± 6.7b 1.1 ± 0.3 1.9 ± 0.4 6.0 ± 1.4 1.3 ± 0.3 
Caco/mCAR DMSO 14 1.3 ± 0.4 0.4 ± 0.1 2.4 ± 0.5 3.7 ± 1.9 1.1 ± 0.2 
 TCPOBOP 14 4.2 ± 1.1 2.5 ± 0.5b,c 4.2 ± 0.8b,c 7.0 ± 2.7b 1.9 ± 0.3 
 TCPOBOP 7 3.7 ± 1.0 2.0 ± 0.4b,c 3.9 ± 0.7b,c 6.6 ± 2.4b 2.0 ± 0.4b 
 TCPOBOP 3 3.5 ± 0.8 1.8 ± 0.5c 3.6 ± 0.7b 4.7 ± 2.6 1.3 ± 0.2 
 Androstenol 14 3.9 ± 1.4 0.2 ± 0.1 2.5 ± 0.5 5.3 ± 2.0 1.3 ± 0.3 
 Androstenol 7 3.5 ± 1.0 0.3 ± 0.1 3.7 ± 0.7b 6.9 ± 3.8 1.6 ± 0.2 
 Androstenol 3 3.3 ± 0.9 0.3 ± 0.1 3.2 ± 0.7b 6.2 ± 2.5 1.6 ± 0.3 
Caco/VD3a Vitamin D3 14 900 ± 140b 1.4 ± 0.1 1.9 ± 0.1 3.3 ± 1.2 1.7 ± 0.3 
 Total RNA was isolated, treated with DNase and reverse transcribed using random priming. 
Samples were amplified using TaqMan-chemistry. mRNA levels were calculated using 
comparative Ct-method. Individual expression levels were normalised to β-actin and 
compared to Caco/WT expression levels. Results are expressed as mean±S.E.M. n=5. 
a Data taken from Chapter 4 
b Significantly different from Caco/WT DMSO according to ANOVA and Dunnett's post hoc 
test, p<0.05 
c Significantly different from the corresponding cell line treated with DMSO according to 
ANOVA and Dunnett's post hoc test, p<0.05 
 
Table 5.2: Quantitative PCR results of Caco-2 cell lines grown on plastic (4 days) 
  Treatment CYP3A4 CYP2B6 CYP2C9 MDR1 MRP2 
Caco/WT - 1.0 ± 0.0 1.0 ± 0.0 1.0 ±0.0 1.0 ± 0.0 1.0 ± 0.0 
Caco/hPXR - 11.3 ± 1.7 4.2 ± 0.2 4.1 ±0.9 2.3 ± 0.0 2.1 ± 0.5 
 Rifampicin 11.0 ± 2.8 3.0 ± 0.8 3.2 ±0.5 1.9 ± 1.2 1.8 ± 1.2 
Caco/mCAR - 0.9 ± 0.7 4.8 ± 2.7 6.2 ±0.3 4.9 ± 1.9 1.8 ± 0.7 
 TCPOBOP 2.9 ± 0.5 15.9 ± 5.3 11.6 ±3.0 9.6 ± 1.4 2.7 ± 0.4 
 Androstenol 0.9 ± 0.4 2.9 ± 0.9 10.3 ±5.0 5.4 ± 0.7 2.4 ± 0.4 
Caco/WT 21 days 11.2 ± 9.2 6.4 ± 0.5 21.6 ±14.8 8.9 ± 3.6 4.1 ± 2.9 
See footnote of Table 5.1 for experimental details. Results are presented as a mean±S.E.M. of 
two independent experiments. 
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5.3.2 Western blot  
CYP3A4 and MDR1 gene expression was quantified at the protein level (Fig 5.1). CYP3A4 
was only detectable in Caco/VD3 cells, which had approximately 0.4 nmol of CYP3A4 per 
milligram of protein. The CYP3A4 protein from the cells migrated at slightly faster than 
CYP3A4 from commercial microsomal preparation. MDR1 gene product P-glycoprotein was 
barely detected in the Caco/WT cells. The stable transfectants showed constitutive expression 
of P-glycoprotein, which was yet increased by nuclear receptor ligands. 
 
 
Figure 5.1: Western blot data. Cells were frown on filters for 21 days and activated with 
indicated chemicals for the last 14 days. (a) 50 µg of total cellular protein was blotted onto 
nitrocellulose membrane and probed with CYP3A4 specific antibody. Commercially available 
microsomes were used as standards. No other specific bands were detected even after long 
exposure times. (b) 20 µg of total cellular protein was blotted into nitrocellulose membrane 
and probed with MDR1 specific antibody. Total protein form MDCK-MDR1 cells was used 
as a positive control. 
 
5.3.3 Calcein-AM 
P-glycoprotein function was evaluated in calcein-AM experiments (Fig 5.2). The basal 
calcein retention was lower in both stable transfectants than in the Caco/WT cells. Inhibitors 
elevated the fluorescence values in Caco/mCAR cells to about the same level as in Caco/WT 
cells. Therefore, retention factors (inhibitor/vehicle ratios) were also significantly higher in 
Caco/mCAR cells. In Caco/hPXR cells, however, the fluorescence levels remained lower than 
in the wild type cells and the retention factors were only non-significantly elevated. Nuclear 
receptor ligands were also tested as inhibitors, but they did not increase the cellular retention 
of calcein (data not shown). 
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Figure 5.2: Cellular retention of calcein after incubating calcein-AM with or without P-
glycoprotein inhibitors. Bars represent background corrected relative cellular fluorescence 
(mean±S.E.M.). Treatments were 1 % DMSO (white), 15 µM cyclosporin A (light grey), 170 
µM progesterone (dark grey) and 600 µM verapamil (black). Numbers above bars are 
inhibitor-to-vehicle fluorescence ratios. n=4-7. 
a Fluorescence significantly different from corresponding Caco/WT fluorescence according to 
ANOVA and Dunnett's post hoc test, p<0.05 
b Inhibitor-to-vehicle ratio significantly different from corresponding Caco/WT value 
according to ANOVA and Dunnett's post hoc test, p<0.05 
 
5.3.4 Permeability experiments 
Mannitol permeability was used to the check monolayer integrity. Permeabilities were 
Caco/WT: 1.85 (±0.17) x 10-6 cm/s, Caco/hPXR: 1.97 (±0.11) x 10-6 cm/s and Caco/mCAR: 
1.03 (±0.09) x 10-6 cm/s. We recovered virtually 100 % of the applied digoxin and mannitol, 
but the mass balance for quinidine was about 80-90 %, probably due to the cellular retention.  
Digoxin was our P-glycoprotein model substrate with low passive permeability. We 
checked with Caco-WT cells whether the nuclear receptor ligands directly affected digoxin 
permeability e.g. by inhibiting some transporters. The transport of digoxin was highly 
polarised in the absence and essentially unpolarised in the presence of the P-glycoprotein 
inhibitor GF120918 (Figure 5.3). 
Rifampicin moderately decreased the BA permeability digoxin (from 16.9 x 10-6 cm/s to 
13.0 x 10-6 cm/s) in the Caco/WT cells when present in the transport buffer, but none of the 
ligands affected the permeability when they were used only in culture medium during the  
growth period. The passive component was similar in Caco/WT and Caco/hPXR cells, but 
Caco/mCAR cells formed a tighter permeability barrier. Caco/hPXR had both decreased 
absorptive and increased secretory transport, indicating elevated P-glycoprotein activity. 
Rifampicin treatment tended to further increase P-glycoprotein-mediated digoxin transport. 
Caco/mCAR cells showed decreased AB permeability, but the secretory transport was similar 
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to that in the Caco/WT cells. Surprisingly, mCAR ligands affected digoxin permeability in 
ways that were opposite to what was anticipated. TCPOBOP reduced and androstenol 
increased the difference between inhibited and uninhibited digoxin permeability.   
 
 
Figure 5.3: Apparent permeability coefficients of digoxin. The transport buffer was spiked 
with radiolabelled digoxin and bidirectional apparent permeability coefficients were 
measured. Bars represent mean±S.E.M. Permeability coefficients were measured in the 
apical-to-basolateral direction without (white) or with (light grey) the inhibitor (GF120918) 
and in the basolateral-to-apical direction with (dark grey) or without (black) the inhibitor. 
n=5-8.  
* Significantly different from Caco/WT according to ANOVA and Dunnett's post hoc test, 
p<0.05 
 
Quinidine is a good P-glycoprotein substrate with high passive permeability. The results of 
the permeability experiments (Figure 5.4) show that passive permeability was similar in 
Caco/WT and Caco/hPXR cells but moderately lower in Caco/mCAR cells. Increased P-
glycoprotein activity in the stable transfectants was evident from the decreased absorptive 
permeability. BA permeability was, however, elevated only in Caco/mCAR cells. Statistical 
testing was omitted because the small number of replicates (n=2) does not allow reliable 
testing. 
The relative role of P-glycoprotein in permeability can be evaluated with absorptive and 
secretory quotients (Troutman and Thakker 2003b), which are presented along with the 
classical apical-to-basolateral / basolateral-to-apical (AB / BA) ratio in Table 5.3. Both 
modified cell lines were able to attenuate the absorption of digoxin (AQ values) more than the 
Caco/WT cells were. Also based on the secretory quotient, the P-glycoprotein activity seems 
to be elevated in the modified cell lines. Rifampicin induced a minor elevation in both 
quotients in the Caco/hPXR cells. As evident also from Figure 5.3, androstenol treatment 
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increased both AQ and SQ in the Caco/mCAR cells for digoxin, while TCPOBOP had 
smaller effect on these parameters. The AB / BA-ratios were significantly lower in both 
modified cell lines than in Caco/WT cells. The AQ of quinidine was elevated similarly in both 
modified cell lines in comparison to the Caco/WT cells. SQ, however, was considerably 
increased only in the Caco/mCAR cells (Table 5.3). Moreover, the reduction of AB / BA-ratio 
of quinidine in stable transfectants clearly indicates increased P-glycoprotein activity 
 
 
Figure 5.4: Apparent permeability coefficients of quinidine. Transport buffer containing 1 
µM unlabelled quinidine was spiked with radiolabelled quinidine and bidirectional apparent 
permeability coefficients were measured.  Bars represent mean±S.E.M. Permeability 
coefficients were measured in the apical-to-basolateral direction without (white) or with (light 
grey) the inhibitor (GF120918) and in the basolateral-to-apical direction with (dark grey) or 
without (black) the inhibitor. n=2. Statistical testing was omitted due to small number of 
replicates 
 
Table 5.3: The relative effect of P-gp activity on digoxin and quinidine permeability 
  Digoxin Quinidine 
 Treatment AQa SQb AB/BAc AQa SQb AB/BAc 
Caco/WT - 0.58 3.3 0.089 0.68 0.52 0.184 
Caco/hPXR - 0.73 4.0 0.045d 0.84 0.64 0.092 
 Rifampicin 0.77d 4.1 0.040d N.D. N.D. N.D. 
Caco/mCAR - 0.69 4.4 0.043d 0.85 1.37 0.063 
 TCPOBOP 0.64 4.8d 0.067 N.D. N.D. N.D. 
 Androstenol 0.75d 5.5d 0.036d N.D. N.D. N.D. 
Caco-2e  0.85 2.0 0.049 0.63 0.95 0.191 
MDCK-MDR1e  0.75 3.8 0.053 0.67 3.90 0.067 
Apparent permeability coefficients are represented as Papp x 10
6 cm/s. N.D. = not done. 
a Absorptive quotient=(Ppass-Papp)/Ppass (Troutman and Thakker 2003b) 
b Secretory quotient=(Papp-Ppass)/Ppass (Troutman and Thakker 2003b) 
c Papp apical-to-basolateral / Papp basolateral-to-apical 
d Significantly different from Caco/WT according to ANOVA and Dunnett's post hoc test, 
p<0.05 
e Data taken for comparison from Troutman and Thakker (Troutman and Thakker 2003b) 
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5.3.5 CYP3A4 activity 
Metabolic activity of CYP3A4 was measured with a coumarin derivative BFC with and 
without ketoconazole (Fig 5.5). The ability of CYP3A4 to metabolise BFC was confirmed 
using commercial CYP3A4 preparation (data not shown). In general, the metabolic activities 
in Caco-2 cell lines were very low since CYP3A4-mediated product formation after 6 hours 
was less than 0.1 % of the initial substrate concentration. Caco/WT had the lowest and 
Caco/VD3 the highest CYP3A4-activity. The modified cell lines fell between these two 
extremes. Uninhibited Caco/WT and Caco/VD3 cells produced an apical concentration of 
21.7 and 42.1 nM, respectively. Ketoconazole reduced these values to 18.4 and 24.6 nM.  
 
 
Figure 5.5: CYP3A4 mediated metabolism in modified cell lines. Cells were incubated in 
HBSS-Hepes containing 50 µM BFC for 6 h with or without 5 µM ketoconazole. The 
concentration of fluorescent metabolite HFC was analysed from the apical chamber. CYP3A4 
mediated metabolism was calculated by subtracting the HFC concentration in inhibited wells 
from that of the uninhibited wells. Bars represent mean±S.E.M. n=3-6. 
* Significantly different from Caco/WT according to ANOVA and Dunnett's post hoc test, 
p<0.05 
 
5.4 Discussion 
First-pass metabolism at the intestinal epithelium is an established fact for certain 
compounds (Thummel et al. 1996) but whether it is generally significant or just a peculiarity 
affecting only a marginal number of compounds is still being debated (Lin et al. 1999; 
Doherty and Charman 2002). Therefore, an in vitro model that could express considerable and 
preferably regulatable amounts of CYP enzymes and efflux pumps would be useful in 
mechanistic studies. Our aim was to study how two nuclear receptors (hPXR and mCAR) 
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affect CYP and efflux pump activities in the Caco-2 cell line and whether we could use 
known ligands to regulate the general level of metabolism in these cells.  
 
5.4.1 Gene expression 
Genes involved in xenobiotic metabolism need to be regulated efficiently in response to 
exposure to various chemicals. Indeed, orphan nuclear receptors, which are thought to be key 
regulators of xenobiotic metabolism, have a wide ligand specificity and several target genes 
that are partially overlapping (Maglich et al. 2002; Rosenfeld et al. 2003). Many important 
CYP genes (e.g. 2B6, 2C9 and 3A4) and efflux pumps (e.g. MDR1 and MRP2) are target 
genes of PXR or CAR or both (Honkakoski 2003). BCRP expression has been correlated to 
PXR expression in small intestinal samples (Albermann et al. 2005), but direct evidence of its 
regulation is missing. 
Both PXR (Bertilsson et al. 1998) and CAR (Arnold et al. 2004) are expressed in the small 
intestine. Caco-2 cells do not express PXR (Pfrunder et al. 2003), but during differentiation 
CAR transcription is elevated (Arnold et al. 2004). Nuclear receptors may show some basal 
activity, which may be due to the presence of endogenous ligands or some chemicals in the 
cell culture medium. PXR has broader ligand specificity than CAR, and most of the PXR 
ligands activate the receptor and increase the expression of target genes (Moore et al. 2002). It 
should be noted, however, that not all the PXR target genes respond similarly to all activators, 
which is probably due to differences in receptor-coactivator interactions (Masuyama et al. 
2005). In contrast to PXR, CAR usually shows considerable basal activity, and its ligands can 
either increase (Honkakoski et al. 1998; Sueyoshi et al. 1999) or decrease (Forman et al. 
1998; Mäkinen et al. 2003) the expression of the target genes.  
mRNA level 
Modified Caco-2 cell lines showed changes in the patterns of gene expression. Caco/hPXR 
cells had higher uninduced levels of expression of CYP3A4 and MDR1 than Caco/mCAR 
cells (Table 5.1). A previous study showed that transient hPXR transfection alone does not 
affect CYP3A4 reporter gene activity in Caco-2 cells, but rifampicin treatment causes nearly 
20-fold activation (Tirona et al. 2003). Compared to this, our Caco/hPXR cells showed 
considerable basal activation of CYP3A4 gene (>20-fold), but further increase with 
rifampicin was modest (1.9-fold). RT-PCR results (Table 5.1) show that hPXR can activate 
CYP3A4 gene in Caco-2 cells only modestly compared to vitamin D-treatment. Vitamin D 
acts through the vitamin D receptor, but this response has been shown to depend on the cell 
line (Schmiedlin-Ren et al. 2001). The activation of CYP2B6 in our Caco/mCAR cells caused 
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by TCPOBOP was strong and in line with the results of a previous study with mouse 
hepatocytes in which 6.5-fold induction of the CYP2B10 gene was reported (Mäkinen et al. 
2003). A recent study reported that stably transfected human CAR could upregulate MDR1, 
CYP3A4 and CYP2B6 in an intestinal cell line to a greater extent than in our study, but there 
were differences in activation profiles between different clones, possibly due to the random 
integration of the vector (Burk et al. 2005). Androstenol could decrease the expression of 
CYP2B6, but other genes were unaffected or even activated. The mechanism of this activation 
is not clear but it may include differences in the cellular environment (Burk et al. 2005) or co-
regulator requirements of promoters (Masuyama et al. 2005) or insufficient HNF4 expression 
(Borlak and Zwadlo 2003; Tirona et al. 2003). It can be concluded that hPXR and mCAR can 
alter gene expression in Caco-2 cells, but complete control of the expression of metabolic 
genes was not achieved, probably partly due to improper expression of the necessary auxiliary 
proteins in the Caco-2 cells. 
We also studied gene expression and induction in less differentiated cells grown on plastic 
multi-well plates for four days that are used for calcein-AM experiments (Table 5.2). In this 
case, TCPOBOP was able to activate Caco/mCAR cells, but rifampicin had virtually no effect 
on Caco/hPXR cells. Again, one explanation for these patterns of regulation might be the 
expression of nuclear receptor coregulators. The original data of Sun et al. (2002) reveal that 
during the Caco-2 cell differentiation the expression of at least three nuclear receptor 
coregulators is elevated. Therefore, the lack of co-activators may hamper the nuclear receptor 
function in these relatively undifferentiated cells.  
Protein level 
Changes in transcription should also alter protein levels. The findings of Taipalensuu et al. 
(2004) suggest that the transcription and protein synthesis of the MDR1 gene correlated well 
in several adherent cell lines used for permeability studies. Our Caco-2 cells had clearly less 
P-glycoprotein than the positive control cell line MDCK-MDR1, which differs considerably 
from the results of Troutman and Thakker (2003b) who reported only a 1.5-fold difference. 
Nuclear receptor transfections produced only small additional increases in P-glycoprotein 
levels. 
Previous studies from other laboratories have shown that Caco-2 cells express very low 
levels of CYP3A4 and CYP1A1 but not CYP1A2, CYP2C9, CYP2D6 or CYP2E1 proteins 
(Lampen et al. 1998; Prueksaritanont et al. 1996). Our CYP3A4 western blot method could 
detect protein only from Caco/VD3 cells (Fig 5.1a). The amount of CYP3A4 in whole-cell 
lysate is 0.4 pmol/mg, which is 40 times less than reported in the original publication 
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(Schmiedlin-Ren et al. 1997). It should be noted, however, that the Matrigel coating used in 
the original study was omitted in our study since we did not observe a significant effect on 
CYP3A4 activity. Nuclear receptor transfections, especially hPXR, were able to increase 
CYP3A4 transcription but not to an extent similar to vitamin D treatment, and the protein 
levels remained below the limit of detection. This result points out the difficulty in 
upregulating CYP gene expression in Caco-2 cells. 
 
5.4.2 Functional activities 
Small changes in transcription or even in protein level do not necessarily change the 
functional properties of the cell. This is especially true if the outcome of an assay depends on 
several mechanisms, including passive diffusion or the activity of other proteins. Therefore, 
we evaluated P-glycoprotein activity with two experimental settings that were cellular 
retention of calcein after calcein-AM exposure and bidirectional permeability experiments 
with digoxin and quinidine. CYP enzyme activities were initially tested with a cocktail 
approach (Turpeinen et al. 2005); but because only traces of midazolam and omeprazole 
metabolites were produced in the positive control cell line (Caco/VD3), we later used a 
fluorescent probe for CYP3A4. 
Calcein-AM  
P-glycoprotein activity in the calcein-AM experiments (Fig 5.2) and the mRNA level of 
MDR1 (Table 5.2) showed a rank order correlation Caco/mCAR > Caco/hPXR > Caco/WT. 
In contrast to MDR1 transcription, nuclear receptor ligands did not change the results of 
calcein-AM experiments. The total fluorescence in the presence of inhibitors was moderately 
but consistently lower in Caco/hPXR than in other cell lines. A similar finding was previously 
made with vincristine-treated Caco-2 cells (Eneroth et al. 2001). As fluorescent calcein is 
effluxed by MRP1 and MRP2 (Prime-Chapman et al. 2004), differences in their expression 
could change the basal retention of calcein. However, this is probably not the explanation, 
since the cellular fluorescence in Caco/hPXR cells remains lower than in the Caco/WT cells 
even in the presence of MDR1/MRP1/MRP2 inhibitor cyclosporin A. One possible reason is 
the moderately slower growth rate of Caco/hPXR cells, which can be seen during routine 
subculturing. Caco/hPXR cells reach confluence on 96-well plates in 24 hours like Caco/WT 
cells, but may form less cell mass during the total 4-day growth period. Of course, the 
intracellular esterase activity also affects the formed fluorescence, and it is possible that this 
activity is lowered in Caco/hPXR cells.  
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Permeability 
Bidirectional permeability experiments can reveal P-glycoprotein activities in cell lines. We 
tested the permeability properties of our transfected cell lines with several compounds 
including P-glycoprotein substrates verapamil and rhodamine-123 (Chapter 4). Those two 
compounds could not differentiate our cell lines, because their permeability is only partly 
dependent on the P-glycoprotein activity as discussed. For this study we chose digoxin and 
quinidine as  model substrates, since they both are good P-glycoprotein substrates (Greiner et 
al. 1999; Polli et al. 2001) and their passive permeabilities differ considerably. However, the 
difficulty of finding marker molecules that would be sole substrates of a single transporter is 
illustrated by a generally accepted P-glycoprotein marker molecule digoxin. In rat and human 
kidney, in addition to P-glycoprotein, digoxin permeability involves basolateral OATP 
transporter (Mikkaichi et al. 2004). An OATP substrate rifampicin has been shown to 
modulate digoxin transport in perfused rat liver (Lau et al. 2004). We also observed changes 
in digoxin permeability if rifampicin was added to the transport buffer. Thus, the apparent 
permeability of digoxin does not depend solely on the P-glycoprotein activity and the passive 
diffusion properties of the monolayer. 
Changes in the P-glycoprotein activity are not necessarily obvious from individual 
permeability values. We used digoxin and quinidine at concentrations that were below Km-
values (Troutman and Thakker 2003a) and differences in apparent permeability should reflect 
altered P-glycoprotein levels. In all cell lines the passive permeability of both molecules was 
essentially unpolarised, but Caco/mCAR cells had slightly lower absolute permeability 
coefficients (Fig. 5.3 and 5.4), which is, at least for digoxin, caused by differences in 
paracellular permeability. Consistent with mRNA and protein data, both P-glycoprotein 
substrates permeated the Caco/mCAR and Caco/hPXR cells slower than the wild type cells, 
and thus the relative attenuation of absorption (Absorptive quotient) was increased (Table 
5.3). The increase in P-glycoprotein activity in the BA direction was less evident because the 
absolute permeability values were not consistently higher in the modified cell lines. Still the 
relative contribution of P-glycoprotein to the secretory permeability (Secretory quotient) was 
at least modestly elevated in each case. In line with the mRNA and protein data, rifampicin 
could increase P-glycoprotein activity but the magnitude of the effect was small. 
Paradoxically, mCAR inhibitor androstenol caused apparent increase and activator 
TCPOBOP caused slight decrease in P-glycoprotein activity.  
Digoxin has been classified as a high responder and quinidine as a low responder to P-
glycoprotein activity according to their sensitivity to changes in P-glycoprotein expression 
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(Troutman and Thakker 2003b). Our results show that generally, SQ for digoxin was more 
sensitive to P-glycoprotein level than SQ for quinidine. However, changes in AQ values were 
very similar for both substrates. Comparison to Caco-2 and MDCK-MDR1 literature data 
(Table 5.3) shows, that P-glycoprotein expression is not the sole factor determining the 
magnitude of AQ and SQ, but the expression of other transporters, the paracellular 
permeability and probably also the details of experimental settings modulate the outcome.  
CYP activity 
The lack of functional CYP enzymes in Caco-2 cells is a major obstacle in studying 
intestinal first-pass metabolism. Previous studies have approached this problem with different 
methods. Crespi et al. (Crespi et al. 1996) transfected Caco-2 cells with CYP cDNAs and later 
also with CYP oxidoreductase (Hu et al. 1999), but this method was reported to be unstable. 
Schmiedlin-Ren et al. increased CYP3A4 activity with vitamin D treatment (Schmiedlin-Ren 
et al. 1997). Our modifications can upregulate endogenous CYP gene transcription (Table 
5.1). The CYP activities of the stable transfectants were tested with a cocktail that has 
substrates for CYP isoforms 1A2, 2A6, 2B6, 2C8, 2C9, 2D6, 2E1 and 3A4 (Turpeinen et al. 
2005). Despite increased CYP transcription, no detectable metabolites were formed in 
Caco/WT, Caco/hPXR and Caco/mCAR cells. Traces of midazolam and omeprazole 
metabolites were produced in Caco/VD3 cells, indicating CYP3A4 activity. Next we tested 
CYP3A4 metabolism with 7-benzyloxy-4-(trifluoromethyl)-coumarin (BFC), which is 
metabolised into a fluorescent compound by CYP3A4 and to some degree by CYP1A2 and 
CYP2B6 (Donato et al. 2004). We used ketoconazole as CYP inhibitor at 5 µM concentration. 
This concentration is sufficient to inhibit CYP3A4 but not CYP1A2 and CYP2B6 (Turpeinen 
et al. 2005). Therefore, CYP3A4-mediated metabolism could be deduced. The activity levels 
were very low, but they agreed moderately with the RT-PCR results (Fig 5.5, Table 5.1) and 
also with the Western blot experiment (Fig 5.1a). In addition to CYP proteins, the observed 
metabolism also depends on CYP oxidoreductase activity. It is possible that the activity of 
this auxiliary protein also limited the metabolic capacity in our cell lines. Yet another reason 
for low metabolic activity may be the insufficient incorporation of heme into CYP 
apoenzyme.  
Previous studies with vitamin D-induced cells have used extracellular matrix coating, 
which has been reported to increase CYP activity (Schmiedlin-Ren et al. 1997; Engman et al. 
2001). Therefore, we tested the effect of Matrigel coating on CYP3A4 activity. The level of 
metabolism increased moderately, but the strong induction described by Schmiedlin-Ren et al. 
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(Schmiedlin-Ren et al. 1997) was not observed. A possible reason for this could be the clonal 
differences in vitamin D response described by Engman et al (Engman et al. 2001).  
 
5.5 Conclusions 
The present study shows that gene expression in Caco-2 cells can be modulated by nuclear 
receptors and corresponding ligand treatments. These changes may also be seen at the 
functional level, but the amplitude is usually much lower than that of mRNA. Increase in 
efflux pump activity is much more evident than in CYP activities, which is probably inherent 
to this cell line since the wild type Caco-2 cells express several efflux pumps but CYP 
activities are virtually absent. These experiments point out the general difficulty of modifying 
the Caco-2 cells and finding an assay that would clearly indicate changes in a single pump 
activity since the result of an experiment may depend on several factors including passive 
diffusion, transport proteins and enzyme activities. 
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6 DECREASE IN INTRACELLULAR CONCENTRATION CAUSES 
THE SHIFT IN KM VALUE OF EFFLUX PUMP SUBSTRATES* 
 
Abstract: Passive permeability and active efflux are parallel processes in transcellular flux. 
Therefore, the observed kinetics of a transporter substrate depends on both of these factors. 
The transporter expression has been shown to affect both the apparent Km and Vmax values. 
Kinetic parameters can be obtained from various experimental settings but these do not 
necessarily reflect the situation in transcellular flux. Kinetic absorption models need reliable 
estimates of saturable kinetics when accurate in silico predictions are to be made. The effect 
of increasing P-glycoprotein expression on apparent transport kinetics was studied using 
quinidine and digoxin as model compounds. The intracellular concentrations of drugs during 
the transport process were also measured. A dynamic simulation model was constructed to 
study the observed data. The apparent Km and Vmax values increased as the P-glycoprotein 
expression increased. Simulations reproduced the shift in both kinetic parameters as a 
function of efflux pump expression. In addition, apparent Km value showed strong inverse 
relationship to the passive permeability. In contrast, the apparent Vmax value reached a 
maximum at intermediate passive permeability and declined above and below this passive 
permeability. The true Vmax and Km values were never reached. The shift in Km was assigned 
to the decrease in intracellular concentration at the P-glycoprotein interaction site with both 
experimental and simulation data. In conclusion, the apparent kinetic parameters in 
transcellular permeability assay depend on passive permeability and efflux pump activity. 
Therefore, parameters that are obtained from in vitro assays should be cautiously applied to in 
vivo. 
 
 
 
 
 
 
* Adapted from: Korjamo T, Kemiläinen H, Heikkinen AT, Mönkkönen J: Decrease in 
intracellular concentration causes the shift in Km value of efflux pump substrates. Drug Metab 
Dispos 35: 1574-9, 2007. Reprinted with kind permission of the American Society for 
Pharmacology and Experimental Therapeutics. All rights reserved. 
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6.1 Introduction 
The determinants of oral drug bioavailability are of major interest in drug research. 
Absorption, distribution, metabolism and excretion (ADME) are intensively studied and in 
vitro-in vivo correlation has become an important issue in these studies. There are several 
applications for prediction of intestinal drug absorption from in vitro data. Compartmental 
absorption and transit (CAT) model (Yu and Amidon 1999) and other physiologically based 
computer models (Willmann et al. 2004; Usansky and Sinko 2005) simulate drug absorption 
using estimates of permeability and solubility properties of drug molecules and physiological 
parameters of the gastrointestinal tract. The present models usually work well for passively 
absorbed drugs but laborious in vivo experiments are required for accurate simulations on 
transporter substrates (Kwon et al. 2004). 
There are several methods available for creating input parameters for these simulation 
models. Passive permeability can relatively easily be measured with parallel artificial 
membrane permeability assay (PAMPA) or cell cultures (Hidalgo 2001) or predicted from the 
molecular properties of the chemical (Bergstrom et al. 2003). Kinetic parameters of a 
transporter, e.g. P-glycoprotein (P-gp), may be evaluated based on binding to the protein 
(Döppenschmitt et al. 1999), ATP hydrolysis in microsomal preparations (Boulton et al. 
2002), inhibition studies (Gao et al. 2001) or permeability experiments with suitable cell 
monolayers (Troutman and Thakker 2003; Horie et al. 2003; Balakrishnan et al. 2007). Since 
the methods usually give different results, the question raises which of these parameters 
should be used in a simulation model. To use the kinetic parameters from studies with isolated 
proteins in a simulation model, one would need a realistic estimate of the concentration at the 
intracellular interaction site. This is not an easy task since many processes are involved in the 
intracellular kinetics of drug molecules, as seen e.g. for paclitaxel (Kuh et al. 2000). 
Monolayer studies combine the expression level of the transporter of interest and the passive 
transport which means that kinetic values obtained vary depending on the cell line. 
Furthermore, the choice of experimental parameters such as pH conditions and stirring rate 
influence the passive permeability of drugs and, thus, different kinetic parameters can be 
obtained despite using identical cell lines.  
Some previous works describe an interesting phenomenon that apparent Km and/or Vmax 
values in a transport experiment increase when the transporter expression increases. This has 
been observed for both influx (Irie et al. 2006; Balakrishnan et al. 2007) and efflux (Zhang 
and Benet 1998; Soldner et al. 2000; Horie et al. 2003). Recent computational analyses 
suggest that transport assays cannot give accurate estimates of the molecular Michaelis-
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Menten parameters (Bentz et al. 2005; Balakrishnan et al. 2007). A very recent theoretical 
study using a basic three compartment transport model suggests that the apparent kinetics of 
efflux pump substrates are direction-dependent and also affected by both passive permeability 
and efflux pump expression (Kalvass and Pollack 2007). Therefore, there is a need to find 
useful relationships for kinetic values obtained from in vitro assays and their significance in 
observed permeability. 
P-gp is of considerable interest because it affects the absorption of several drugs. However, 
it is not known how the expression level of P-gp affects the apparent Michaelis-Menten 
constants in a permeability assay. In this report, the changes in the apparent kinetic 
parameters of known P-gp substrates quinidine and digoxin were studied with cell lines 
expressing various amounts of P-gp (Caco/WT, Caco/hPXR and MDCK-MDR1). Direct 
experimental evidence was obtained that the changes in the intracellular drug concentrations 
lead to shift in the apparent kinetic parameters. The effect of passive permeability on the 
apparent transport kinetics was investigated with a novel simulation model. 
 
6.2 Methods 
Section 4.2 describes the culture of Caco-2/WT and Caco-2/hPXR cell lines. Permeability 
experiments were conducted at several initial substrate concentrations with or without P-gp 
inhibitor GF120918 at 450 rpm as described in section 4.2. Sources of chemicals are given in 
sections 4.2 and 5.2. 
 
6.2.1 MDCK-MDR1 cell culture 
MDCK-MDR1 cells were purchased from Netherlands Cancer Institute (Netherlands). 
Growth medium was Dulbecco's modified Eagle's medium (Gibco 61965-026, Invitrogen) 
with 10 % heat inactivated fetal bovine serum and 100 U/ml penicillin, 100 µg/ml 
streptomycin. The cells were grown in 75 cm3 flasks at +37 °C in 95% air/5% CO2 
atmosphere and subcultured twice a week.  
For permeability experiments 390000 cells/cm2 (MDCKII-MDR1) were seeded onto 
uncoated polycarbonate filters (pore size 0.4 µM, area 1.1 cm2, Costar, Corning, NY). Cell 
passage numbers were 29-46. The growth medium was changed daily and the monolayer 
experiments were performed on the 4th day.  
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6.2.2 Unstirred water layer 
We studied the effect of the unstirred water layer (UWL) on quinidine permeability with 
Caco-2/WT cells at 0.3 µM concentration using various stirring rates (250-450 rpm). The 
assay was performed in both directions with and without 5 µM GF120918 at each stirring 
rate.   
 
6.2.3 Cellular retention 
After the kinetic parameters were determined, the cellular accumulation of drugs during a 
permeability experiment was determined at two concentrations (below and above observed 
Km value). The concentrations were: Quinidine Caco/WT 1 and 10 µM, Caco/hPXR and 
MDCK-MDR1 10 and 100 µM; Digoxin 50 µM onl y because of solubility problems. 
Altogether twelve inserts were prepared and the permeability experiment started as described 
above. At time points 5, 15, 30 and 60 min, three inserts were sampled on both chambers. 
These same inserts were washed from both sides with ice cold Hanks' balanced salt solution 
(HBSS) buffered with 25 mM Hepes. Thereafter, 300 µl of HBSS-Hepes containing 1 % 
Triton X-100 was added and the monolayers were lysed on an orbital shaker for 20-30 
minutes. A 100 µl sample was taken for liquid scintillation counting.  
 
6.2.4 Sample detection and result analysis 
Radioactivity of the assay samples was measured with MicroBeta liquid scintillation 
counter (Wallac, Finland) using OptiPhase HiSafe scintillation cocktail (Wallac, Finland). 
Apparent permeability coefficients under sink conditions were calculated for each drug 
concentration according to the equation  
 
0CA
JPapp ×=                         (Equation 6.1) 
 
where J = flux across the cell monolayer (nmol/s), A = area of the filter (cm2) and C0 = initial 
donor concentration (µM). Each drug concentration was plotted against the flux (J) and 
Michaelis-Menten kinetic parameter values Vmax and Km were calculated from these curves 
according to the equation  
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where Ppass = passive permeability in the presence of P-gp inhibitor GF120918 (cm/s), A = 
area of the filter (cm2), C0 = initial donor concentration (µM). GraphPad Prism® software 
(GraphPad Software, San Diego, CA) was applied for curve fitting. Weighting of 
1/concentration was used in the fitting procedure. 
 
6.2.5 Simulations 
A novel three compartment model (Fig. 6.1) was constructed with Stella 8.1.4 software 
(isee systems, Lebanon, NH) to simulate mass flow in a permeability experiment. Three 
compartmental models have been used to simulate in vitro permeability experiments (Ito et al. 
1999; Gonzalez-Alvarez et al. 2005). We introduce an apparent cellular distribution 
coefficient (K=Mbound/Mfree) to the model. Mfree represents the drug amount in cytosol that is 
available for diffusion across cell membranes and Mbound is the amount of drug that is bound 
intracellular structures, which leads to high cellular drug accumulation. This approach can 
accurately simulate time course of intracellular accumulation of drug during a permeability 
experiment (unpublished results). The flux across the basolateral membrane was assumed 
purely passive. In addition to the passive component, an efflux transporter obeying regular 
Michaelis-Menten kinetics affected the flux across the apical membrane. A virtual efflux 
pump substrate with high cellular retention (K=200, corresponding to a fitted value for 
quinidine, unpublished results) was created. The Km value was fixed to 5 µM. The volumes of 
the compartments were 0.5 (apical), 1.5 (basolateral) and 0.0022 (cellular assuming cell 
height of 20 µm) ml. The virtual compounds accumulated into cells according to apparent 
cellular distribution coefficient. The efflux pump used the "free" cellular concentration as its 
substrate. The true Vmax and membrane permeabilities were varied 26 (80-2100 fmol/s) and 5 
(50-250 x 10-6 cm/s) fold, respectively. Each simulation was run at eight initial concentrations 
(0.1-300 µM). For each parameter combination, the simulation with Vmax=0 was considered 
as efflux pump inhibited experiment. For each simulation, the highest flux (one minute 
intervals) to the receiver chamber was searched. The initial applied donor concentration was 
used for calculations. The passive flux (true Vmax=0) was subtracted from the total flux in the 
presence of efflux activity. This "active flux" data was then fitted to the regular Michaelis-
Menten equation  
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×=                         (Equation 6.3) 
 
where A = area of the filter (cm2), C0 = initial donor concentration (µM). GraphPad Prism® 
software (GraphPad Software, San Diego, CA) was applied for curve fitting. Weighting could 
be omitted because simulation data lacks experimental error. 
 
 
Figure 6.1: An overview of the three compartmental simulation model. Virtual compound 
was applied to either the apical or the basolateral chamber. The mass was transferred 
according to equations next to the arrows. Distribution into intracellular structures was 
modeled with apparent cellular distribution coefficient K=Mbound/Mfree. Passive transport 
(Pa=20-500 x 10
-6 cm/s and Pb=20-500 x 10
-6 cm/s) proceeded bi-directionally and was driven 
by the concentration gradient of free molecules across the cell membrane. Active efflux 
(Km=5 µM, Vmax=0-3600 fmol/s) took its substrate from the free intracellular pool. The 
simulation was run up to 120 minutes. 
 
6.2.6  Statistical testing 
The difference in the intracellular accumulation between P-gp inhibited and uninhibited 
wells at every time point was tested with student's t-test. The analysis was carried out with 
GraphPad Prism® software 
 
6.3 Results 
 
6.3.1 Permeability 
The passive permeability of quinidine was unpolarised and of similar magnitude in all cell 
lines (Table 6.1). The mass balance of quinidine was 75-80 % in the AB direction and 87-90 
% in the BA direction. The Ppass of digoxin was moderately lower in the MDCK-MDR1 cells 
than in the Caco-2 cell lines, and the mass balance was practically 100 %. P-gp inhibited 
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digoxin permeability decreased at concentrations above 200 µM in all cell lines in both (data 
not shown), and permeability values obtained at higher concentrations were not used for curve 
fitting.  
 
Table 6.1: Passive permeability and kinetic parameters of quinidine and digoxin. The 
apparent permeability of quinidine and digoxin across cell monolayers were determined at 
stirring rate of 450 rpm. Passive permeability was determined in the presence of 5 µM P-
glycoprotein inhibitor GF120918. Total fluxes at different concentrations were calculated and 
the results were fitted to the equation 6.2. 
 Apical-to-Basolateral Basolateral-to-Apical 
 
Caco/ 
WT 
Caco/ 
hPXR 
MDCK/ 
MDR1 
Caco/ 
WT 
Caco/ 
hPXR 
MDCK/ 
MDR1 
Quinidine       
Ppass (x10
-6 cm/s) 53 ± 8.9 57 ± 7.9 51 ± 5.8  55 ± 8.1 60 ± 10.0 50 ± 2.4  
Vmax (fmol/s) 180 ± 34 770 ± 61 1700 ± 170 260 ± 63 540 ± 120 4500 ± 870 
Km (µM) 3.1 ± 1.1 13 ± 1.4 27 ± 4.4 6.0 ± 2.6 15 ± 5.4 52 ± 15 
Digoxin       
Ppass (x10
-6 cm/s) 3.4 ± 0.4 3.3 ± 1.1 1.3 ± 0.2 4.1 ± 1.3 3.4 ± 0.7 2.6 ± 0.4 
Vmax (fmol/s) N.D. 
a N.D. a N.D. a 2100 ± 300 3600 ± 460 9900 ± 4500 
Km (µM) N.D.
 a N.D. a N.D. a 130 ± 32 190 ± 38 1000 ± 550 
Permeabilities are expressed as mean ± SD and kinetic parameters as mean ± standard error. 
a Not determined. Digoxin showed no saturation of transport in the AB direction at 
concentrations below 200 µM 
 
The differences in P-gp activity between the cell lines was readily seen when the total flux 
across the cell monolayers was plotted against the donor concentrations. Fig 6.2 shows this 
relationship for quinidine in the AB direction.  
 
 
Figure 6.2: The total flux of quinidine in the AB direction across the Caco/WT (diamonds), 
Caco/hPXR (triangles) and MDCK-MDR1 (squares) monolayers. The solid curves represent 
the results of fitting the data to Eq. 6.2.  
 
The unstirred water layer forms a considerable permeability barrier for compounds that 
traverse the cell monolayer very rapidly (Karlsson and Artursson 1991). Therefore, we 
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determined the Papp values at low quinidine concentration (0.3 µM) in both directions at 
various stirring rates. The passive permeability in both directions increased as the stirring 
became more vigorous (Fig. 6.3). The uninhibited transport, however, was increased only in 
the BA direction. Thus, the apparent P-gp mediated transport (|Papp-Ppass|) was relatively 
constant in the BA direction but increased considerably in the AB direction at higher stirring 
rates. Therefore, the kinetic studies were conducted at the highest stirring rate (450 rpm). The 
apparent permeability of digoxin did not change at different stirring speeds (data not shown). 
 
 
Figure 6.3: The apparent permeability of quinidine across Caco/WT cells at different stirring 
rates in the AB (triangles) and BA (squares) direction. Experiments were conducted both with 
(open symbols) and without (filled symbols) 5 µM P-glycoprotein inhibitor GF120918. 
Symbols represent average values of 3 filters and bars represent SD. 
 
6.3.2 Cellular retention 
The expression of P-gp affects the intracellular drug concentrations. The P-gp inhibitor 
GF120918 increases the cellular retention of quinidine in Caco/WT at early time points at 1 
µM concentration (Fig. 6.4a). In contrast, no difference in cellular quinidine amount between 
inhibited and uninhibited cells is observed when the concentration is increased well above the 
apparent Km-values (10 µM). Caco/hPXR and MDCK-MDR1 cells have sufficient P-gp 
expression to maintain decreased cellular quinidine levels at 10 µM (Fig. 6.4b-c). However, 
considerable increase (to 100 µM) in donor concentration removes the difference in cellular 
retention between inhibited and uninhibited wells. The results were similar in the BA 
direction even though the time courses of accumulation were somewhat different (data not 
shown). The overall mass balance (apical + basolateral + cellular) remained constant after 
initial drop of 3-9 % which is probably due to binding to the apparatus (Palmgren et al. 2006) 
or small pipetting errors. Similar observations on cellular accumulation were made in the 
simulation experiments when the efflux pump expression level was altered (Fig. 6.5). 
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Figure 6.4: The accumulation of quinidine into Caco/WT (a), Caco/hPXR (b) and MDCK-
MDR1 (c) cell monolayers during an apical-to-basolateral permeability experiment. At each 
indicated time point, the cell monolayers were washed with ice cold buffer and lysed with 1 % 
Triton X-100. Drug amount was determined from the lysate and normalized to the initial drug 
amount in the donor. Initial substrate concentrations were 1 (circles), 10 (triangles) and 100 
(squares) µM. The experiments were performed in the absence (filled symbols, solid lines) or 
presence (open symbols, dashed lines) of 5 µM P-glycoprotein inhibitor GF120918. Symbols 
represent average values of 3-12 filters. Error bars were omitted for clarity but the CV was 
generally < 10 %. The difference in intracellular quinidine amounts between inhibited and 
uninhibited wells were statistically tested with student's t-test at each time point. Statistical 
significance is indicated as n.s.=p>0.05, *=p<0.05, **=p<0.01, ***=p<0.001. The upper 
symbols refer to lower and lower symbols to higher initial quinidine concentration. 
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Figure 6.5: The cellular accumulation of quinidine-like virtual compound (Pa=Pb=250 x 10-6 
cm/s, Kbound/free=200) during an apical-to-basolateral simulation at 10 µM initial donor 
concentration. The total cellular amount of virtual compound after each time interval was 
normalized to the initial donor amount. The true Vmax of the efflux pump was set to 0 (open 
squares, dashed line), 400 (filled squares), 1800 (filled triangles) or 3600 (filled circles) 
fmol/s which corresponded the same fold differences of P-gp expression that was observed in 
our cell lines (Table 6.2). The difference in intracellular quinidine amounts between inhibited 
and uninhibited wells were statistically tested with student's t-test. Intracellular accumulation 
was statistically lower in the absence than in the presence of GF120918 at all time points 
(p<0.05). 
 
Cellular retention of digoxin was clearly lower than that of quinidine (Fig. 6.6) and the 
mass balance nearly 100 %. P-gp could reduce the cellular accumulation to a similar extent in 
the two Caco-2 cell lines. However, MDCK-MDR1 cells retained much less digoxin than the 
Caco-2 cells and P-gp could only modestly decrease its accumulation.  
 
 
Figure 6.6: The accumulation of digoxin (50 µM) into Caco/WT (diamonds), Caco/hPXR 
(triangles) and MDCK-MDR1 (squares) cells during a basolateral-to-apical permeability 
experiment. At each indicated time point, the cell monolayers were washed with ice cold 
buffer and lysed with 1 % Triton X-100. Drug amount was determined from the lysate and 
normalized to the initial drug amount in the donor. The experiments were performed in the 
absence (filled symbols, solid lines) or presence (open symbols, dashed lines) of 5 µM P-
glycoprotein inhibitor GF120918. Symbols represent average values of 3-12 filters. Error bars 
were omitted for clarity but the CV was generally < 10 %.  
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6.3.3 Experimental kinetic parameters 
The apparent kinetic transport parameters are presented in Table 6.1. The Km and Vmax 
values increased in the order Caco/WT < Caco/hPXR < MDCK-MDR1 with both substrates. 
However, parameters obtained for digoxin from MDCK-MDR1 cells should be dealt with 
caution since the Km value is 5-fold higher than the highest experimental concentration. A 
practically linear relationship was obtained when Km and Vmax values of quinidine in the AB 
direction are plotted against each other (Fig. 6.7). A similar but not equally linear relationship 
was seen for both drug molecules in the BA direction. Some literature data are also presented 
for comparison in these figures.  
 
 
Figure 6.7: Correlation of the apparent kinetic parameters (Km and Vmax) of (a) quinidine and 
(b) digoxin in cells expressing different amounts of P-glycoprotein. Figures include our 
experimental data in the AB (solid squares) and/or BA (solid triangles) direction and literature 
data (open symbols) from refs (Troutman and Thakker 2003), (Lowes et al. 2003) and 
(Stephens et al. 2001). 
 
The total P-gp levels in the cell lines were obtained from the optical density values 
(corrected for background) of the western blot Fig. 5.1. Table 6.2 presents the protein levels 
and kinetic parameters in relation to Caco/WT cells. The kinetic parameters of quinidine in 
the AB direction correlate almost perfectly to the protein data. Other apparent kinetic 
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parameters of Caco/hPXR cells change less than expected from the protein data. The Km 
values from MDCK-MDR1 cells show consistency to protein data but there is more variation 
in Vmax. 
 
Table 6.2: Comparison of P-gp protein level and kinetic parameters to those in Caco/WT 
cells. 
  Quinidine AB Quinidine BA Digoxin BA 
 Proteina Km
 Vmax
 Km
 Vmax
 Km
 Vmax
 
Caco/WT 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
Caco/hPXR 4.5 4.0 4.3 2.5 2.1 1.5 1.7 
MDCK-MDR1 8.9 8.8 9.6 8.7 17.1 7.9 4.8 
a Data extracted from Fig. 5.1  
 
6.3.4 Simulations 
The apparent Km and Vmax values both increased as the efflux pump expression increased. 
This shift in the apparent Km value increased as the passive permeability decreased (Fig. 
6.8a). At low passive permeability, the apparent Vmax was low (Fig. 6.8b). When the 
permeability increased to medium levels, the apparent Vmax reached its peak value. Finally, 
apparent Vmax decreases again at high passive permeability. Similar to the experimental 
observations, an increase in efflux pump expression decreased the intracellular drug 
concentration (Fig. 6.5). The apparent Km was always considerably higher in the AB than in 
the BA direction (Table 6.4). 
 
Table 6.3: The apparent kinetic parameters of a quinidine-like (Pa=Pb=250 x 10-6 cm/s, 
Kbound/free=200) virtual compound in AB and BA directions at various efflux pump expression 
levels. 
 Km (µM)  Vmax (fmol/s) 
True Vmax (fmol/s) AB BA  AB BA 
80 19.6 8.0  21 29 
400 20.8 8.2  106 147 
1250 23.4 9.1  324 452 
2100 25.8 9.8  548 765 
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Figure 6.8: The effect of efflux pump expression and passive permeability on the apparent 
kinetic parameters of a virtual compound (Kbound/free=200) in apical-to-basolateral simulations 
at different expression levels of efflux pump. (a) The apparent Km is plotted against the true 
Vmax (80-2100 fmol/s). Membrane permeabilities were set to equal values of 20 (crosses), 50 
(squares), 125 (triangles), 250 (diamonds) or 500 (circles) x 10-6 cm/s. (b) The apparent Vmax 
is plotted against passive membrane permeability (20-500 x 10-6 cm/s). The true Vmax values 
were 80 (diamonds), 400 (circles), 1250 (triangles) or 2100 (squares) fmol/s. 
 
6.4 Discussion 
The apparent transport kinetics of both influx and efflux transporter substrates depend on 
the access of the substrate to the interaction site. The increase in transporter expression leads 
to biased apparent kinetic parameters in monolayer transport assays. These observed shifts 
have been hypothesised to result either from decreased concentration in the unstirred water 
layer (UWL) next to the plasma membrane (Winne 1977; Balakrishnan et al. 2007) or from 
decreased intracellular concentration (Bentz et al. 2005). The previous works have based their 
hypotheses mainly on computational data. This study is the first that shows direct 
experimental evidence how the increase in efflux pump expression decreases the intracellular 
drug amount which then leads to larger shifts in the apparent kinetic parameters. Our novel 
simulation model can reproduce the time course of intracellular drug accumulation. 
Simulations show that the passive membrane permeability altered the bias in kinetic 
parameters. The shift in the apparent Km value is inversely proportional to the passive 
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permeability. In contrast, the apparent Vmax first increases and then decreases as the passive 
permeability increases. 
Digoxin permeabilities up to 500 µM have been reported (Troutman and Thakker 2003). 
However, we detected that the Ppass decreased above 200 µM (data not shown), probably due 
to precipitation of the drug or saturation of some uptake transporter. Indeed, OATP-E has 
been shown to transport digoxin (Mikkaichi et al. 2004). However, its expression is low both 
in Caco-2 (Hilgendorf et al. 2007) and MDCK cells (Goh et al. 2002). UWL affects the 
kinetic parameters of absorptive transporters (Winne 1977; Balakrishnan et al. 2007). It is 
hypothesised but not experimentally proven that the apparent Km value increases because the 
concentration next to plasma membrane decreases as the UWL thickness increases. In the 
present quinidine experiments, the UWL affected the Papp in the BA direction and the Ppass in 
both directions (Fig. 6.3) but Papp in the AB direction remained fairly constant. Therefore, the 
UWL influences the kinetic parameters also for efflux transporter substrates. The kinetic 
parameters in the AB direction may be more sensitive to changes in the stirring rate than those 
in the BA direction because the P-gp effect (|Papp-Ppass|) changes considerably in the AB but 
not in the BA direction. Digoxin permeability and, consequently, the kinetic parameters are 
fairly insensitive to the stirring rate because its transport is not rate limited by the UWL.   
The apparent kinetic values (Table 6.1) show that both Km and Vmax increase as the P-gp 
activity increases and that these values are strongly correlated (Fig. 6.7). Moreover, there is 
often a good correlation between the kinetic parameters and the expression of P-gp (Table 
6.2). A plausible explanation for this is that P-gp reduces the drug concentration at the 
interaction site below saturation concentrations. Therefore, the donor concentration does not 
reflect the concentration at the P-gp interaction site. Indeed, the total cellular amount of 
quinidine (Fig. 6.4) and digoxin (Fig. 6.6) are smaller in the absence than in the presence of 
P-gp inhibitor when the donor concentration does not saturate P-gp. In addition, the 
simulation model reproduced the experimental data for quinidine (Fig. 6.5). Together these 
data confirm the hypothesis that the reduced intracellular concentration causes a shift in 
observed kinetic parameters in monolayer permeability assays. The actual concentration at the 
interaction site may be even more reduced if the efflux pump is able to create a concentration 
gradient inside the cell.   
Recent results from a simulation model suggest that apparent Vmax of P-gp from 
permeability experiments follows reasonably well the molecular Vmax and, thus, the protein 
expression level (Bentz et al. 2005). However, the apparent Km value is always expected to be 
higher than the molecular Km, and it was shown to depend on the passive permeability and the 
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maximal pumping capacity of P-gp. Our simulation model (Fig. 6.1) is fairly simple since it 
does not account for e.g. basolateral transporterd. However, it was constructed to study the 
effect of reducing intracellular concentration on apparent kinetic parameters which was 
experimentally observed in this study. Supporting the results of Bentz et al. (2005), our 
simulations show that the decrease in passive permeability increases the observed Km shift 
when efflux pump expression increases (Fig. 6.8a). In contrast, the apparent Vmax value at a 
particular transporter expression level increases up to a certain passive permeability and starts 
to decline thereafter (Fig. 6.8b). The apparent Vmax never reached the true Vmax but only <50 
% of this value. The decrease in apparent Vmax at low passive permeability may be caused by 
the combination of slow entrance and high accumulation into cellular structures. On the other 
hand, the high passive permeability masks the active transport and the apparent Vmax 
decreases. Thus, the parallel active and passive transport processes prevent obtaining true 
kinetic values of transporters, at least with simple approaches (Eq. 6.2 and Eq. 6.3) that are 
used to treat such permeability data. Recently a new kinetic approach for calculating the 
parameters in transport experiments has been suggested (Kalvass and Pollack 2007). 
Nevertheless, the present results give idea how different parameters affect the apparent 
transport kinetics viewed from the donor solution. Actually, the UWL and the plasma 
membrane both form a diffusion barrier to the interaction site, and the Km shift is expected to 
be more pronounced for efflux than for influx transporters with extracellular interaction site 
(Balakrishnan et al. 2007).  
The relationship between P-gp expression and kinetic parameters is not simple and it can 
vary depending on the substrate and transport direction (Table 6.2). A previous study reported 
that the apparent Km value is always higher in the AB than in the BA direction (Troutman and 
Thakker 2003). This was explained by rigidity of the apical membrane which results in lower 
permeability than at the basolateral membrane. In this study, digoxin behaved similarly, since 
the Km value in the AB direction is much higher than 200 µM (Table 6.1). The fact that our 
simulations with equal membrane permeabilities gave higher Km values in the AB than in the 
BA direction (Table 6.3) suggests that the observed difference may partly be an artefact 
caused by the Transwell® apparatus. Because the donor and receiver volumes are unequal and 
small, the donor concentration decreases more rapidly in the AB than in the BA direction. 
Thus, the cellular concentrations remain lower in the AB than in the BA direction at any given 
donor concentrations and the Km shift increases. Moreover, the donor concentration is 
considerably below the initial concentration at steady state in which the maximal flux is taken. 
The directional difference in the apparent Km value was practically abolished when both 
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apical and basolateral chambers were increased to 5000 ml in simulations (data not shown). 
Now the sink conditions could be maintained and the donor concentration remained at initial 
level. The present experimental data suggests that the apparent Km value may also be higher in 
the secretory than in the absorptive direction (quinidine, Table 6.1). This requires that the 
resistance at the apical membrane is considerably lower than at the basolateral membrane. 
Our hypothesis is that the applied vigorous stirring decreases the total passive resistance 
(UWL + cell membrane) at the apical membrane to a lower value than at the basolateral 
membrane. This hypothesis needs further experimental evidence.  
 
6.5 Conclusions 
The apparent kinetic parameters of drug permeation shift when a diffusion barrier is placed 
between the donor and the interaction site. The access to the interaction site may be very 
different in simple laboratory experiments and in whole organisms. Therefore, scaling in vitro 
parameters to permeability at different locations in vivo is not straightforward. Further studies 
are needed to understand the relationships between permeability barriers and observed 
kinetics. Ultimately, a predictive permeability model may be constructed using simple in vitro 
parameters reflecting the passive permeability, intracellular distribution and transporter 
affinity. 
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7 THE ASYMMETRY OF THE UNSTIRRED WATER LAYER IN 
PERMEABILITY EXPERIMENTS* 
 
Abstract: The purpose of this study was to elucidate the apical and basolateral components 
of the total unstirred water layer in regular permeability experiment.A novel stirring 
apparatus was constructed to remove the basolateral unstirred water layer. Caco-2 cells 
were used as the permeability barrier both in Transwell®-type and side-by-side apparatuses. 
Permeability experiments were done with several ionisable compounds at various pH and 
stirring conditions. The permeabilities of the cell monolayer, the unstirred water layer and 
the polycarbonate filter were calculated either from experimental data or theoretically. The 
unstirred water layer was thicker in the Transwell® apparatus than in the side-by-side 
chamber even in the presence of vigorous basolateral magnetic stirring. Calculations 
indicated that the apical unstirred water layer is thicker than the basolateral layer. Different 
cellular permeability coefficients were obtained from the two permeability apparatuses. An 
orbital shaker does not produce symmetric hydrodynamics in both chambers of Transwell® 
apparatus. The asymmetric unstirred water layer may complicate the exact analysis of 
polarized transport. 
 
 
 
 
 
 
 
 
 
 
 
* Adapted from manuscript: Korjamo T, Heikkinen AT, Waltari P, Mönkkönen J.: The 
asymmetry of the unstirred water layer in permeability experiments (Submitted Jan. 2008) 
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7.1 Introduction 
A typical in vitro permeability experiment is conducted in a Transwell® type of plate using 
orbital shaking. The apical compartment has free air-to-liquid interface on top of the cell 
monolayer while the basolateral space is only 1 millimeter in height and restricted by solid 
surfaces. Therefore, the UWL in the upper (apical) and lower (basolateral) compartments may 
be different. However, the total measurable UWL resistance is usually considered to be 
equally distributed on both sides (Adson et al. 1995; Balakrishnan et al. 2007). An 
asymmetric UWL does not cause a big problem if the studied molecule is transported 
passively. However, this asymmetry would lead into difficulties if an active transporter is 
involved. Balakhrisnan et al. (2007) showed that the UWL affects the apparent kinetics of 
influx transporter substrates. UWL should also affect the apparent kinetics of efflux pump 
substrates (Chapter 6). If the UWL resistance is not equal on both sides of the cell monolayer, 
the access of the drug to and the exit from the interaction site is partly dependent on the 
geometry of the experimental apparatus. Therefore, knowledge of the individual UWL layers 
in an experimental in vitro permeability setting is needed for interpreting the experimental 
data and for constructing predictive computer simulations. The present literature describes 
only total UWL resistances in Transwell® apparatuses (Karlsson and Artursson 1991; Adson 
et al. 1995). In addition, some alternative apparatuses have been build to study the UWL 
(Hidalgo et al. 1991; Karlsson and Artursson 1992; Yu and Sinko 1997) but these 
experimental setups do not reflect the commonly used Transwell® apparatus. So far, no 
attempts to dissect the UWL resistance into apical and basolateral parts in Transwell® 
apparatus have been published. 
To achieve this goal, a novel 12 place magnetic stirrer was constructed. The permeabilities 
of total and apical UWLs were determined without and with vigorous basolateral stirring, 
respectively. The permeability of the UWL layer was studied by both stirring (Karlsson and 
Artursson 1991; Adson et al. 1995; Yu and Sinko 1997) and pH (Winne 1977; Avdeef et al. 
2005) methods. In addition, the permeabilities were studied also in a side-by-side apparatus to 
compare the hydrodynamics in these two different experimental settings. 
 
7.2 Materials and methods 
 
Chemicals, cell culture and HPLC methods are described in section 4.2 
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7.2.1 Permeability experiments 
The model compounds and their physicochemical properties are given in Table 7.1. The 
compounds were selected to span a range of lipophilicities and, hence, permeabilities. The 
compounds are known traverse the cells primarily passively with the exception of verapamil 
which is a substrate for P-glycoprotein. The compounds were used in a mixture, each at 50 
µM initial concentration. Drug concentrations in samples were analysed with HPLC-
UV/fluorescence as described previously (Palmgrén et al. 2004). 
 
 
Table 7.1: Properties of the model compounds 
    LogPa      
  pKaa Neutral Charged MW Db Pf
c 
Metoprolol 9.56 1.95 -1.1 267.7 7.80 980 
Propranolol 9.53 3.48 0.78 259.3 7.91 994 
Verapamil 9.07 4.33 0.71 491.1 5.94 747 
Ibuprofen 4.45 4.13 -0.15 260.0 7.90 993 
Atenolol 9.54 0.22 N.R. 266.3 7.82 983 
Antipyrine 1.44 0.56 N.R. 188.2 9.13 1148
N.R. =not reported.  
a Data taken from (Avdeef 2003).  
b Aqueous diffusion coefficient at +37ºC (x10-6 cm2/s). Calculated using equation presented in 
(Avdeef et al. 2004) with temperature correction (Avdeef et al. 2005) 
c Permeability across blank filter (x10-6 cm/s). Calculated according to Eq. 7.3 
 
The bi-directional apparent permeability coefficients in Transwell® apparatus (TW) were 
determined at four different pH values (5.8, 6.5, 7.0 and 7.4) and at four different verified 
stirring speeds (250, 320, 370 and 420 rpm) on an orbital shaker (Titramax 1000, Heidolph, 
Germany). The pH was always the same in the apical and basolateral chambers (no pH-
gradient experiments were conducted). The transport medium was Hanks' balanced salt 
solution (HBSS) buffered with either MES (5.8 and 6.5) or HEPES (7.0 and 7.4). One set of 
experiments was conducted on regular Transwell® plates (AB and BA). In the other set of 
experiments, the basolateral unstirred water layer was assumed to be removed by applying 
vigorous (1600 rpm) magnetic stirring in the basolateral chamber using a custom-made 
magnetic stirrer (AB Stir and BA Stir). The magnetic stirrer was placed on the orbital shaker 
and the apical hydrodynamics were assumed to remain unaffected. Since the space below the 
filter is only one millimeter in depth, a special three millimeters thick mask was used to 
elevate the filter to create sufficient space to accommodate a small (2 x 2 x 7 mm) magnetic 
bar. The stirring did not damage the cell monolayer since mannitol permeability was 
essentially unchanged (1.99 x 10-6 cm/s vs. 2.25 x 10-6 cm/s). 
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The experiments were re-designed to avoid mass balance problems. The initial apical 
volume was always 0.6 ml and the initial basolateral volumes were 1.6 ml and 2.6 ml in the 
absence and presence of the elevation mask, respectively. After the cells were washed twice 
and equilibrated for 20-30 minutes, all liquids were removed. The donor solution was applied 
either to the apical (AB and AB Stir) or to the basolateral (BA and BA Stir) compartment. 
After five minutes, fresh buffer was added to the receiver compartment and the magnetic 
stirring was started. Samples of 50 µl were withdrawn from both chambers and the 
experimental time was started. Thereafter, 50 µl samples from both chambers were taken at 5, 
20 and 40 minutes. No replacements were made and, therefore, there were no sudden changes 
in concentrations. The apparent permeability coefficients were calculated using iterative 
equation that accounts of the changes in concentration gradient and backflux (Palm et al. 
1999) 
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where CR,a and CR,b are receiver concentrations at the beginning and at the end of time interval 
a->b, M is the total amount of drug at the beginning of time interval, VD and VR are the donor 
and receiver volumes, A is the area of the filter, Papp is the apparent permeability coefficient 
and Δt is the length of the time interval. Data from two time intervals (5 to 20 min and 20 to 
40 min) were used for the non-linear least-squares fitting which was calculated with Microsoft 
Excel software. The experiments were conducted twice in triplicate. 
To compare the hydrodynamics of orbitally shaked TW to a well stirred situation, the 
permeabilities were also measured in a side-by-side chamber (SbS) (PermeGear, Inc., 
Bethlehem PA, USA). A Snapwell insert (similar to Transwell® inserts, catalog number 3407) 
was fitted between the chambers. The area of the hole between the chambers was 0.64 cm2 
and both chambers had magnetic stirring (500 rpm). The initial volumes were 3.8 (apical) and 
3.3 (basolateral) ml and a sample of 100 µl was withdrawn from both chambers at 0, 10, 20, 
30 and 60 minutes without buffer replacements. 
Atenolol served as the integrity control. If its permeability was unexpectedly high in one 
well then all data from that particular replicate was discarded. All experiments were 
conducted twice with three parallel wells. Since the charge state of antipyrine is virtually zero 
throughout the applied pH-range, it was used as a control of passive transcellular permeability 
under different pH conditions. 
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The total permeability was assumed to consist of UWL, cell monolayer and filter 
permeabilities 
 
BUWLfcAUWLobs PPPPP ,,
11111 +++=                        (Equation 7.2) 
 
where Pobs is the observed apparent permeability, PUWL,A/B is the permeability of the unstirred 
water layer on the apical/basolateral side, Pc is the permeability across the cell monolayer and 
Pf is the permeability across the polycarbonate filter. The term 1/ PUWL,B was assumed to be 
zero when basolateral magnetic stirring was applied. 
The apparent permeability of the filter was calculated as previously proposed (Karlsson and 
Artursson 1991) 
 
h
DPf
ε=                          (Equation 7.3) 
 
where D is the aqueous diffusion coefficient (Table 7.1) calculated with the equation 
presented in (Avdeef et al. 2004) using temperature correction (Avdeef et al. 2005), ε is the 
porosity of the filter calculated according to the manufacturer’s documentation (0.4 µm pore 
diameter, 1x108 pores/cm2 yielding a nominal porosity of 0.126) and h is the thickness of the 
filter (10 µm). Since the permeability of the filter is independent of the ionization of the 
molecule and it was also assumed to be independent of stirring, Pf was subtracted from the 
observed permeabilities to obtain the corrected apparent permeabilities for curve fitting.  
 
fobsapp PPP
111 −=                         (Equation 7.4) 
 
7.2.2 Analysis of the thickness of the unstirred water layer 
Two approaches were used to analyze the thickness of the unstirred water layer. The first is 
based on the change of the ionization state of acidic and basic molecules (Winne 1977; 
Avdeef et al. 2005) 
 
  
 119
( ) iiuuUWLiiuuUWLcUWLapp PPPfPPfPfPPPP +−+=++=+=
1111111
                   (Equation 7.5) 
 
where Papp is the apparent permeability corrected for filter permeability, PUWL is the 
permeability of the unstirred water layer, Pc is the permeability across the cell monolayer, Pu 
and Pi are the permeabilities of the unionized and ionized species across the cell monolayer 
and fu is the fraction of the unionized species. For fitting purposes, the equation was 
transformed into a logarithmic form 
 
( )( ) ( )( )iiuuUWLUWLiiuuapp PPPfPPPPPfP +−++++−−= loglogloglog        (Equation 7.6)  
 
The data from different pH values at a constant stirring rate was analyzed with Eq. 7.6. The 
fitting for metoprolol, propranolol and ibuprofen was constrained by setting the Pu and Pi 
values to be equal in all directions at all stirring rates. The reported PUWL values are averages 
of AB and BA values. Because verapamil is a P-glycoprotein substrate, its AB and AB Stir 
data was treated separately from BA and BA Stir data. 
The second approach is based on changing the stirring speed while keeping the monolayer 
permeability constant (pH is constant) (Karlsson and Artursson 1991; Adson et al. 1995). It is 
assumed that the PUWL can be described as a function of the stirring rate 
 
αKvPUWL =                         (Equation 7.7) 
 
where K is a fitted constant relating stirring speed to permeability, v is the stirring speed and α 
is an exponent proposed to reflect the type of hydrodynamics (Adson et al. 1995). Thus, the 
apparent permeabilities can be fitted into 
ccUWLapp PKvPPP
11111 +=+= α                       (Equation 7.8) 
 
The curve fitting was constrained so that each pair (same pH, same basolateral stirring, e.g. 
AB 6.5 and BA 6.5 or AB Stir 7.4 and BA Stir 7.4) was forced to have the same values of K, 
α and Pc. Each verapamil data set was, however, analyzed separately since its cellular 
permeability was assumed to be asymmetric. 
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All curve fittings were done using Prism 4.0 software (GraphPad Software Inc., San Diego, 
CA).  
When the total (PUWL,total) and apical (PUWL,a) UWL permeabilities were obtained, the 
PUWL,b was calculated by simple subtraction. 
 
AUWLtotalUWLBUWL PPP ,,,
111 −=                        (Equation 7.9) 
 
The apparent thickness of the unstirred water layer was finally calculated by 
 
UWL
UWL P
Dh =                       (Equation 7.10) 
 
where D is the aqueous diffusion coefficient. 
 
7.3 Results 
The observed permeabilities of model compounds are presented in Table 7.2. Only a few 
filters were discarded because of elevated atenolol permeability (data not shown). The 
permeability of antipyrine was pH independent and, thus the change in pH did not change 
considerably passive permeability properties of the monolayer (data not shown). Generally, 
propranolol, verapamil and ibuprofen permeabilities were of similar magnitude while that of 
metoprolol was lower. The ionization state clearly affected the observed permeabilities. In 
TW at pH 5.8, the permeability of metoprolol appears to be rate limited purely by the cell 
monolayer since it is independent of stirring conditions. In addition, the observed 
permeability value was very close to the calculated Pcell value (Table 7.5). However, a 
considerably higher permeability of metoprolol was observed in SbS. The stirring rate 
affected the observed permeability in all other instances. With the exception of basic 
compounds at pH 5.8, basolateral stirring could increase the permeability when compared to 
orbital shaking only. The experimental permeabilities in TW approached the permeabilities in 
SbS when orbital stirring was high and basolateral magnetic stirring was applied. The highest 
observed permeabilities were around 300 x 10-6 cm/s.  
The data shows that the in vitro metoprolol permeability can vary between 14 and 140 in 
the physiological pH range, depending on the applied stirring rate (Table 7.2). This may partly 
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explain the extensive interlaboratory variability in Caco-2 permeability results. Figure 7.1 
shows the relative contribution of the cell monolayer, filter and UWL resistance to the total 
permeability at the low (metoprolol AB pH 5.8) and high (ibuprofen AB Stir pH 5.8) 
extremes of apparent permeabilities in the Transwell® apparatus. Metoprolol is primarily rate 
limited by the cell monolayer while ibuprofen permeability is governed by aqueous diffusion 
through the UWL and the filter. 
The experimental data (antipyrine, metoprolol, propranolol, verapamil and ibuprofen) did 
not fit properly into Eq. 7.8. The intercept (1/Pcell) was in most instances negative despite 
changing the stirring exponent, rendering the results physiologically meaningless (data not 
shown). 
 
Table 7.2: Observed bidirectional permeabilities of model compounds (x10-6 cm/s). Mean ± 
S.D. 
    Transwell
® systema Side-by-side 
  pH rpm Pobs AB Pobs BA Pobs AB Stir Pobs BA Stir rpm Pobs AB 
5.8 250 14 ± 2 17 ± 2 14 ± 2 16 ± 2      
 320 14 ± 2 18 ± 1 12 ± 2 14 ± 1      
 370 15 ± 1 21 ± 1 13 ± 2 15 ± 2      
 420 16 ± 2 19 ± 2 12 ± 2 15 ± 3  500 41 ± 1 
6.5 250 39 ± 6 39 ± 2 40 ± 6 45 ± 3      
 320 47 ± 15 44 ± 6 39 ± 3 48 ± 9      
 370 46 ± 7 56 ± 4 48 ± 7 47 ± 4      
 420 49 ± 4 57 ± 6 48 ± 6 47 ± 2  500 110 ± 3 
7.0 250 48 ± 6 59 ± 6 71 ± 6 70 ± 5      
 320 73 ± 3 75 ± 8 75 ± 8 88 ± 8      
 370 92 ± 7 88 ± 5 84 ± 5 97 ± 7      
 420 99 ± 10 103 ± 4 95 ± 11 117 ± 16  500 150 ± 9 
7.4 250 69 ± 7 67 ± 13 90 ± 4 105 ± 15      
 320 95 ± 8 98 ± 6 111 ± 9 129 ± 6      
 370 113 ± 5 122 ± 10 115 ± 10 143 ± 11      
M
et
op
ro
lo
l 
  420 137 ± 7 128 ± 9 148 ± 13 150 ± 14  500 210 ± 1 
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Table 7.2: Continued 
5.8 250 50 ± 5 57 ± 6 56 ± 6 72 ± 4         
 320 60 ± 10 66 ± 9 60 ± 8 74 ± 11      
 370 68 ± 5 82 ± 5 64 ± 4 77 ± 4      
 420 75 ± 4 84 ± 9 68 ± 10 85 ± 11  500 160 ± 6 
6.5 250 73 ± 14 73 ± 7 103 ± 15 118 ± 6      
 320 110 ± 23 97 ± 15 104 ± 12 136 ± 27      
 370 108 ± 15 120 ± 7 150 ± 18 135 ± 11      
 420 125 ± 8 130 ± 12 159 ± 18 154 ± 11  500 250 ± 5 
7.0 250 79 ± 9 77 ± 7 128 ± 13 121 ± 5      
 320 113 ± 6 107 ± 17 147 ± 9 168 ± 26      
 370 161 ± 13 134 ± 9 174 ± 13 207 ± 16      
 420 186 ± 26 161 ± 5 224 ± 16 254 ± 16  500 280 ± 21 
7.4 250 75 ± 10 72 ± 11 127 ± 14 137 ± 27      
 320 112 ± 12 108 ± 8 158 ± 16 198 ± 10      
 370 167 ± 30 151 ± 12 216 ± 35 254 ± 22      
Pr
op
ra
no
lo
l 
  420 221 ± 13 161 ± 11 277 ± 19 296 ± 22  500 310 ± 1 
5.8 250 35 ± 5 53 ± 5 34 ± 6 66 ± 2         
 320 45 ± 9 63 ± 10 43 ± 6 69 ± 16      
 370 55 ± 8 73 ± 7 42 ± 1 73 ± 4      
 420 60 ± 8 79 ± 10 46 ± 8 76 ± 10  500 140 ± 6 
6.5 250 56 ± 7 67 ± 9 77 ± 11 99 ± 6      
 320 82 ± 24 91 ± 16 67 ± 13 119 ± 32      
 370 78 ± 21 93 ± 9 102 ± 17 109 ± 11      
 420 99 ± 8 111 ± 16 102 ± 7 120 ± 22  500 210 ± 26 
7.0 250 49 ± 9 59 ± 6 81 ± 13 85 ± 9      
 320 93 ± 6 90 ± 21 95 ± 17 140 ± 18      
 370 112 ± 7 125 ± 19 102 ± 19 169 ± 32      
 420 143 ± 16 134 ± 10 144 ± 21 188 ± 11  500 230 ± 25 
7.4 250 57 ± 6 64 ± 14 86 ± 14 116 ± 19      
 320 91 ± 8 98 ± 13 130 ± 28 154 ± 10      
 370 115 ± 14 137 ± 23 154 ± 18 173 ± 13      
V
er
ap
am
il 
  420 174 ± 15 140 ± 11 190 ± 40 219 ± 260  500 312 ± 9 
5.8 250 93 ± 6 114 ± 3 149 ± 9 155 ± 25         
 320 121 ± 9 117 ± 11 202 ± 27 187 ± 8      
 370 191 ± 9 181 ± 14 306 ± 32 256 ± 29      
 420 225 ± 42 183 ± 21 318 ± 45 260 ± 42  500 330 ± 22 
6.5 250 88 ± 24 110 ± 14 173 ± 18 167 ± 21      
 320 133 ± 9 140 ± 19 167 ± 15 184 ± 15      
 370 166 ± 40 205 ± 16 255 ± 19 254 ± 24      
 420 161 ± 26 203 ± 29 271 ± 71 209 ± 13  500 280 ± 5 
7.0 250 80 ± 14 82 ± 15 122 ± 4 99 ± 9      
 320 116 ± 3 123 ± 10 147 ± 13 157 ± 20      
 370 164 ± 12 153 ± 10 158 ± 16 203 ± 11      
 420 165 ± 34 192 ± 17 231 ± 26 238 ± 12  500 230 ± 13 
7.4 250 74 ± 9 81 ± 14 112 ± 11 122 ± 16      
 320 92 ± 8 109 ± 8 113 ± 13 139 ± 4      
 370 118 ± 27 148 ± 13 141 ± 23 162 ± 12      
Ib
up
ro
fe
n 
  420 129 ± 9 149 ± 9 159 ± 23 174 ± 7  500 160 ± 10 
a The experiments were conducted in the apical-to-basolateral (AB) or basolateral-to-apical 
(BA) directions on an orbital shaker. The inclusion of the basolateral magnetic stirring is 
indicated (AB Stir and BA Stir). 
 
The PUWL values and the corresponding apparent UWL thicknesses are presented in Table 
7.3. The apparent thickness of the total UWL (hUWL,total) in TW ranged from 180 to 920 µm 
depending on the stirring rate and compound. The hUWL,total in TW was always larger than the 
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corresponding value in SbS. hUWL,A in TW at the highest orbital stirring rate approached but 
generally did not reach hUWL,total in SbS. The hUWL,total values in TW for basic compounds were 
of similar magnitude. hUWL,total for acidic ibuprofen was somewhat lower. In contrast, hUWL,A 
of metoprolol in TW was larger than hUWL,A for the remainder of the compounds. Similarly, 
metoprolol seemed to display the thickest UWL in SbS. The calculated hUWL,B was smaller 
than hUWL,A at all stirring rates. 
 
 
Figure 7.1: The relative contribution of the cell monolayer (solid line), filter (dotted line) and 
UWL (dashed line) to the overall permeability resistance of metoprolol AB (A) and ibuprofen 
AB Stir (B) at pH 5.8 at different orbital stirring rates 
 
 
 
  
 124
Table 7.3: Apparent permeabilities across the unstirred water layer and the calculated UWL 
thicknesses. 
  Transwell
® system Side-by-side 
 rpm PUWL.total
a hUWL,total
c PUWL.A
a hUWL,a
c PUWL.B
b hUWL,b
c rpm PUWL.total
a hUWL,total
c 
250 85 ± 1 920 ± 13 130 ± 2 600 ± 8 240 320              
320 140 ± 2 570 ± 10 170 ± 3 460 ± 8 680 120       
370 190 ± 3 410 ± 7 200 ± 3 380 ± 5 3310 24       
M
et
op
ro
lo
l 
420 230 ± 4 330 ± 5 260 ± 6 300 ± 7 2130 37  500 320 ± 24 240 ± 18
250 95 ± 1 830 ± 8 170 ± 2 470 ± 5 220 360              
320 140 ± 2 550 ± 7 230 ± 3 340 ± 4 380 210       
370 210 ± 2 380 ± 4 330 ± 4 240 ± 3 570 140       
Pr
op
ra
nl
ol
 
420 260 ± 3 300 ± 3 460 ± 6 170 ± 2 630 130  500 460 ± 25 170 ± 9 
250 73 ± 1 820 ± 15 120 ± 3 480 ± 9 180 340              
320 120 ± 3 480 ± 11 180 ± 5 330 ± 9 410 150       
370 170 ± 4 350 ± 8 220 ± 6 270 ± 7 700 85       
V
er
ap
am
il 
420 260 ± 6 230 ± 5 360 ± 9 160 ± 5 960 62  500 430 ± 43 140 ± 14
250 110 ± 1 720 ± 8 190 ± 2 420 ± 5 260 300              
320 150 ± 1 510 ± 4 240 ± 2 330 ± 3 430 180       
370 240 ± 3 330 ± 4 370 ± 5 210 ± 3 710 110       
Ib
up
ro
fe
n 
420 280 ± 3 290 ± 3 440 ± 7 180 ± 3 740 110  500 640 ± 47 120 ± 9 
a Obtained from fitting  the experimental data into Eq. 7.6. (x10-6 cm/s). The reported number 
is the average from the corresponding AB and BA data. Mean ± S.E. 
b Calculated using Eq. 7.9 (x10-6 cm/s). 
c Calculated from the corresponding PUWL value using Eq. 7.10 (µm). 
 
The experimentally determined PUWL values were fitted to Eq. 7.7 (Table 7.4). The constant 
term K was very variable as the obtained values spanned several orders of magnitude. The 
stirring exponent α was mostly between 1.8 and 2.6, the only exception being the PUWL,A of 
metoprolol. 
 
Table 7.4: Parameters describing the unstirred water layer as a function of stirring rate.  
  PUWL.total
a PUWL.A
a 
Metoprolol            
K 0.0017 ± 0.0011 0.049 ± 0.047 
α 1.97 ± 0.12 1.42 ± 0.16 
Propranolol           
K 0.001 ± 0.0008 0.001 ± 0.0016 
α 2.07 ± 0.14 2.15 ± 0.27 
Verapamil           
K 0.00002 ± 0.00004 0.0002 ± 0.001 
α 2.674 ± 0.29 2.36 ± 0.49 
Ibuprofen           
K 0.0035 ± 0.006 0.0078 ± 0.013 
α 1.872 ± 0.31 1.812 ± 0.28 
a Data from Table 7.3 was fitted into Eq. 7.7. Mean ± S.E. 
 
Pu and Pi were obtained from global fitting of the experimental data of a compound into Eq. 
7.6 (Table 7.5). The Pu and Pi for all basic compounds were considerably higher in SbS than 
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in TW. In contrast, these values for ibuprofen were very similar in both apparatuses.  The Pu 
initially increased as LogP increased but seemed to decline after a LogP value of 4. The 
permeability of the charged metoprolol species was in the range of paracellular permeability 
in TW but considerably higher in SbS. The more lipophilic compounds appeared to be able to 
traverse the cell membranes also in their charged forms. There was a moderate difference in 
verapamil permeability between the AB and BA directions. The calculated cellular 
permeability of metoprolol at pH 5.8 was similar to the observed permeabilities. In all other 
instances, the calculated Pcell values were clearly higher than the experimentally observed 
permeabilities. The ratio Pu/Pi varied between 1000 and 18000. 
 
Table 7.5: Apparent permeabilities of unionized and ionized species across the cell 
monolayer 
                   Pcell (at pH)
b 
      Pu
a Pi
a Pu/ Pi 5.8 6.5 7.0 7.4 
Metoprolol   73000 ± 3000 4 ± 1 18250 17 68 200 510 
Propranolol  320000 ± 27000 55 ± 5 5820 93 330 970 2390 
Verapamil AB 65000 ± 9400 37 ± 6 1760 72 210 590 1400 
 BA 89000 ± 16000 86 ± 10 1030 130 320 840 1950 T
ra
ns
w
el
l®
 
Ibuprofen   220000 ± 40000 120 ± 44 1770 9520 2060 740 370 
Metoprolol   190000 ± 26000 16 ± 5 11880 50 180 540 1320 
Propranolol  1200000 ± 400000 120 ± 70 10000 340 1240 3650 8950 
Verapamil AB 270000 ± 160000 170 ± 86 1590 310 890 2450 5820 
 BA N.D. N.D. N.D. N.D. N.D. N.D. N.D. 
Si
de
-b
y-
si
de
 
Ibuprofen   180000 ± 48000 110 ± 59 1620 7800 1700 620 310 
N.D. =not determined. Side-by-side experiments were conducted only in the AB direction. 
a Cellular permeability of unionized / ionized species across the cell monolayer (x10-6 cm/s).  
Obtained from fitting the permeability data into Eq. 7.6. Mean ± S.E. 
b Total cellular permeability at a given pH calculated by fu x Pu + fi x Pi (x10
-6 cm/s). 
 
7.4 Discussion 
The unstirred water layer has an established effect in in vitro permeability assays (Karlsson 
and Artursson 1991; Adson et al. 1995; Avdeef et al. 2005). This work describes a novel 
approach to remove basolateral stirring problems in the Transwell® system. The permeability 
of several drug molecules across Caco-2 cells was assessed in Transwell® apparatus (in the 
presence and absence of basolateral unstirred water layer) and in a well stirred side-by-side 
chamber. This is the first attempt to dissect the total observed UWL in apical and basolateral 
components. This kind of knowledge is of major importance when asymmetric transport is 
modeled. The present data suggest that the total UWL resistance in TW is present to a greater 
extent at the apical side of the membrane. 
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The primary objective was to dissect the total UWL resistance in TW into apical and 
basolateral components. The space below the filter is only 1 mm thick and, thus, the 
movement of liquid is greatly restricted in the basolateral chamber. Therefore, it would seem 
to be logical to presume that the basolateral chamber would possess a thicker UWL than its 
apical counterpart. However, the calculated hUWL,B values are lower than hUWL,A (Table 7.3), 
in other words the apical UWL appears to be the principal hydrodynamic barrier. The stirring 
exponents further support this claim (Table 7.4). The apical UWL appears to control the 
overall hydrodynamics since α values are similar in the absence and presence of basolateral 
stirring. It is, however, possible that the apical and basolateral UWLs are not completely 
independent. The UWL is not a sharp edged zone but rather a continuous gradient where the 
liquid velocity ranges non-linearly from near zero next to surface to its maximum value in the 
bulk phase (Barry and Diamond 1984; Pedley 1983; Pohl et al. 1998). Similarly, a curved 
concentration gradient from the surface concentration to the bulk concentration is formed. The 
removal of the basolateral UWL increases the net flux of molecules. This may increase the 
apical UWL resistance analogous to a change in UWL thickness as a function of ion mobility 
reported previously (Pohl et al. 1998). Furthermore, permeability equations are based on the 
fundamental concept that the net movement of molecules proceeds only in one dimension. 
However, the water layer below the membrane is only one millimeter in depth and the 
samples are taken from the side of the filter. Therefore, it is likely that a radial concentration 
gradient is formed in the basolateral side of the membrane and the initial assumptions of 
permeability equations do not hold. In addition, our assumption of total absence of the 
basolateral unstirred water layer may be invalid since regular magnetic stirring forms a small 
stagnant area near the center of the filter (Pedley 1983). The thinnest observed UWLs in 
stirred membrane systems are around 25 µm (Barry and Diamond 1984). Therefore, the 
PUWL,A values may still contain a basolateral component. 
The Pf is also a crucial parameter when the unstirred water layers are analyzed. In our 
approach (experiments with and without basolateral UWL), the Pf only affects the PUWL,A 
value. Therefore, if Pf is overestimated, PUWL,A will be underestimated and vice versa. It has 
been suggested that the commonly used polycarbonate filters would have a true Pf value of 
about half of that calculated with Eq. 7.3 (Yu and Sinko 1997). The technical documentation 
of the filters also supports this possibility, since the manufacturer considers that as much as 60 
% difference may occur in the actual filter thickness compared to the nominal value of 10 µm. 
Therefore, PUWL,A maybe underestimated and, consequently, the true hUWL,A would be much 
thinner than Table 7.3 suggests. All the calculations were performed also with 50 % reduced 
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Pf values (data not shown). Then hUWL,B was indeed thicker than hUWL,A in most cases. 
However, the hUWL,total in SbS was reduced to a value even less than 10 µm, which is not 
likely to be true. Unfortunately, it is impossible to determine the permeability across blank 
filter in TW since there is a considerable net flux of water across the filter, especially at high 
stirring rates. Therefore, the present calculations were conducted with the theoretical Pf. value  
The observed permeabilities in TW at different stirring conditions provide some indication 
for a threshold permeability beyond which the UWL becomes significant in TW (Table 7.2). 
The data suggests that the limit would lie around 20 x 10-6 cm/s. However, the metoprolol 
data at pH 5.8 from SbS reveals that the TW suffers from poor hydrodynamics already at this 
level. In fact, all basic compounds show lower maximum permeability in TW than in SbS. In 
contrast, the highest observed ibuprofen permeabilities in TW were similar to those in SbS. 
This discrepancy between the two apparatuses may also originate from intracellular kinetics. 
The weakly basic molecules usually undergo lysosomal sequestration, called ion-trapping 
(Duvvuri et al. 2004). In SbS, the volumes of donor and receiver chambers are considerably 
larger than in TW and, therefore, a small portion of the total drug amount is present in the 
kinetically slow compartment (lysosomes) in SbS than in TW. This may lead to a situation 
where steady state flux is not attained, despite an apparently constant mass balance. Acidic 
ibuprofen is not subjected to this intracellular sequestration and, hence, its behavior is similar 
in both apparatuses. 
The literature often describes apparent thickness of the calculated UWL. Our results (Table 
7.3) are comparable to several published reports. Karlsson and Artursson (1991) reported 128-
1544 µm UWL thickness at stirring rates 0-1090 rpm and to Avdeef et al. (2005) estimated 
the UWL thickness to be 381 µm for verapamil at 100 rpm, 303 µm for metoprolol at 450 rpm 
and 341 µm for propranolol at 450 rpm. Adson et al. (1995) reported 220-930 µm for 
testosterone at 25-150 rpm. The stirring conditions in SbS are better than in TW but the 
apparent UWL thickness still does not achieve the values obtained in turbulent gas lift 
chambers (Karlsson and Artursson 1992; Yu and Sinko 1997) or the reported UWL thickness 
range of 30-100 µm in the intestine (Lennernas 1998) 
Equation 6 allows the estimation of the cellular permeability of neutral and charged form of 
acidic and basic compounds. Our results follow the general pattern that the permeability 
across cell monolayer increases as a function of lipophilicity but starts to decline with very 
lipophilic compounds (Tables 7.1 and 7.5). The absolute values are higher than those reported 
previously (Avdeef et al. 2005). The Pu/Pi-ratio was considerably higher than that described 
previously by Palm et al. (Palm et al. 1999). This difference may arise not only from different 
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mathematical approaches but also from the major differences in the paracellular permeability 
of Caco-2 monolayers between laboratories. The calculated Pu and Pi values for basic 
compounds were even higher in SbS than in TW, but for ibuprofen they were very similar. 
Together, these lead to the conclusion that the hydrodynamic conditions of the experimental 
apparatus are bound to affect the Pu and Pi values that are obtained from curve fitting. 
The present data also suggests that the PUWL and, consequently, the hUWL values are not 
equal for all compounds under identical stirring conditions (Table 7.3). A similar observation 
has been made previously with Caco-2 data from various sources (Avdeef et al. 2005) and 
with a parallel artificial membrane permeability assay (Nielsen and Avdeef 2004). The 
differences cannot be explained by aqueous diffusion coefficients since these are almost 
identical for metoprolol, propranolol and ibuprofen. The only common trend is that the higher 
the apparent permeability, the lower is the hUWL observed both in TW and in SbS. This 
contrasts with the previous findings that an increase in ion mobility (permeability) leads to an 
increase in the UWL thickness (Pohl et al. 1998). For stagnant point flow hydrodynamics, it 
may be possible to calculate the hUWL for molecules based on one calibration molecule (Pohl 
et al. 1998). However, in the case of less ideal mixing in in vitro permeability experiments, it 
is not likely that any general correlation can be calculated. Therefore, if accurate PUWL and 
Pcell values are needed, the UWL resistance needs to be determined for each individual 
molecule. 
The stirring exponent α is thought to depend on the type of hydrodynamics (Adson et al. 
1995). Yet, only in a few ideal and symmetric cases can its value be calculated exactly (either 
1/3 or 1/2) and the experimentally obtained values in reaction kinetic experiments are usually 
between 0.5 and 1 (Levich 1962). The fitted exponent is therefore an abstract number without 
any true physiological meaning. It has been speculated that the relatively high fitted values in 
6-well TW plates (0.8) would reflect the asymmetric hydrodynamics (Adson et al. 1995). 
Avdeef et al. (Avdeef et al. 2005) analyzed the UWL resistance with three different molecules 
and obtained different exponents (0.89-1.22) that could describe the PUWL as a function of the 
stirring rate. An early work found a linear (α=1) relationship between stirring rate and PUWL 
(Karlsson and Artursson 1991). The present data set yielded considerably higher values for α 
(Table 7.4) which has been considered to reflect poorer stirring (Adson et al. 1995). In 
practice, this means that the UWL thickness is clearly dependent on the stirring rate. The 
discrepancy between the present data and published values may indeed originate from the 
hydrodynamics. Adson et al. (Adson et al. 1995) used a “break sandwich” procedure where 
the filter was frequently transferred into a new well which renews the basolateral sink. The 
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more recent work by Avdeef et al. (Avdeef et al. 2005) was conducted with an orbital stirrer 
that has an orbit diameter of 3 mm while our stirrer has only 1.5 mm amplitude in its rotatory 
motion.. Naturally, this leads to considerable differences in the orbit speed at an equal angle 
speed. These differences are probably the main reasons accounting for different stirring 
exponents. It may also explain why the stirring method did not seem to work with the present 
data. Based on these observations, it can be concluded that UWL calculations derived from 
pH methodology are more robust than those based on the stirring rate methodology. 
The present data emphasizes the poor hydrodynamics in TW. A novel modification of 
traditional Transwell® system has been introduced that greatly reduces the basolateral UWL 
thickness (12-place magnetic stirrer) and prolongs the time before the sink conditions are lost 
in a typical AB transport experiment (increase in basolateral chamber volume). Experiments 
with this apparatus indicate that the apical UWL appears to be at least an equally large 
resistance to permeability than the basolateral UWL despite the different geometries. 
However, the apical and basolateral UWLs are not independent of each other and, therefore, 
further studies on the possible asymmetry of the UWL in the Transwell® apparatus and its 
effects on kinetics of actively transported compounds are warranted. 
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8 GENERAL DISCUSSION 
Biorelevant cell culture models for intestinal permeability are yearned since the in vivo 
methods are cumbersome and expensive. Moreover, interspecies differences cannot be easily 
corrected for accurate human predictions. The present novel cell models will not probably be 
the first choice for high throughput screening of absorption potential of new chemical entities 
(NCE) in the early discovery phase. This rough screening of passive permeability will be done 
in silico, with PAMPA or with traditional validated cell lines. However, the increase and 
adjustability of efflux pump expression could be utilised at later stages of lead selection since 
the sensitivity of transporter interaction studies can be increased with these cell lines. The 
adjustability of expression levels of transporters gives a valuable tool to evaluate relative 
importance of passive and active transport on the permeability of a given compound. 
Sensitivity of permeability to changes in transporter expression would suggest increased risk 
of drug-drug interactions and inter-individual variability in absorption. However, these types 
of studies and conclusions are still on basic research level since the FDA draft guidance deals 
the possible transporter interactions primarily as a yes/no matter. It must be admitted that 
these cell lines need further optimisation and validation before entering preclinical 
development programs because they have been utilised thus far only in our laboratory. Still, 
the extensive characterisation of the cell lines (Chapters 4 and 5) is a good basis to evaluate 
the properties of these modified cell lines.   
The disappointing CYP activity prevents the use Caco/hPXR and Caco/mCAR cells to 
study the intestinal first-pass metabolism of drugs which was one of the original goals of the 
project. However, the variable and controllable efflux pump expression was successfully 
applied to basic research (Chapter 6) and yielded an important finding on the intracellular 
events during an in vitro permeability experiment. The in vitro bias in kinetic transport 
parameters emphasises the importance of thorough understanding of the phenomenon of 
interest before meaningful and accurate in vivo predictions can be made on the basis of single 
in vitro results. 
The last part of the study (Chapter 7) dwelled deep into hydrodynamics of the in vitro 
permeability experiments. The results give clear signal to screening laboratories that what is 
actually measured in permeability experiments may well be the aqueous diffusion. The 
discovery phase ADME scientists naturally apply control substances in their experiments but, 
if the aqueous diffusion forms the apparent roof in permeability values, highly permeable 
compounds cannot be distinguished from the ultra-rapidly absorbed compounds. This 
  
 132
limitation may skew the simulated plasma curves that are constructed from in vitro 
dissolution and permeability data. A more serious consequence of poor stirring may be the 
distortion of in vitro kinetic parameters because unphysiological diffusion barriers either 
before or after the transporter interaction site. The proposed stirring apparatus is technically 
fairly simple and can efficiently tackle two in vitro artefacts, basolateral UWL and rapid loss 
of sink conditions, by increasing the convection and liquid volume in the basolateral 
compartment. 
  
 133
9 SUMMARY AND CONCLUSIONS 
This study aimed at improving cell lines and methodologies used in vitro permeability 
experiments. Caco-2 cell line was selected for the starting material since it is the most widely 
used in vitro model for intestinal absorption and many of its deficiencies are well known. The 
expression levels of efflux pumps and CYP enzymes were selected as targets since they are 
important in drug absorption and disposition but the lack of models expressing different levels 
of these proteins hampers both the basic and applied research in this field. Hydrodynamics is 
definitely an issue in in vitro permeability experiments. The very efficient luminal stirring 
observed in intact intestine cannot be mimicked in commonly used permeability assays. 
Therefore, the detailed understanding of the contribution of UWL to in vitro permeability 
results is crucial for usefulness of the data. The most important findings of the study are 
summarized below. 
1. Caco-2 cells can be modified in several ways including chemical activations and 
transfections. Several changes are seen at the transcriptional level. Efflux pump genes 
respond better to induction than CYP genes. Changes in functional level are usually less 
pronounced and even some adverse effects, such as downregulation of endogenous 
absorptive transporters and compromise of monolayer integrity, can be seen. 
2. Despite low level of endogenous nuclear receptors, Caco-2 cells apparently have at least 
some expression of nuclear receptor cofactors since transfected hPXR and mCAR can 
elicit ligand dependent changes in gene expression. However, only prototypical target 
genes are affected to a significant extent. CYP protein levels and activities do not 
increase to detectable levels. Therefore, further modifications of Caco-2 cells with more 
efficient regulators are warranted. 
3. Kinetic parameters obtained from in vitro experiments can be biased by permeability 
barriers (UWL, cell membrane) between the donor and the active site of the protein of 
interest. Therefore, the properties of the experimental model must be known well if 
accurate in vivo predictions are to be made. 
4. The commonly used permeability apparatus shows asymmetric hydrodynamics because 
of its constricted geometry. Actually, even the basic assumptions made when 
permeability equations were derived do not necessarily hold. This can lead to, for 
example, radial concentration gradients which can be difficult to model kinetically. 
  
 134
10 FUTURE PERSPECTIVES 
The refinement of in vitro ADME models will continue since several important models are 
still missing and several fundamental questions are unanswered. The constant development of 
molecular biological methods and increase both in genomic data and understanding of cellular 
physiology provide novel tools to improve the cell-based models. 
Elucidation of true transporter interactions of molecules will probably be one of the most 
intensively studied fields in pharmaceutical research in the near future. The method of choice 
will be mostly cell cultures. Some new organotypic cell lines will probably be established but 
also genetic and chemical modifications of current cell lines, similar to this study, will 
certainly be utilised. Increasing knowledge on transporters is needed to further develop drug 
targeting to tissues and to their ultimate sites of action within the individual cells. The 
intracellular kinetic studies must be taken one or two steps further form our "total cellular 
lysate" strategy. The distribution of molecules into and between cytosol, cellular lipids and 
sub-cellular organelles should be quantified. This will allow more specific therapies with less 
side effects and drug-drug interactions. In addition, understanding of intracellular kinetics 
may ultimately lead to mechanistic understanding of factors affecting the apparent kinetics on 
integral membrane transporters. Emerging individual genotyping will eventually enable more 
individualized drug therapy based on for example the individual transporter phenotype that is 
caused e.g. by single nucleotide polymorphisms. To take full advantage of this diagnostic 
possibility, transporter and CYP interactions of the molecule of interest need to be known in 
detail. 
The desire to speed up the drug development process and cut down its costs requires 
constantly improved in silico models that could predict pharmacological activity, basic 
ADME properties and even complete systemic pharmacokinetics already when the new 
molecule is only on the computer screen of the pharmaceutical chemist. However, these 
computer models rise and fall along with the biological data physiological understanding that 
is used to construct them. This data can range from individual Michaelis-Menten parameters 
from microsomal incubations to drug distribution data in intact organisms. Therefore, both 
biological data and basic knowledge on cellular events must be constantly gathered in order to 
make wise and rapid decisions, whether based on in vitro screening data or computer 
simulations and predictions. 
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